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Abstract 
Saccharomyces cerevisiae has been widely established as a platform microorganism for 
industrial production of a wide variety of products including but not limited to ethanol, organic 
acids, amino acids, enzymes, and therapeutic proteins, owing to its high tolerance to harsh 
industrial conditions, such as low pH, high sugar concentration and growth inhibitors in the 
biomass hydrolysate, as well as resistance to phage infection. However, one of the major 
challenges for high level production of value-added compounds other than ethanol is the strong 
fluxes for ethanol formation even under aerobic condition, a phenomenon known as Crabtree 
effect. Notably, a wide variety of products with industrial interest are derived from a few 
precursor metabolites, such as 2,3-butanediol (BDO) and iso-butanol from pyruvate, n-butanol, 
polyhydroxybutyrate, and isoprenoids from acetyl-CoA, and free fatty acids, fatty alcohols, and 
fatty acid ethyl esters from long chain acyl-CoAs. Therefore, metabolic engineering and 
synthetic biology approaches were applied to engineer S. cerevisiae with enhanced supply of 
these precursor metabolites for efficient production of fuels and chemicals. More importantly, 
these engineering efforts can be integrated to construct a platform yeast cell factory, since 
pyruvate is the direct precursor for acetyl-CoA generation and enhanced acetyl-CoA levels will 
provide a driving force for acyl-CoAs pool engineering. 
To construct a pyruvate overproducing yeast strain, three structural genes encoding 
pyruvate decarboxylases, PDC1, PDC5, and PDC6 were deleted to completely eliminate ethanol 
production. Followed by overexpression of MTH1 and adaptive evolution, the resultant Pdc- 
yeast strain grew on glucose as the sole carbon source with pyruvate as the major product. 
Subsequent introduction of a BDO biosynthetic pathway resulted in the production of BDO at a 
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yield over 70% of the theoretical value and a titer higher than 100 g/L using fed-batch 
fermentation.  
To engineer acetyl-CoA pool in S. cerevisiae, alternative acetyl-CoA biosynthesis routes 
were characterized using synthetic biology approaches and metabolic engineering was applied to 
redirect the metabolic fluxes towards acetyl-CoA biosynthesis. Acetyl-CoA biosynthetic 
pathways from Escherichia coli (pyruvate dehydrogenase, PDH) and Yarrowia lipolytica (ATP-
dependent citrate lyase, ACL) were found to enable the growth of the Acs- (acs1Δ acs2Δ) strain 
on glucose as the sole source. To construct a functional PDH in the cytosol of yeast, different 
lipoylation pathways were introduced and engineered. Besides the naturally existing scavenging 
pathway and de novo biosynthetic pathway, we also designed a semi-synthetic lipoylation 
pathway based on the acyl-ACP synthetase (AasS). The scavenging pathway resulted in a 
functional PDH that enabled the growth of Acs- strain to a similar level of the wild-type strain. 
The de novo biosynthetic lipoylation pathway was hindered by the difficulty in reconstituting a 
functional type II fatty acid synthase (FAS) in the cytosol to provide the precursor (octanoyl-
ACP) for protein lipoylation. The introduction of the semi-synthetic lipoylation pathway 
(VhAasS-cytoACP1-cytoPPT2) resulted in functional PDH and rescued the growth of the Acs- 
strain when octanoic acid was supplementated. Based on these results, a de novo biosynthetic 
lipoylation pathway was re-designed and proposed. Then these heterologous biosynthetic 
pathways were combined with host engineering to design and construct acetyl-CoA 
overproducing yeast strains. By deleting ADH1, ADH4, GPD1, and GPD2 involved in ethanol 
and glycerol formation, the glycolytic flux was redirected towards this precursor metabolite, 
resulting in a 4 fold improvement in n-butanol production. Subsequent introduction of alternative 
acetyl-CoA biosynthetic pathways, the production of n-butanol was further increased. Although 
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significant improvement of n-butanol production was achieved, the final titer was still much 
lower than that of ethanol and the resultant yeast strains suffered from accumulation of the toxic 
intermediates such as acetaldehyde and acetate. Therefore, more efforts were put into the 
engineering of acetyl-CoA pools in the Pdc- strain, where ethanol production was completely 
eliminated and pyruvate was accumulated to high levels.  
 To engineer acyl-CoAs levels in S. cerevisiae, a new biosynthesis platform based on the 
reversal of β-oxidation cycle was constructed using synthetic biology approaches. Compared 
with the conical FAS, which is ATP, ACP, and NADPH dependent, the reversed β-oxidation 
pathway is featured for its ATP and ACP independence and CoA and NADH dependence. The 
energetic benefits of ATP independence and availability of CoA and NADH versus ACP and 
NADPH confer advantages for acyl-CoAs biosynthesis. Reversed β-oxidation pathways were 
constructed and found to produce n-butanol, decanoic acid, and ethyl decanoate, indicating the 
functional reversal of β-oxidation cycle at least 4 turns.  
To facilitate the engineering in S. cerevisiae, new synthetic biology tools was also 
developed. First, plasmids with step-wise increased copy numbers (20-100 copies per cell) were 
constructed by engineering the expression level of selection marker proteins, including both 
auxotrophic and dominant markers. More importantly, the copy number of the plasmids with 
engineered dominant markers (5-100 copies per cell) showed a positive correlation with the 
concentration of antibiotics supplemented to the growth media. Based on this finding, a new and 
simplest synthetic biology approach named induced pathway optimization by antibiotic doses 
(iPOAD) was developed to optimize the performance of multi-gene biosynthetic pathways by 
different combination of antibiotic concentrations in S. cerevisiae. To demonstrate this approach, 
iPOAD was applied to optimize the lycopene and n-butanol biosynthetic pathways, with the 
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production of lycopene and n-butanol increased by 10- and 100-fold, respectively. Finally, the 
iPOAD optimized pathway was integrated to chromosomes to increase the strain stability and 
eliminate the requirement of antibiotic supplementation, by taking advantage of the iPOAD and 
CRISPR-Cas9 technologies for multiplex pathway integration.  
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Chapter 1 Introduction 
1.1 Yeast Cell Factory 
Biological conversion of renewable feedstock into fuels and chemicals has been 
intensively investigated due to increasing concerns on sustainability and global climate change 
(1). Many chemicals, such as lactic acid, succinic acid, and iso-butanol, used to be produced by 
chemical processes are synthesized biologically with microbial fermentation. Microorganisms 
are able to convert a wide range of substrates, such as plant biomass and agricultural waste, to 
value-added chemicals and fuels, promising a low carbon economy and sustainable future. 
Biofuels and chemicals are preferred to be produced at large scales using industrially friendly 
hosts such as Escherichia coli and Saccharomyces cerevisiae. Besides these two model 
microorganisms, cyanobacteria (2) and oleaginous yeasts (3) have also been explored as cell 
factories. Compared with its counterparts, S. cerevisiae is more industrially relevant thanks to the 
well-studied genetic and physiological background, the availability of a large collection of 
genetic tools, the compatibility of high-density and large-scale fermentation, the resistance to 
phage infection, and the high tolerance against toxic inhibitors and products (4). Therefore, S. 
cerevisiae is one of the most popular cell factories and has been successfully used in modern 
fermentation industry to produce a wide variety of products including but not limited to ethanol, 
organic acids, amino acids, enzymes, and therapeutic proteins (1, 4). 
Compared with ethanol, the production of other molecules, especially advanced biofuels 
and low value-added chemicals, using yeast cell factories is less successful, in terms of the titer, 
yield, and productivity. One major reason is due to the well-known Crabtree effect: most of the 
glycolytic fluxes going through ethanol formation even under respiration conditions. Thus, 
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various metabolic engineering strategies have been applied to redirect the metabolic fluxes from 
ethanol to the desired products, such as the inactivation of the alcohol dehydrogenases (ADHs) (5) 
or the pyruvate decarboxylases (PDCs) (6, 7). Notably, a wide variety of products with industrial 
interests are derived from a few precursor metabolites, such as lactate, 2,3-butanediol (BDO), 
and iso-butanol from pyruvate, n-butanol, polyhydroxybutyrate (PHB), and isoprenoids from 
acetyl-CoA, and free fatty acids (FFAs), fatty alcohols (FALs), alkanes, and fatty acid ethyl 
esters (FAEEs) from long chain acyl-CoAs (Figure 1.1). Therefore, the design and construction 
of S. cerevisiae strains with enhanced supply of these precursor metabolites, including pyruvate, 
acetyl-CoA, and acyl-CoAs, will develop this yeast as a platform cell factory for efficient 
production of biofuels and chemicals besides ethanol. 
1.2 Engineering Pyruvate Metabolism 
As an end product of glycolysis, pyruvate is the branch point to control the flow of 
metabolic fluxes, especially for respiration and fermentation. In addition, pyruvate is the 
precursor for the production of a wide range of fuel and chemical molecules, such as ethanol, 
iso-butanol, 2,3-butanediol, lactate, malate, and succinate (7). In S. cerevisiae, there are three 
major fates of pyruvate metabolism, pyruvate decarboxylase (PDC) mediated ethanol 
fermentation, pyruvate dehydrogenase (PDH) mediated acetyl-CoA generation and respiration, 
and pyruvate carboxylase (PYC) initiated gluconeogenesis (8).  
1.2.1 Distribution of glycolytic fluxes at the pyruvate branch 
How the carbon flow is controlled at the pyruvate branch is an interesting and ongoing 
study. Although the KM of PDH (0.6 mM at pH8.1 and 0.2 mM at pH6.5) (9) and PYC (c.a. 0.8 
mM) (10) towards pyruvate is an order of magnitude lower than that of pyruvate decarboxylase 
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(c.a. 5 mM, 1-3 mM in the absence of phosphate, fourfold higher in the presence of 25 mM 
phosphate, while normal intracellular phosphate concentration in S. cerevisiae is 5-15 mM) (11), 
most of the metabolic fluxes go through ethanol fermentation even under aerobic conditions. The 
first explanation of such dilemma is due to glucose repression (also known as Crabtree effect), 
meaning that the expression or enzymatic activities of respiratory proteins are inhibited by the 
presence of glucose (12). Another explanation lies in the higher capacity (Vmax) of PDC. It is 
estimated that the capacity of mitochondrial pyruvate oxidation is at least ten-fold lower than that 
of pyruvate decarboxylase (8).  
1.2.1.1 Pyruvate dehydrogenase (PDH) 
The PDH complex consists of three major catalytic components, El, E2, and E3, which 
are encoded by PDA1 and PDB1, LAT1, and LPD1, respectively. A fourth component X encoded 
by PDX1 does not have any catalytic function but may be involved in the assembly of the 
complex (9). In the first step, pyruvate is covalently linked to thiamine pyrophosphate (TPP), the 
cofactor of El, to form acetaldehyde-TPP (the active aldehyde). Then the acetaldehyde group is 
oxidized and the resulting acetyl moiety is coupled to the lipoamide cofactor of E2, which is 
subsequently transferred to CoA. During the oxidation of the active aldehyde, the E2 lipoamide 
group is reduced to dihydrolipoamide, whose reoxidation is catalyzed by E3 using NAD+ as the 
electron acceptor. Overall, one acetyl-CoA molecule and an NADH reducing force are generated 
from one pyruvate molecule. The disruption of the PDH structural genes, including PDA1, PDB1, 
LAT1, and PDX1, results in complete loss of pyruvate dehydrogenase activity. Interestingly, 
these Pdh- strains do not have significant growth defects compared with the wild-type strain, 
indicating that acetyl-CoA generated by the PDH-bypass pathway in the cytosol is sufficient for 
cellular demands. 
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1.2.1.2 Pyruvate decarboxylase (PDC) 
PDC catalyzes the TPP- and Mg2+ -dependent decarboxylation of pyruvate to 
acetaldehyde and CO2. The pyruvate decarboxylation activity results from the expression of 
three structural genes, PDC1, PDC5, and PDC6, whose expression levels are dependent on the 
transcription factor, Pdc2p (13).  While PDC1 is highly expressed under most of the conditions 
tested, the expression level of PDC5 is much higher in the PDC1 deletion strain, suggesting an 
auto-regulation system of the expression of PDC genes (14). Interestingly, although the PDC6 
sequence has a high similarity with PDC1 and PDC5, its expression is not detectable in the wild-
type S. cerevisiae strain. The disruption of all three structural genes (pdc1Δ pdc5Δ pdc6Δ) 
completely abolishes PDC activity. The resulting Pdc- strain cannot grow in defined medium 
with glucose as the sole carbon source, although its growth on ethanol is not affected (15). Since 
PDC activity is required for acetyl-CoA generation in the cytosol, the growth of the Pdc- strain in 
glucose minimal medium is possible only when a C2 compound such as acetate or ethanol is 
supplemented. It is suggested that the inability of the Pdc- strain to grow in glucose minimal 
medium might result from two factors, glucose repression of the expression of respiratory genes 
and a lack of route to generate cytosolic acetyl-CoA. 
1.2.1.3 Pyruvate carboxylase (PYC) 
Pyruvate carboxylase, encoded by PYC1 and PYC2 in S. cerevisiae, catalyzes the 
anaplerotic synthesis of oxaloacetate from pyruvate (10). Oxaloacetate produced by PYC is an 
important intermediate, which plays a crucial role in gluconeogenesis and lipogenesis. 
Gluconeogenesis, a metabolic pathway for the generation of glucose from non-carbohydrate 
carbon substrates, begins with the formation of oxaloacetate by the carboxylation of pyruvate at 
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the cost of one ATP molecule. PYC is stimulated by high levels of acetyl-CoA and inhibited by 
high levels of ADP and glucose. Although PYC in higher eukaryotes is located in the 
mitochondria, both Pyc1p and Pyc2p are completely cytosolic in S. cerevisiae. When both PYC1 
and PYC2 are disrupted, the resulting Pyc- strain cannot grow in glucose as the sole carbon 
source. Growth of this pyruvate carboxylase-negative (Pyc-) mutant is possible when aspartate 
instead of ammonium is provided as the primary nitrogen source, thus by-passing the anaplerotic 
function of pyruvate carboxylase (16). Although oxaloacetate can also be synthesized by the 
glyoxylate cycle, the inability of Pyc- strains to grow on glucose indicates that the glyoxylate-
cycle enzymes (such as the isocitrate lyase) are repressed or even inactivated in the presence of 
glucose. Interestingly, a dominant suppressor mutation (DGT1-1), which causes a reduced uptake 
of glucose and thus alleviates glucose catabolite repression, has been isolated which allows Pyc- 
strain to grow on glucose defined medium (17). 
1.2.2 Engineering at the pyruvate branch for biosynthesis 
As mentioned above, since most of the glycolytic fluxes go through ethanol fermentation 
even under aerobic conditions, PDC is often chosen as the major target for metabolic engineering. 
Unfortunately, the Pdc- strain (either pdc2Δ or pdc1Δ pdc5Δ pdc6Δ) is notorious for its inability 
to grow on glucose as the sole carbon source and the requirement of a C2 compound (acetate or 
ethanol) supplementation to synthesize cytoplasmic acetyl-CoA (15). Inverse metabolic 
engineering revealed that an internal deletion in the MTH1 coding sequence enabled the growth 
of Pdc- strain on glucose (18, 19). In another study, a mutation in the Mth1p coding sequence 
(Ala81Pro) was also found in the evolved Pdc- strain that was able to grow on glucose as the sole 
carbon source (20). Mth1p is a transcription factor involved in glucose sensing which can inhibit 
the expression of hexose transporter genes (HXTs), thus the uptake of glucose. The internal 
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deletion or single amino acid mutation increases the stability of Mth1p by removing the putative 
sites related to protein degradation (19), maintaining the intracellular glucose concentration to a 
low level and alleviating glucose repression.  
However, how cytosolic acetyl-CoA is generated in the evolved Pdc- strain is still an 
interesting question. Previously work indicated that acetaldehyde generated by the cleavage of 
threonine, a reaction catalyzed by threonine aldolase (encoded by GLY1), might serve as a 
precursor for the synthesis of cytosolic acetyl-CoA (21). A recent study (22) also confirmed that 
Ach1p, the acetyl-CoA hydrolase (later renamed as CoA transferase) located in the mitochondria, 
might function as the acetyl-CoA shuttle between the mitochondria and the cytosol in the form of 
acetate. In wild-type S. cerevisiae strain, the expression of ACH1 was repressed in the presence 
of glucose; while in the evolved Pdc- strain, glucose repression was alleviated and Ach1p was 
functionally expressed. Acetyl-CoA was hydrolyzed by Ach1p in the mitochondria to release 
acetate, which could freely exit mitochondria and be re-activated by acetyl-CoA synthetase to 
form acetyl-CoA in the cytosol. 
Since pyruvate is accumulated to a level as high as 135 g/L (6), the Pdc- strain can be 
developed into an important platform cell factory to produce a wide range of biofuels and value-
added chemicals other than ethanol, including but not limited to iso-butanol, 2,3-butanediol, 
lactate, malate, succinate, and glycerol. Lactate with a titer up to 110 g/L could be obtained in a 
Pdc- strain expressing an LDH gene from Lactobacillus casei in 1 L fermenter under aerobic 
conditions (7). High titer and yield production of 2,3-butanediol was also reported using an 
evolved Pdc- strain overexpressing an acetolactate synthase (alsS) and acetolactate decarboxylase 
(alsD) from Bacillus subtilis as well as the endogenous butanediol dehydrogenase (BDH1) from 
various carbon sources, such as glucose (20), cellobiose (23), and xylose (24). The highest 
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production was achieved using glucose fed-batch fermentation, with a titer and yield as high as 
96.2 g/L and 0.28 g/g, respectively (20). Fermentative production of malate using the Pdc- strain 
was also attempted by combined overexpression of a pyruvate carboxylase (PYC2), a 
cytosolically located malate dehydrogenase (MDH3ΔSKL) and a malate transporter from 
Schizosaccharomyces pombe (SpMAE1). Malate titer of up to 59 g/L was reached with a yield of 
0.42 mol/mol glucose in shake flask fermentation (25). Recently, the malate producer was further 
engineered to produce succinate. Under optimal conditions in a bioreactor, the engineered strain 
produced around 13 g/L succinate with a yield of 0.21 mol/mol glucose at low pH (26). Although 
glycerol is not directly derived from pyruvate, the elimination of ethanol formation in the Pdc- 
strain may redirect the metabolic fluxes to glycerol formation, especially under low-oxygen or 
anaerobic conditions. By further engineering cytosolic NADH availability and overexpressing 
GPD2, glycerol titer of higher than 50 g/L and yield as high as 1.08 mol/mol glucose were 
achieved in aerobic and glucose-limited chemostat cultures with formate co-feeding (27). 
1.3 Engineering Acetyl-CoA Metabolism 
As a central metabolite, acetyl-CoA plays important roles in a series of cellular functions. 
It’s also a key precursor in the biosynthesis of sterols, amino acids, fatty acids, and polyketides. 
In S. cerevisiae, acetyl-CoA metabolism occurs in various compartments, including 
mitochondria, peroxisomes, nucleus, and cytosol (28). In the cytosol where biosynthesis 
generally occurs, acetyl-CoA is generated via the PDH-bypass pathway, from pyruvate to 
acetaldehyde and then to acetate, which is activated to acetyl-CoA by the acetyl-CoA synthetase 
(ACS) at the cost of two ATP equivalents (Figure 1.3). Due to the feedback inhibition of ACS 
and high energy input requirement, the activation of acetate is a rate-limiting step. In addition, 
due to the Crabtree effect, the glycolytic fluxes mainly go through ethanol formation and the 
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supply of acetyl-CoA is very limited. Several metabolic engineering strategies have been 
attempted to boost the availability of acetyl-CoA in the cytosol of yeast, such as to redirect the 
metabolic fluxes to acetyl-CoA biosynthesis, to inactivate the competing pathways, and to 
introduce heterologous biosynthetic pathways with higher efficiency and lower energy input 
requirement (Figure 1.3). 
1.3.1 Metabolic engineering to redirect the metabolic fluxes  
Due to the Crabtree effect, most of the metabolic fluxes go through ethanol formation 
during glucose fermentation in S. cerevisiae, which means that the central metabolism of yeast 
should be engineered to redirect the metabolic fluxes to acetyl-CoA biosynthesis. As shown in 
Figure 1.3, acetaldehyde is the branch point to control the flux distribution between ethanol and 
acetyl-CoA. Therefore, the inactivation of alcohol dehydrogenases (ADHs) was chosen as first 
the metabolic engineering target. By the deletion of ADH1, a major ADH responsible for ethanol 
fermentation, 1.9-fold improvement in FFAs production was achieved in a fatty acids producing 
host (29). The major concerns with ADH inactivation are the poor growth of the resultant yeast 
strain resulted from the accumulation of the toxic intermediates [acetaldehyde and acetate] and 
the residual production of ethanol as the major product due to the redundancy of ADHs in the S. 
cerevisiae genome (5, 30). 
Since most of the acetyl-CoA involved reactions are essential to maintain cellular 
functions, there were not many successful examples by eliminating the acetyl-CoA consuming 
pathways. Most current efforts targeted toward the glyoxylate shunt, which contributes to the 
transport and consumption of cytosolic acetyl-CoA in yeast (28, 31). The glyoxylate shunt can be 
disrupted by knocking out CIT2 or MLS1, which encodes peroxisomal citrate synthase and 
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cytosolic malate synthase, respectively (31). Compared with the reference strain with an intact 
glyoxylate shunt, the inactivation of CIT2 or MLS1 increased the production of α-santalene by 
1.36- and 2.27-fold (32), 3-hydroxypropionic acid (3-HP) by 1.19- and 1.20-fold (33), and n-
butanol by 1.58- and 1.36-fold (34), respectively. Interestingly, it was found that the production 
of polyhydroxybutyrate (PHB) was impaired in the cit2∆ or mls1∆ yeast strain (35). 
In terms of the acetyl-CoA consuming pathways that are essential for cell survival, such 
as the biosynthesis of sterols and amino acids down regulating the expression of genes encoding 
the initial or rate-limiting enzymes of these biosynthetic pathways, such as ERG10 and HMG1 in 
the sterols pathway, will be more desirable rather than completely eliminating the enzyme 
activity by gene knockout. Basically, the expression of essential genes can be knocked down by 
replacing the endogenous promoter with a very weak or inducible/repressible one (36). A more 
powerful and flexible strategy is to reconstruct the RNA interference (RNAi) machinery in S. 
cerevisiae and knock down the targeted genes with the customized small interfering RNA (37-
39).  
1.3.2 Synthetic biology for alternative acetyl-CoA biosynthetic pathways 
Due to feedback inhibition and high energy input requirement, the endogenous PDH-
bypass pathway suffered from low efficiency for acetyl-CoA biosynthesis. To overcome such 
limitations, a feedback inhibition insensitive ACS mutant from Salmonella enterica (SeAcsL641P) 
(32, 34, 35, 40) and/or alternative acetyl-CoA biosynthetic pathways with less energy input 
requirement (Figure 1.3) have been introduced to boost the availability of acetyl-CoA in yeast 
(41, 42). Notably, improved production of amorphadiene (40), α-santalene (32), PHB (35, 41), n-
butanol (34), 3-HP (33), and FFAs (42) were achieved by engineering the acetyl-CoA pool in S. 
10 
 
cerevisiae. Considering the significance of acetyl-CoA in cellular metabolism, nature has 
evolved various routes to synthesize acetyl-CoA under different conditions. The biosynthetic 
routes of acetyl-CoA from central metabolites, such as pyruvate, acetate, and citrate, and their 
(potential) applications in improved production of fuels and chemicals in yeast are discussed 
below.  
1.3.2.1 Engineered PDH-bypass pathway  
Although ACS was determined to be rate-limiting, the overexpression of the endogenous 
ACS1 or ACS2 led to no or limited improvement in acetyl-CoA levels in yeast (40). It was found 
that ACS was post-translationally deactivated via acetylation (43). In other words, ACS is 
subject to feedback inhibition by acetyl-CoA. A point mutation at the acetylation position could 
maintain ACS at the active form and increase the acetyl-CoA supply, one such example is the 
feedback inhibition insensitive ACS mutant from Salmonella enterica (SeAcsL641P). In wild-type 
yeast strains, the supply of acetate was found to limit acetyl-CoA biosynthesis as well. Thus, 
upstream genes including ethanol dehydrogenase (ADH2) and/or aldehyde dehydrogenase 
(ALD6) were co-expressed with SeAcsL641P to direct the metabolic fluxes to acetate and then 
acetyl-CoA biosynthesis. By introducing the engineered PDH-bypass pathway, the production of 
α-santalene was increased by 1.75-fold (32), amorphadiene by 1.22-fold (40), 3-HP by about 
1.50-fold (33), PHB by 18-fold (35), and n-butanol by 3.10-fold (34), respectively. In another 
study, the production of FALs could be increased from 140 mg/L to 236 mg/L by introducing 
such an acetyl-CoA boosting pathway into the engineered yeast strain with increased fluxes to 
fatty acid biosynthesis (FAB). 
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1.3.2.2 Pyruvate dehydrogenase (PDH), pyruvate:ferrodoxin oxidoreductase (PFO), and 
pyruvate:NADP+ oxidoreductase (PNO) 
PDH catalyzes the oxidative degradation of pyruvate to generate acetyl-CoA in an ATP-
independent manner (Figure 1.3), which is the most widely existed and probably the most 
efficient route for acetyl-CoA generation. Unfortunately, PDHs are only found in prokaryotes 
and eukaryotic organelles. By expressing the mitochondrial PDH structural genes without the 
mitochondrial targeting sequences (PDA1-PDB1-PDX1-LAT1-LPD1) or the bacterial PDH genes 
(lpdA-aceE-aceF), a new route of acetyl-CoA biosynthesis can be constructed in the cytosol of 
yeast. As mentioned above, TPP, FAD, NAD+, and lipoic acid are used as cofactors for PDH 
catalyzed reactions. TPP, FAD, and NAD+ are readily available in the cytosol of yeast, while 
lipoic acid is only present in the mitochondria. Recently, functional expression of PDH complex 
in the cytosol of yeast was achieved by co-expressing PDH structural genes (pdhA pdhB aceF 
lpd) and protein-lipoate ligase genes (lplA lplA2) from Enterococcus faecalis. When lipoic acid 
was supplemented to the growth medium, functional PDH complex can fully replace the 
endogenous pathway for cytosolic acetyl-CoA synthesis, with a growth rate similar to the wild-
type yeast strain (44). Although it has been validated by growth complementation, functional 
PDH in the cytosol has not been used for metabolic engineering applications yet. 
Rather than PDH, some anaerobic fungi use pyruvate:ferrodoxin oxidoredutase (PFO) 
(45) or pyruvate:NADP+ oxidoreductase (PNO) (46) for oxidative degradation of pyruvate to 
generate acetyl-CoA. Instead of NADH, reduced ferrodoxin and NADPH are released as 
reducing agents by PFO and PNO, respectively (Figure 1.3). Compared with other routes for 
acetyl-CoA generation, PNO possesses several advantages to construct an acetyl-CoA 
overproducing strain for FAB, since it supplies both acetyl-CoA and NADPH and functions 
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under anaerobic conditions in an ATP-independent manner (46). Interestingly, PNO is a fusion 
protein with an N-terminal PFO domain fused to a C-terminal flavoprotein domain, which 
transports electrons from the FeS clusters of the PFO domain to NADPH (47).  
1.3.2.3 Pyruvate:formate lyase (PFL)  
Pyruvate:formate lyase (PFL) was reported to be able to fully replace the endogenous 
pathway for cytosolic acetyl-CoA generation (48). PFL is generally found in prokaryotes for 
acetyl-CoA biosynthesis under anaerobic conditions, but also in some anaerobic eukaryotes. 
Different from PDH, PFO, or PNO, which generates acetyl-CoA via oxidative decarboxylation 
of pyruvate, PFL follows a radical chemistry to convert pyruvate into acetyl-CoA and formate 
(Figure 1.3). PFL was tested in the Ald- (ald2∆ ald3∆ ald4∆ ald5∆ ald6∆) and/or Acs- (acs1∆-
acs2∆) yeast strains as an alternative route for acetyl-CoA biosynthesis (48). Neither Ald- nor 
Acs- yeast strain can grow on glucose as the sole carbon source due to the lack of a route for 
cytosolic acetyl-CoA generation. The introduction of PFL rescued the growth on glucose as the 
sole carbon source under strictly anaerobic conditions, accompanied with the production of 
formate (48). The growth rate of the Ald- or Acs- strain with PFL was lower than that of the wild-
type strain, and the application for the production of acetyl-CoA derived molecules has not been 
evaluated yet. Considering the accumulation of formate in the PFL containing yeast strain, 
NADH can be generated by co-expression of a formate dehydrogenase (FDH) (49) and used as a 
reducing force for biosynthesis.  
1.3.2.4 Pyruvate oxidase (POX) 
Pyruvate oxidase, also named as phosphate-dependent pyruvate oxidase, converts 
pyruvate directly to acetyl-phosphate, CO2, and H2O2 under aerobic conditions. TPP and FAD 
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are the two cofactors involved in this enzymatic reaction. Although acetyl-CoA can be readily 
generated by PDH under aerobic conditions at higher efficiency and without the production of 
toxic compound, it is found that PoxB is used preferentially at low growth rates and that E. coli 
benefits from being able to convert pyruvate to acetyl-CoA by a seemingly wasteful route (50). 
1.3.2.5 Acetylating aldehyde dehydrogenase (A-ALD) 
The activation of acetate is so ATP intensive that it constrains the maximal yield of the 
acetyl-CoA derived products. In addition, the supply of acetyl-CoA is even more limited under 
anaerobic conditions, a preferred process for industrial applications. Many prokaryotes contain 
an acetylating acetaldehyde dehydrogenase (A-ALD), which catalyzes the reversible conversion 
of acetaldehyde and acetyl-CoA in an ATP-independent manner (Figure 1.3). As a proof of 
concept, A-ALD was also tested in the Ald- and/or Acs- yeast strains as an alternative route for 
acetyl-CoA biosynthesis (48). Among different bacterial A-ALDs, EutE from E. coli (EcEutE) 
was determined to possess the highest activity and enable the highest specific growth rate on 
glucose. Although A-ALD could fully replace the endogenous acetyl-CoA biosynthetic route, the 
engineered strains still grew more slowly than the wild-type yeast strain. In addition, the use of 
A-ALD was only demonstrated by growth complementation, and its energetic benefit for the 
synthesis of acetyl-CoA derived products still needs further evaluation. Recently, EcEutE was 
introduced into a fatty acids producing host but only marginal improvement was observed in 
FFAs production (29).  
1.3.2.6 ATP-dependent citrate lyase (ACL)  
ATP-dependent citrate lyase (ACL) uses a tricarboxylic acid (TCA) cycle intermediate 
citrate as the substrate (Figure 1.3), which is enzymatically converted to acetyl-CoA and 
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oxaloacetate at the cost of one ATP molecule (51). Notably, comparative genomic studies 
reveals the presence of ACL in oleaginous yeasts such as Yarrowia lipolytica, while not in non-
oleaginous yeasts such as S. cerevisiae (52). Such difference may imply the significance of ACL 
in providing precursor metabolites for the biosynthesis of fatty acids and lipids. ACLs from 
oleaginous yeasts , plants (53), and mammalian cells (42, 54) have been functionally expressed 
in S. cerevisiae and were able to increase the production of FFAs by 1.17-fold (42, 54) and n-
butanol by about 2-fold . In another study, ACL from Arabidopsis thaliana and Y. lipolytica were 
introduced into a yeast strain engineered for overproducing FALs, whose titer was increased 
from 140 mg/L to 217 mg/L and 330 mg/L, respectively (55).  
Due to the Crabtree effect and compartmentalization of cellular metabolism, citrate 
concentration in the cytosol may be low and rate-limiting for ACL activity (Figure 1.3). To 
increase the intracellular citrate level, both metabolic engineering strategies and process 
optimization have been attempted. To decrease the consumption of citrate through TCA cycle, 
IDH1 and/or IDH2 were deleted and citrate level was increased about 5-fold (42). Under 
nitrogen-limited conditions, a 3-fold increase in intracellular citrate concentration was achieved 
(54). Accordingly, the introduction of an ACL to the citrate accumulating strain led to increased 
production of FFAs (42, 54). 
1.3.2.7 Phosphoketolase (PK) 
Phosphoketolase, which catalyzes the cleavage of D-xylulose-5-phosphate into acetyl 
phosphate and glyceraldehyde-3-phosphate, is generally found in some filamentous fungi for 
cytosolic acetyl-CoA biosynthesis, such as Aspergillus nidulans (56). The phosphoketolase 
pathway was originally introduced into S. cerevisiae for improved xylose utilization (57), and 
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later was found to enhance the synthesis of acetyl-CoA as well (41, 58, 59) (Figure 1.3). By 
heterologous expression of the phosphoketolase pathway in a yeast strain producing PHB, the 
production could be improved from 4 mg/g dry cell weight in the reference strain to 28 mg/g dry 
cell weight, while only 16 mg/g dry cell weight was produced in the same background strain 
with the engineered PDH-bypass pathway (41). The phosphoketolase pathway was also 
introduced to the FAEEs producing yeast strain, and the production of FAEEs was increased by 
5.7-fold compared with the reference strain (59). Since the metabolic flux to pentose phosphate 
pathway is limited during glucose fermentation, the intracellular concentration of D-xylulose-5-
phosphate can be rate-limiting for acetyl-CoA biosynthesis via the phosphoketolase pathway. On 
the contrary, xylose is consumed via D-xylulose-5-phosphate. Therefore, it will be interesting to 
test the production of acetyl-CoA derived fuels and chemicals from xylose using the S. 
cerevisiae strains containing the phosphoketolase pathway (Figure 1.3). 
1.4 Engineering Fatty Acyl-CoAs Metabolism 
In yeast, FAB is carried out by the type I fatty acid synthase (FAS) system with all 
functional domains organized in two polypeptides, Fas1p and Fas2p. Although the organization 
of the FAS system varies between different organisms, the individual enzymatic reactions of 
FAB are essentially the same (60, 61). FAB begins with the conversion of acetyl-CoA into 
malonyl-CoA by acetyl-CoA carboxylase (ACC) at the cost of ATP. Malonyl-CoA is then 
transferred to ACP by malonyl-CoA:ACP transacylase. The generated malonyl-ACP is used as 
an extender unit, condensing with acyl-ACP to form β-ketoacyl-ACP with two more carbon units. 
The extended β-ketoacyl-ACP is subject to an NADPH-dependent reduction to form β-
hydroxyacyl-ACP, whose hydroxyl group is removed by β-hydroxyacyl-ACP dehydratase, 
leading to the formation of trans-2-enoyl-ACP. The double bond is then reduced in another 
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NADPH-dependent reaction by the trans-2-enoyl-ACP reductase. Each elongation cycle results 
in the synthesis of acyl-ACP with the fatty acyl chain extended by two carbon units (Figure 
1.4A). Besides the canonical FAB mechanisms shared by most of organisms, nature also evolved 
several special mechanisms to synthesize fatty acids de novo, such as the elongase system (62, 
63) (Figure 1.4B) and the fermentative pathway (64, 65) (Figure 1.4C). Although not widely 
distributed in nature, these special pathways possess significant advantages over the canonical 
ones, in terms of pathway efficiency and controllability of the fatty acids chain lengths. Since the 
endogenous FAS system suffer from low efficiency and high regulation (66), such as coordinated 
induction of FAB genes, feedback inhibition, and inositol-mediated repression (60, 67), fatty 
acids do not naturally accumulate to high levels. Therefore, the hijack of FAB regulatory 
network by engineering of the transcriptional factors and heterologous expression of FASs have 
been tried to overcome the limitations of the endogenous system. 
1.4.1 Engineering of structural genes  
To increase the metabolic fluxes to FAB, the most straightforward strategy is to 
overexpress ACC1, FAS1 and FAS2. By replacing the native promoters of ACC1, FAS1, and 
FAS2 with strong and constitutive promoters, their expression levels were increased about 7- to 
16-fold. Accordingly, the production of FFAs, FALs, and FAEEs were increased by about 11-, 
2-, and 4-fold, respectively (68). 
To improve the fatty acyl-CoA levels, competing pathways were also engineered in S. 
cerevisiae. For example, the β-oxidation cycle, contributing to the degradation of fatty-CoAs, 
can be disrupted by the deletion of POX1. Unfortunately, the disruption of β-oxidation cycle led 
to lower production of FALs and FAEEs (55, 68). Besides β-oxidation, a large fraction of fatty 
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acids are utilized to synthesize steryl esters (SEs) and triacylglycerols (TAGs) in S. cerevisiae. 
Compared with the wild-type strain, FFAs content was increased about 3-fold in a strain (are1∆ 
dga1∆ are2∆ lro1∆) devoid of TAG and SE formation, 4-fold in a strain (pox1∆) incapable of β-
oxidation, and 5-fold in a strain (are1∆ dga1∆ are2∆ lro1∆ pox1∆) lacking both TAG and SE 
biosynthesis and β-oxidation pathways (69). Highest FFAs production, 2.2 g/L with 32% of the 
theoretical yield, was achieved in a recent study (70) by combining the disruption of β-oxidation 
and fatty acid activation (faa1Δ faa4Δ fat1Δ faa2Δ pxa1Δ pox1Δ) and the overexpression of the 
diacylglycerol acyltransferase (DGA1) and the triacylglycerol lipase (TGL3). 
1.4.2 Engineering of regulatory genes  
Due to the limited success in improving the efficiency of FAB by engineering structural 
genes, another study targeted the transcriptional regulators involved in FAB to increase the 
production of FALs (55). By manipulating the structural genes in fatty acids synthesis and 
degradation pathways, the production of FALs was increased less than 1.6-fold. On the contrary, 
the disruption of the regulatory network by knocking out transcriptional factors improved the 
production of FALs by 1.6- to 2.7-fold. Specifically, the deletion of RPD3, a negative regulator 
of phospholipids metabolism, enabled the highest production of FALs at a titer around 122 mg/L. 
Since the phospholipids synthesis requires fatty acids as the precursors, the deletion of negative 
regulators of phospholipids metabolism can enhance the phospholipids production and create a 
driving force for FAB. 
It is well known that FAB is also subject to feedback inhibition by fatty acyl-CoAs or 
fatty acyl-ACPs. In eukaryotes, acyl-CoA binding protein (encoded by ACB1) plays an important 
role in transporting fatty acyl-CoAs in different compartments and attenuating the feedback 
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inhibitory effect of acyl-CoAs on FAB enzymes, such as Acc1p, Fas1p, and Fas2p (71). A recent 
report found that overexpression of ACB1 could enhance the supply of fatty acyl-CoAs and 
increase the production of FAEEs by around 1.2-fold (72). On the contrary, another study found 
that the deletion of ACB1 could enhance the cytosolic acyl-CoAs and increase the production of 
FAEEs by 1.48-fold (73). 
1.4.3 Synthetic biology for alternative FAS  
1.4.3.1 Bacterial type I FAS (bFAS) 
Due to their coordinated biosynthesis, type I FASs are generally considered to be 
kinetically more efficient than the dissociated type II FASs. However, FAS may still be rate-
limiting for FAB in yeast, because of its highly regulated network. Type I FASs are mainly 
present in eukaryotes, but also found in some actinomycetes, such as Mycobacterium species 
(74). Considering the significant differences between prokaryotes and eukaryotes, heterologous 
expression of a bacterial type I FAS (bFAS) was proposed for efficient FAB in yeast, by taking 
the advantage of the type I FAS while bypassing the endogenous regulation. It was found that a 
bFAS (FAS-B) from Brevibacterium ammoniagenes (also known as Corynebacterium 
ammoniagenes) together with its activation protein (phosphopantetheinyl transferase, PptA) 
could complement the growth of a fas1Δ mutant on fatty acids free medium, indicating that FAS-
B could be functionally expressed in yeast and synthesize all necessary fatty acids or fatty acyl-
CoAs to maintain cellular functions (75). Subsequent introduction of a wax synthase gene 
redirected the additional FAB fluxes to the synthesis of FAEEs, whose titer was 6-fold higher 
than that in the wild-type strain. It was also shown that a FAS-B mutant (Y2226F), whose 
19 
 
ketoacyl-ACP reductase activity was eliminated by point mutation at the catalytic center, enabled 
the production of triacetic acid lactone (TAL) at a titer higher than 50 mg/L in S. cerevisiae (76). 
1.4.3.2 Homo sapiens type I FAS (hFAS) 
Considering the kinetics advantage of the type I FASs, another strategy is to use the 
Homo sapiens type I FAS (hFAS). Different with the yeast counterpart, whose structure is well 
organized and highly complex, hFAS is not constrained by a scaffolding structure and displays a 
remarkable degree of flexibility (77). Especially for the TE domain, this fatty acids cleaving unit 
is on the C-terminus and isolated from the core scaffold. It was found that the removal of the TE 
domain (hFAS∆TE) eliminated the native TE activity, but had no negative effect on the activity 
of other domains (78). Coexpression of a short-medium chain specific TE (FatB1 from Cuphea 
palustris or TEII from Rattus norvegicus) together with the engineered hFAS resulted in the shift 
of fatty acids profiles. C6, C8, and C10 fatty acids were detected at high levels in the engineered 
strain, and the production of the major fatty acid (C8) was increased more than 17-fold compared 
with the wild-type strain. By replacing the native TE domain, the short-medium chain specific 
TEs were linked to hFAS and the closer proximity of TE and FAS domains resulted in a 4- to 9-
fold increase in C8 fatty acid levels over the unlinked counterparts and a 64-fold increase over 
the wild type strain (78). The flexibility, high activity, and probably feedback inhibition 
insensitivity make hFAS a promising platform to produce fatty acids derived molecules with 
different chain lengths. 
1.4.3.3 Elongase 
As mentioned above, the traditional FAS system utilizes malonyl-ACP as the extender 
unit and NADPH as the reducing force to elongate the acyl chains, highlighting the ATP, 
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NADPH, and ACP dependence (60). A different de novo FAS system, the microsomal elongase, 
was described in Trypanosoma brucei, a eukaryotic human parasite that causes sleeping sickness 
(62, 63). Genome sequence indicates the presence of a putative type II FAS system, but 
experimental results suggest that the type II FAS is not responsible for de novo FAB. For 
example, 1) the components are membrane associated proteins, while soluble proteins are 
generally found for a type II FAS system. 2) Several type II FAS inhibitors, such as triclosan and 
cerulenin, which inhibit trans-2-enoyl-ACP reductase and β-ketoacyl-ACP synthase (79), 
respectively, will not affect FAB. 3) RNA interference (RNAi) silencing of ACP, a key 
component of type II systems, has no effect on de novo FAB either. Later, the system was 
characterized to use three elongases instead of a type II FAS (Figure 1.4B).  
In this microsomal elongase system, malonyl-CoA serves as the extender unit and CoA is 
the acyl chain carrier (Figure 1.4B). In other words, this system is ATP, NADPH, and CoA 
dependent. In addition, trypanosomes have different fatty acids requirements during their life 
cycle, as they encounter various growth environments (62). It is found that the fatty acids 
requirement was achieved via the chain specificity of elongases, with ELO1 converting C4 to 
C10-CoA, ELO2 extending C10 to C14-CoA, and ELO3 elongating C14 to C18-CoA (Figure 1.4B). 
The modular feature of the elongase system will allow the accessibility for chain length 
engineering. For example, if only ELO1 is included together with the cyanobacterial alkane 
biosynthetic pathway, C7 and C9 alkanes will be the major products, which are the same as 
gasoline. Compared with E. coli, S. cerevisiae possess the intracellular membrane network and 
may be a better host for functional reconstitution of the elongase system, whose components are 
membrane associated proteins.  
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1.4.3.4 Fermentative pathway via the reversed β-oxidation cycle 
Another special mechanism for de novo FAB is described in the mitochondria of Euglena 
gracilis (64, 65). So far, five different FAS systems have been reported for E. gracilis, two type 
II FAS localized in the chloroplasts, one type I FAS in the cytosol, one microsomal FAS, and 
one mitochondrial FAS. The mitochondrial system is involved in anaerobic wax ester 
fermentation. This fermentative pathway is malonyl-CoA (or ATP) independent, and has the 
ability to synthesize fatty acids directly from acetyl-CoA as both starter and extender units (64). 
In addition, NADH, instead of NADPH, serves as the reducing power (Figure 1.4C). Due to the 
ATP and ACP independence and CoA and NADH dependence, the fermentative FAB proceeds 
by reversal of the β-oxidation cycle. Compared with the canonical FAB, the fermentative 
pathway is advantageous for its energetic benefits of ATP independence and availability of CoA 
and NADH versus ACP and NADPH inside the cell (Figure 1.4C). Although genes coding the 
fermentative fatty acid synthesis pathway are not well characterized yet, the availability of the 
genome sequence of E. gracilis will definitely help to decipher the genetic code and benefit in 
designing efficient fatty acids derived biofuel synthetic pathways.  
The advantages of such system were demonstrated in recent reports to reverse the β-
oxidation cycles for efficient production of a series of fatty acids derived fuels and chemicals 
with different chain lengths (80, 81). By manipulating several global transcriptional regulators 
involved in fatty acids metabolism and carbon catabolite repression, all β-oxidation enzymes 
were constitutively expressed under anaerobic conditions even with the absence of fatty acids 
and presence of glucose (80). The resultant strain could reverse the β-oxidation cycle to produce 
n-butanol, long chain alcohols, and FFAs at much higher titers and yields than previous studies. 
Similarly, functional reversal of the β-oxidation cycle was achieved via a synthetic biology 
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approach by overexpressing all the structural genes of the β-oxidation cycle (81). Although the 
efficiency of the latter system was much lower than the former one, it represented a well-defined 
platform that could be readily transferred to other hosts, such as S. cerevisiae.  
1.5 Project Overview 
This thesis focuses on design and engineering of S. cerevisiae for efficient production of 
advanced biofuels and chemicals using metabolic engineering and synthetic biology approaches. 
One of the major challenges for high level production of value-added compounds other than 
ethanol in S. cerevisiae is the strong fluxes for ethanol formation even under aerobic conditions. 
Since many of the molecules of interest are derived from a few precursor metabolites, such as 
pyruvate, acetyl-CoA, and acyl-CoAs, this work aims to enhance the supply of these precursor 
metabolites in S. cerevisiae for efficient production of fuels and chemicals. Notably, the aims of 
this research can be integrated to construct a platform yeast cell factory, meaning that pyruvate is 
the direct precursor for acetyl-CoA generation and enhanced acetyl-CoA levels will provide a 
driving force for acyl-CoAs pool engineering. 
In the second chapter of this thesis, a pyruvate overproducing yeast strain was 
constructed by deleting three structural genes encoding pyruvate decarboxylases, PDC1, PDC5, 
and PDC6. The resulting Pdc- strain could not grow on glucose as the sole carbon source and 
required C2 (ethanol or acetate) supplementation to synthesize cytosolic acetyl-CoA (6, 15). 
Followed by overexpression of MTH1 and adaptive evolution, the resultant yeast grew on 
glucose as the sole carbon source with pyruvate as the major product. Interestingly, the evolved 
Pdc- strain was found to enable simultaneous consumption of glucose and galactose, the two 
major components of red algae. Subsequent introduction of a BDO biosynthetic pathway 
consisting of the cytosolic acetolactate synthase (cytoILV2), an acetolactate decarboxylase from 
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Bacillus subtilis (BsAlsD), and the endogenous butanediol dehydrogenase (BDH1) resulted in the 
production of enantiopure (2R,3R)-butanediol (R-BDO). A yield over 70% of the theoretical 
value was achieved in the shaker flask. Using fed-batch fermentation, more than 100 g/L R-BDO 
(1100 mM) was synthesized from a mixture of glucose and galactose. The high titer and yield of 
the enantiopure R-BDO produced and the ability to co-ferment glucose and galactose make our 
engineered yeast strain a superior host for cost-effective production of bio-based BDO from 
renewable resources. In addition, further metabolic engineering was applied to construct a yeast 
strain that produced high levels of enantiopure meso-BDO, whose further conversion to 2-
butanone (methyl ethyl ketone, MEK) and 2-butanol was also attempted. 
Chapter 3 and Chapter 4 mainly focus on acetyl-CoA pool engineering in S. cerevisiae. In 
Chapter 3, alternative acetyl-CoA routes were characterized using synthetic biology approaches. 
Acetyl-CoA biosynthetic pathways from E. coli and Yarrowia lipolytica were introduced and 
found to complement the growth of Acs- (acs1Δ acs2Δ) strain on glucose as the sole source. 
These results indicated that the heterologous pathways were functional in S. cerevisiae and could 
fully replace the endogenous ACS-dependent pathway for acetyl-CoA generation in the cytosol. 
By co-expressing PDH structural genes and a lipoate-protein ligase gene in the Acs- strain, 
growth rate similar to the wild-type yeast strain could be achieved, if lipoic acid was 
supplemented to the growth medium. To eliminate the lipoic acid auxotroph, de novo lipoic acid 
biosynthesis and lipoylation machinery were also reconstituted in the cytosol of yeast, together 
with the PDH structural components. Due to the difficulty in reconstituting a functional type II 
fatty acid synthase (FAS) system, a semi-synthetic lipoylation pathway was designed to provide 
the precursor (octanoyl-ACP) of protein lipoylation, by co-expressing the acyl-ACP synthetase 
from Vibrio harveyi (VhAasS), free ACP (cytoACP1), and ACP activator (cytoPPT2). The 
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growth complementation of the Acs- strain indicated that PDH was lipoylated by the semi-
synthetic pathway and functional, when octanoic acid was supplemented. Based on these results, 
a de novo biosynthetic lipoylation pathway was re-designed. 
In the 4th chapter of this thesis, the characterized acetyl-CoA biosynthetic pathways in the 
previous chapter were used for metabolic engineering applications, with the aim to design and 
construct acetyl-CoA overproducing yeast strains. Combined strategies of disrupting competing 
pathways and introducing heterologous biosynthetic pathways were carried out to enhance 
acetyl-CoA levels, with the CoA-dependent n-butanol production as the reporter.  By deleting 
ADH1, ADH4, GPD1, and GPD2 involved in ethanol and glycerol formation, the glycolytic flux 
was redirected towards this precursor metabolite, resulting in a 4 fold improvement in n-butanol 
production. Subsequent introduction of heterologous acetyl-CoA biosynthetic pathways, 
including pyruvate dehydrogenase (PDH), ATP-dependent citrate lyase (ACL), and PDH-bypass 
further increased the production of n-butanol. Although significant improvement of n-butanol 
production was achieved, the final titer was still much lower than that of ethanol. In addition, the 
resultant yeast strains suffered from accumulation of the toxic intermediates, acetaldehyde and 
acetate, as well as the residual production of ethanol as the major product due to the redundancy 
of ADHs in the S. cerevisiae genome (5, 30). Therefore, more efforts were put into the 
engineering of acetyl-CoA pools in the Pdc- strain (constructed in Chapter 2), where ethanol 
production was completely eliminated.  
 Different from pyruvate and acetyl-CoA as general precursor metabolites for a series of 
biological reactions, acyl-CoAs are the direct substrates of many fuels and chemicals, such as 
FFAs, FALs, and FAEEs. Thus, the goal of Chapter 5 is to construct a new biosynthesis platform 
for acyl-CoAs in S. cerevisiae based on the reversal of β-oxidation cycle. Compared with the 
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traditional FAB, which is ATP, ACP, and NADPH dependent, the reversed β-oxidation pathway 
is featured for its ATP and ACP independence and CoA and NADH dependence. The energetic 
benefits of ATP independence and availability of CoA and NADH versus ACP and NADPH 
confer advantages for efficient FAB. Recent reports to synthesize a series of chemicals and fuels 
were achieved by reversing β-oxidation cycles in E. coli via systems biology and synthetic 
biology approaches. The advantage of such system was demonstrated by the highest reported 
titer of fuels and chemicals produced. Taking the merits of yeast for biofuel production into 
account, we sought to develop a platform for advanced biofuel production based on the reversal 
of β-oxidation cycles in S. cerevisiae. Using synthetic biology approaches, reversed β-oxidation 
pathways were constructed and found to produce n-butanol, decanoic acid, and ethyl decanoate, 
indicating the functional reversal of β-oxidation cycle at least 4 turns.  
In the last chapter of this thesis, I focused on the development of new synthetic biology 
tools for engineering in S. cerevisiae. First of all, plasmids with different copy numbers (20-100 
copies per cell) were constructed by engineering the expression level of selection marker 
proteins, including both auxotrophic and dominant markers. More importantly, the copy number 
of the plasmids with engineered dominant markers (5-100 copies per cell) showed a positive 
correlation with the concentration of antibiotics supplemented to the growth media. Based on this 
finding, a new and simplest synthetic biology approach, named induced pathway optimization by 
antibiotic doses (iPOAD), to improve the performance of multi-gene biosynthetic pathways in S. 
cerevisiae was developed through modular optimization of multi-gene pathways by different 
combinations of antibiotic concentrations. To demonstrate this approach, iPOAD was applied to 
optimize the lycopene and n-butanol biosynthetic pathways, with the production of lycopene and 
n-butanol increased by 10- and 100-fold, respectively. Finally, the iPOAD optimized pathways 
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were integrated to the chromosome to increase the strain stability and eliminate the requirement 
of antibiotic supplementation, by taking advantage of the CRISPR-Cas9 technology for 
multiplex pathway integration. 
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1.7 Figures 
 
 
 Figure 1.1 Overview of yeast cell factory for high-level production of biofuels and chemicals 
via engineering the supply of precursor metabolites. A wide range of biofuels and value-added 
chemicals (shown in purple) are derived from a few precursor metabolites (shown in box), such 
as pyruvate, acetyl-CoA, and acyl-CoAs. Metabolic engineering targets to enhance precursor 
supply by decreasing or eliminating undesirable by-product formation are shown in red. 
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Figure 1.2 Control of yeast metabolism at the pyruvate branch point. The metabolic fluxes are 
mainly divided to fermentation (PDC for ethanol formation), respiration (PDH for TCA cycle), 
and gluconeogenesis (PYC). 
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Figure 1.3 Design and construction of acetyl-CoA overproducing yeast strains via synthetic 
biology and metabolic engineering strategies. The metabolic engineering targets (glycerol 
production and ethanol formation) to redirect the glycolytic fluxes to acetyl-CoA biosynthesis 
are shown in blue. Heterologous pathways, including pyruvate dehydrogenase (PDH), 
pyruvate:formate lyase (PFL), pyruvate:ferrodoxin oxidoreductase (PFO), pyruvate:NADP+ 
oxidoreductase (PNO), engineered PDH-bypass pathway, ATP-dependent citrate lyase (ACL), 
acetylating aldehyde dehydrogenase (A-ALD), pyruvate oxidase (POX) pathway, and 
phosphoketolase pathway (PK), which demonstrate higher efficiency and/or lower energy input 
requirement and may enhance the acetyl-CoA level in the cytosol of yeast, are shown in red. 
ACS: acetyl-CoA synthetase; PTA: phosphotransacetylase. 
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Figure 1.4 Overview of the general and two non-canonical schemes for fatty acid biosynthesis. 
Fatty acyl chain is extended by two carbon units after each elongation cycle including 
condensation, reduction, dehydration, and reduction. Different with the canonical scheme (A), 
which shows ATP/malonyl-CoA, ACP, and NADPH dependence, the elongase system (B) is 
ATP, CoA, and NADPH dependent (ACP independent), while the fermentative pathway (C) is 
CoA and NADH dependent (ATP, ACP, and NADPH independent).  
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Chapter 2 Pyruvate Pool Engineering and its Application in Efficient 
Production of 2,3-Butanediol  
2.1 Introduction  
As an end product of glycolysis and a central metabolite, pyruvate is the entry point of 
many cellular reactions and the branch point to control the flow of metabolic fluxes, especially 
for respiration and fermentation. Notably, several of the pyruvate involved reactions will lead to 
the synthesis of a wide range of fuel and chemical molecules, such as ethanol, iso-butanol, 2,3-
butanediol, lactate, malate, and succinate (1). In Saccharomyces cerevisiae, most of the 
glycolytic fluxes go through ethanol fermentation even under aerobic conditions, known as 
Crabtree effect. To redirect the metabolic flux from ethanol to the synthesis of other pyruvate 
derived products, pyruvate decarboxylases (PDCs), the branch point controlling enzymes to 
convert pyruvate to ethanol, were chosen as the target for metabolic engineering. The pyruvate 
decarboxylation activity results from the expression of three structural genes, PDC1, PDC5, and 
PDC6. However, the Pdc- strain (pdc1Δ pdc5Δ pdc6Δ) cannot grow on glucose as the sole 
carbon source and requires C2 (acetate or ethanol) supplementation to synthesize cytoplasmic 
acetyl-CoA (2), which makes it not ideal for industrial applications. Inverse metabolic 
engineering revealed that an internal deletion or a single mutation in the Mth1p coding sequence 
enabled the growth of the Pdc- strain on glucose (3). Mth1p is a transcription factor involved in 
glucose sensing which can inhibit the expression of hexose transporter genes (HXTs) to retard 
glucose uptake. The internal deletion increased the stability of Mth1p by removing the putative 
sites related to protein degradation (3), maintaining the intracellular glucose concentration to a 
low level and alleviating glucose repression.  
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To demonstrate the utility of the pyruvate overproducing yeast strain, biological 
production of 2,3-butanediol (BDO) was chosen as a case study. BDO is an important chemical 
with extensive industrial applications (4-6). Due to its low freezing point, BDO can be used as an 
antifreeze agent. A more important application is its potential to produce 1,3-butanediene, the 
monomer of synthetic rubber. In addition, BDO derivatives, such as methyl ethyl ketone and 
diacetyl, have found applications in fuel and food industries (4). BDO exists in three isomeric 
forms, (2S,3S)-butanediol (S-BDO), meso-butanediol (meso-BDO), and (2R,3R)-butanediol (R-
BDO). Many native hosts such as Klebsiella and Enterobacter species can accumulate BDO to 
high levels. Nevertheless, these native producers are pathogenic and synthesize a mixture of 
BDO stereoisomers, which prevents their commercial application (5). Therefore, the 
development of an industrially friendly host for biological production of BDO from renewable 
resources is highly desirable.  
 Recently, the use of marine macroalgae as a renewable feedstock has attracted increasing 
attention mainly because the lack of lignin makes the hydrolysis of seaweed rather simple and 
straightforward (7, 8). Among several different types of marine macroalgae, the red algae, such 
as Gelidium amansii, are known for high carbohydrate content and abundance in nature. The 
major carbohydrate components of red algae are glucose and galactose, which are mainly 
released from cellulose and agarose, respectively (9). To make a biorefinery process based on a 
renewable feedstock economically feasible, the producing host should be able to utilize all sugars 
efficiently and simultaneously (10). However, catabolite repression is widely found in 
microorganisms, which means glucose is the preferred carbon source and the utilization of other 
carbon sources will be inhibited until glucose is depleted. As a result, sequential utilization or 
diauxic growth is observed during mixed sugar fermentation, leading to low yield and 
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productivity of the final products (11). A cellobiose utilization pathway consisting of a 
cellodextrin transporter and a β-glucosidase was recently introduced into S. cerevisiae to 
overcome glucose repression (12, 13), which enabled the consumption of cellobiose and 
galactose simultaneously (14). Nevertheless, the cellobiose consumption rate is much slower 
than that of glucose even after intensive protein engineering and pathway optimization (15-19), 
making co-utilization of glucose and galactose still a preferred process.  
 In this chapter, a pyruvate overproducing S. cerevisiae strain was engineered and applied 
to produce BDO at high titer and yield. The growth of the Pdc- strain on glucose was restored 
through the introduction of the internal truncated MTH1 (MTH1T) followed by adaptive 
evolution. In the presence of an R-BDO biosynthetic pathway, efficient production of 
enantiopure R-BDO was achieved by completely eliminating ethanol production (Figure 2.1). In 
addition, an enantiopure meso-BDO producing yeast strain was constructed and the further 
conversion of meso-BDO to 2-butanol was attempted as well. Moreover, the engineered Pdc- 
strain showed glucose-derepressed properties, enabling co-fermentation of glucose and galactose. 
Notably, this strain has the potential to be further engineered for simultaneous utilization of a 
mixture of sugars derived from other renewable resources, such as brown macroalgae and 
cellulosic biomass, for cost-effective production of fuels and chemicals. Notably, a major part of 
this chapter is adapted from one of my research articles published in Metabolic Engineering (20). 
2.2 Results 
2.2.1 Construction of a pyruvate overproducing yeast strain 
To redirect the flux from ethanol to the desired products, the three structural genes 
encoding pyruvate decarboxylase, PDC1, PDC5, and PDC6, were knocked out consecutively 
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using the classic loxP-KanMX-loxP method (21). As expected, the Pdc- strain could not grow on 
hexose (such as glucose or galactose) as the sole carbon source, while the growth on ethanol was 
not affected. The introduction of an internal truncated MTH1 was reported to enable the growth 
of Pdc- strain on glucose (3, 22). Since the truncated Mth1p was claimed to have increased 
intracellular stability and abundance to better repress glucose uptake, a similar strategy was 
carried out by over-expressing MTH1 on a multi-copy plasmid in this study. Accordingly, the 
overexpression of either the full length MTH1 or the truncated version (MTH1T) could rescue the 
growth in the medium with low glucose concentration, where Pdc-/MTH1T grew slightly better 
(Figure 2.2A). These results in turn supported the assumption that the internal deletion in Mth1p 
alleviated glucose repression by interfering degradation of this transcriptional regulator protein.  
Nevertheless, the growth on higher sugar concentration was still poor. To make this strain 
more suitable for industrial applications, adaptive evolution was carried out to improve the cell 
growth rate on high glucose concentrations. After 10 rounds of serial transfer in SC medium 
containing 20 g/L glucose, three single clones, Pdc-/MTH1T-e1 (E10), Pdc-/MTH1T-e2, and 
Pdc-/MTH1T-e3, were isolated and the cell growth rate of the evolved strains was found to be 
significantly improved (Figure 2.2B).  
The whole genomes of the parent strain Pdc-/MTH1T and the three evolved strains were 
sequenced to identify the mutations that might be responsible for the improved growth on high 
concentrations of glucose. Approximately 30 SNVs unique to each of the evolved strain relative 
to the parent strain were identified, and a majority of the SNVs were intergenic (non-coding 
regions). Four out of five non-synonymous SNVs were shared by all the evolved strains (Table 
2.1). YHR094C (HXT1) encodes a low affinity hexose transporter induced only at high glucose 
concentration, and the loss of function would decrease the glucose uptake rate when its 
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concentration was high (23, 24). YML088W (UFO1) encodes a subunit of the SCF ubiquitin 
ligase complex responsible for the ubiquitination and subsequent degradation of regulatory and 
signaling proteins (25), and the inactivation might enhance the intracellular stability of Mth1p. 
The mechanisms of YER046W and YLR412C mutations in the evolved phenotype remain unclear. 
Notably, about 25% of the SNVs were found in the mitochondrial DNA (Table 2.1), which 
agreed with the requirement of mitochondrial activity for cell growth in the Pdc- strain. Since the 
phenotypes of the three evolved strains were similar, Pdc-/MTH1T-e1 (E10) was chosen for 
further studies. 
2.2.2 Simultaneous utilization of glucose and non-glucose carbon sources by the pyruvate 
overproducing yeast strain 
2.2.2.1 Co-utilization of glucose and galactose 
Since the overexpression of MTH1 released glucose repression, we hypothesized that this 
engineered strain (E10) might enable the utilization of glucose and non-glucose sugars 
simultaneously. To test this hypothesis, co-fermentation of glucose and galactose, which are the 
major carbohydrate components of red algae, was carried out. Although S. cerevisiae can 
consume galactose efficiently using the endogenous Leloir pathway, its utilization is completely 
inhibited with the presence of glucose in the wild-type strain (14). Interestingly, glucose and 
galactose were consumed simultaneously in the Pdc- strain, without any glucose repression 
phenomena observed (Figure 2.3A). 10 g/L glucose and 10 g/L galactose were metabolized in 20 
hours after inoculation, and the specific consumption rate of glucose and galactose was rather 
similar. 
 
41 
 
2.2.2.2 Co-utilization of glucose, galactose, and acetate 
Although acetate was not reported to be present in the hydrolysate of red seaweed at high 
concentration, acetic acid hydrolysis was proposed to be a better method than the traditional 
sulfuric acid hydrolytic technology (26, 27). Therefore, co-fermentation of glucose and galactose 
was also carried out in the presence of acetate. As shown in Figure 2.3B, all three components, 
10 g/L glucose, 10 g/L galactose, and 2 g/L acetate, were consumed nearly at the same rate. 
Interestingly, the sugar consumption rate was even higher with the presence of acetate, which 
may serve as a source to generate cytosolic acetyl-CoA for lipid and hormone biosynthesis. 
Similar growth and sugar consumption rates were observed if acetate is supplemented to the 
medium in the range of 5% to 15% of total sugar (data not shown). In other words, acetate, the 
previously reported inhibitor (28), can unexpectedly enhance the cell growth and sugar 
consumption rates of the engineered strain at the concentration range typically found in the 
biomass hydrolysate (5-10% of total sugar) (29). 
2.2.3 Co-fermentation of glucose and galactose to produce enantiopure (2R,3R)-butanediol at 
high titer and yield  
2.2.3.1 BDO production in the evolved Pdc- strain 
By introducing a BDO biosynthetic pathway into the Pdc- strain, glycolytic flux was 
redirected into BDO fermentation (Figure 2.1). Notably, better cell growth and enhanced sugar 
consumption were observed in the strain containing the BDO pathway (E10/RBDO) when the 
oxygen level was low (Figure 2.4). Particularly, BDO fermentation enabled the growth and sugar 
utilization of the engineered Pdc- strain under anaerobic condition. In other words, the 
introduction of the BDO pathway could partially restore anaerobic growth of the Pdc- yeast strain. 
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Acetoin was accumulated to a high level under aerobic condition, while glycerol was the major 
byproduct under anaerobic condition (Figure 2.4 and Table 2.2). In addition, higher BDO yield 
and productivity were achieved in YP medium than those in SC medium (Table 2.2). Therefore, 
subsequent BDO fermentation studies were carried out under oxygen-limited condition in a rich 
medium. In YP medium supplemented with 10 g/L glucose and 10 g/L galactose, the BDO yield 
was higher than 70% of the theoretical value (Figure 2.5A and Table 2.2).  
2.2.3.2 Chirality of BDO produced in the evolved Pdc- strain 
Interestingly, only one peak for BDO was detected in the HPLC chromatogram of the 
fermentation broth, indicating the production of enantiopure BDO in strain E10/RBDO. To 
determine the chirality of the BDO produced, enantiopure R-BDO and meso-BDO were loaded 
to the column. Using the HPLC method mentioned in Methods and Materials, acetoin, meso-
BDO and R-BDO can be separated (Figure 2.6A, B, C, and D). Owing to the stereospecificity of 
the yeast BDH, R-BDO and meso-BDO are synthesized from R-acetoin and S-acetoin, 
respectively (30). Thus, S-BDO was not included in this study. Accordingly, it could be 
concluded that only R-BDO, with R-acetoin as the intermediate, was synthesized in the Pdc- 
yeast strain (Figure 2.6E, F, and G). As a comparison, in our previous work to redirect the flux 
from ethanol to BDO by inactivating ADHs, a mixture of R-BDO and meso-BDO were produced 
at low yield and productivity, and the production of ethanol as the major product as well as the 
accumulation of acetate were observed (Figure 2.6H).  
2.2.3.3 Fed-batch fermentation to improve BDO production 
Similar to previously reported results (3, 22), sugar utilization was severely impaired 
after complete disruption of PDCs. Although the Pdc- strain was engineered for better growth on 
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glucose via introduction of MTH1 and adaptive evolution, the sugar consumption rate and BDO 
productivity were decreased at higher sugar concentrations (Table 2.3). Thus fed-batch 
fermentation was carried out to produce more BDO in a fermentor. By feeding the same 
concentration of glucose and galactose continuously to the bioreactor, BDO continued to be 
synthesized in up to 300 hours, and more than 100 g/L (roughly 1100 mM) was produced at the 
end of fermentation (Figure 2.5B). Moreover, the concentration of glucose and galactose in the 
bioreactor was maintained relatively constant, indicating the simultaneous utilization of glucose 
and galactose during the whole fermentation process. 
2.2.4 Construction of an enantiopure meso-BDO producer and its further conversion to MEK 
and 2-butanol 
2.2.4.1 Construction of an enantiopure meso-BDO producer 
Although R-BDO has advantages to be used as an anti-freeze agent, meso-BDO will be 
desired in some cases, such as the further biological conversion to methyl ethyl ketone (MEK, 
also known as 2-butanone) and 2-butanol. A meso-BDO biosynthetic pathway containing the 
acetolactate synthase gene from Bacillus licheniformis (BlBudB), the acetolactate decarboxylase 
gene from Enterobacter cloacae (EcBudA), and the meso-butanediol dehydrogenase gene from E. 
cloacae (EcBudC) was introduced into E10 to construct E10/mBDO, which produced a mixture 
of R-BDO and meso-BDO. This results indicated that the endogenous (2R,3R)-butanediol 
dehydrogenases (R-BDHs), encoded by BDH1 and BDH2, were sufficient for R-BDO production. 
Since only meso-BDO could be biologically converted to MEK and 2-butanol, both BDH1 and 
BDH2 were disrupted to construct PB, a strain deficient in both PDC and BDH activities. As 
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expected, introduction of the meso-BDO pathway into strain PB allowed the production of 
enantiopure meso-BDO (Figure 2.6I), which has not been reported in literature yet. 
2.2.4.2 Further conversion of meso-BDO to MEK and 2-butanol using B12-dependent diol 
dehydratases 
The production of MEK and 2-butanol from meso-BDO was first described in 
Lactobacilli and the biosynthetic pathway (Figure 2.7) was proposed as a two-step process, 
dehydration of meso-BDO to MEK by a diol dehydratase and hydrogenation of MEK to 2-
butanol by a secondary alcohol dehydrogenase (Sadh) (31). Later it was found that the diol 
dehydratase was induced by the presence of a diol substrate, such as 1,2-propanediol and meso-
BDO (32), indicating its involvement in the conversion of meso-BDO. Naturally, diol 
dehydratase is involved in fucose utilization with 1,2-propanediol as the native substrate (33), 
but has been widely used for 1,3-propanediol production from glycerol (34) (named glycerol 
dehydratase or GDH in this case). Although the activity towards BDO has been reported, the use 
of diol dehydratase for MEK and 2-butanol production is rather limited. Recently, MEK or 2-
butanol production from meso-BDO was reported in both Escherichia coli (35) and S. cerevisiae 
(36). In the former work, diol dehydratase (dhaB123, also named as pduCDE) and its reactivator 
genes (orfz and orfB2, also known as pduGH) from Klebsiella pneumonia were introduced into E. 
coli, which was able to produce 13.2 mg/L MEK from 5g/L meso-BDO. When the MEK 
pathway was combined with a meso-BDO pathway, the new strain could produce up to 151 mg/L 
MEK from glucose directly. In the latter work, a diol dehydratase and its reactivator genes 
(pdcCDEGH) from Lactobacillus reuterii and a Sadh gene from Gordonia sp. were introduced 
into a gpd1Δ gpd2Δ S. cerevisiae strain, which was able to produce small amount of MEK and 2-
butanol under anaerobic condition (36).  
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Based on these studies, diol dehydratase and its re-activator genes from both K. 
pneumonia (KpPduCDEGH) and L. reuterii (LrPduCDEGH) were cloned and tested in our 
enantiopure meso-BDO producing yeast. Since MEK is rather volatile, the production of 2-
butanol was attempted first, by co-expressing a Sadh. First of all, several endogenous ADHs and 
those from E. coli were tested for their activity to reduce MEK to 2-butanol. Unfortunately, 
except that Adh2p and FucO from E. coli showed little activity, none of these ADHs showed 
much higher activity than the control strain (Figure 2.8). Then a Sadh gene from Achromobacter 
xylosoxidans (AxSadh or AxBdh) was codon-optimized and cloned using two gBlocks. Indeed, 
significant MEK reducing activity was detected in AxBdh containing yeast strain, which was 
then used for following 2-butanol production studies. 
The production of 2-butanol was tested in the wild-type strains expressing either 
KpPduCDEGH or LrPduCDEGH with meso-BDO supplementation (butanediol to 2-butanol, 
B2B). Unfortunately, none of the recombinant yeast strains (CEN/KpB2B, CEN/LrB2B, and 
CEN/LrB2B2) could produce any detectable levels of MEK or 2-butanol. Since the intracellular 
concentration of meso-BDO for bioconversion might be limited by its uptake rate, especially 
when glucose was present, it was desirable to test the production of 2-butanol in the meso-BDO 
producing strains (glucose to 2-butanol, D2B). Since glycerol was produced at high levels under 
anaerobic condition and proposed to be a competitive inhibitor for BDO dehydration, GPD1 and 
GPD2 responsible for glycerol formation were further deleted in the iPB strain to construct iGPB 
(Figure 2.9), a strain deficient in GPD, PDC, and BDH activities. As expected, no glycerol 
formation was observed in the iGPB/mBDO strain, which still produced enantiopure meso-BDO 
(Figure 2.6J). Again, no MEK or 2-butanol could be detected in all recombinant yeast strains 
(iGPB/KpD2B and iGPB/LrD2B) under all tested conditions, probably due to a lack of 
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coenzyme B12 uptake system in S. cerevisiae, which was a required cofactor for diol 
dehydratases from both K. pneumonia and L. reuterii. Although the production of MEK and 2-
butanol using the diol dehydratase from L. reuterii was reported, the titer was extremely low and 
the identities of MEK or 2-butanol were not further confirmed by MS (36). 
2.2.4.3 B12-independent diol dehydratases for meso-BDO conversion  
Besides B12-dependent ones, there are also B12-independent diol dehydratases in nature, 
which are oxygen-sensitive and require S-adenosylmethionine (SAM) as a cofactor. Since SAM 
is a natural metabolite in S. cerevisiae and anaerobic fermentation is preferred for industrial 
applications, we then switched to B12-independent diol dehydratases. Although the importance 
for cost-effective production of 1,3-propanediol, there have been only a few B12-independent diol 
dehydratases reported so far, such as those from Clostridium butyricum (37), Clostridium 
phytofermentans (38), and Roseburia inulinivorans (33). In this work, genes encoding the diol 
dehydratase (RiGdhA) and its activator (RiGdhB) from R. inulinivorans were codon-optimized 
for expression in S. cerevisiae and cloned into high copy number plasmids with HIS3 and LEU2 
selection marker, respectively, by DNA2.0. Unfortunately, there was still no production of MEK 
and 2-butanol either in the wild-type strain with meso-BDO supplementation (CEN/RiB2B) or 
the meso-BDO producing strain (iGPB/RiD2B).  
2.2.4.4 Diol dehydratase-mediated n-propanol production from 1,2-propanediol 
As mentioned above, 1,2-propanediol is the natural substrate of diol dehydratases. To 
confirm that diol dehydratases could be functionally expressed in S. cerevisiae, 1,2-propanediol 
was fed to the growth medium instead of meso-BDO, which might result in the production of n-
propanol. However, no production of n-propanol was detected. Although vacuum and nitrogen 
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purge was repeated several cycles, the presence of small amount of oxygen in the medium could 
still completely abolish the B12-independent diol dehydratase activities. Therefore, high cell 
density fermentation was used for n-propanol production, assuming that small amount of oxygen 
could be consumed by yeast metabolism. Interestingly, a small peak with the same retention time 
as n-propanol standard was detected by GC-MS (Figure 2.10). Although the MS fragmentation 
patterns were not exactly the same, all characteristic MS fragments of n-propanol (m/z 31, 42, 
and 59) were identified. The peak was so small that the additional noisy fragments might result 
from the background. Although we tried to optimize the GC-MS program, the separation of the 
“n-propanol peak” and the “background peak” was not successful. In addition, the area of this 
peak was positively correlated with the exogenously added SAM (Figure 2.10F), a cofactor of 
B12-independent diol dehydratase, further confirming that it was indeed the n-propanol peak. 
Considering the low production of n-propanol and the much lower activity of diol dehydratase 
towards meso-BDO, the conversion of meso-BDO to MEK and 2-butanol was not further 
attempted. 
2.3 Discussions 
Unlike many BDO native producers, S. cerevisiae is an industrially friendly cell factory 
for the production of bio-based fuels and chemicals (39). During normal alcoholic fermentation, 
several endogenous pathways in S. cerevisiae, mainly the PDC-dependent pathway and 
acetolactate synthase-dependent pathway, lead to the formation of a small amount of BDO (30). 
Although at a low concentration around 1 mM, the BDO produced by the wild-type yeast 
constitutes a mixture of 67% R-BDO and 33% meso-BDO, derived from (3R)-acetoin and (3S)-
acetoin, respectively (30). Metabolic engineering, which has been widely used to redirect the 
metabolic flux to the desired products in various hosts (40-43), was also applied to the 
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production of BDO in S. cerevisiae. By disrupting the pyruvate decarboxylases and introducing a 
BDO biosynthetic pathway (Figure 2.1), BDO was produced at high titer and yield. Moreover, 
only one enantiopure form (R-BDO) was produced in the Pdc- strain (Figure 2.6), indicating the 
important role of PDCs in the biosynthesis of meso-BDO. For certain applications where 
enantiopure BDO is needed, e.g. the use of R-BDO as an antifreeze agent, the yeast strain 
constructed in this study should be advantageous compared to other reported engineered yeast 
strains and the native BDO producers. 
 Many renewable feedstocks contain different sugar components, such as glucose and 
xylose from cellulosic biomass, glucose and galactose from red algae, and glucose and mannitol 
from brown algae. To increase the productivity of the fermentation process, it is desirable to 
engineer a yeast strain capable of consuming a mixture of sugars simultaneously. Although 
intensive studies have contributed to understanding the mechanisms of catabolite repression, the 
construction of a glucose-derepressed yeast strain has never been achieved, probably due to the 
complex regulation of the glucose signaling network (11, 44). In the present work, the Pdc- strain 
was found to enable co-utilization of glucose and galactose, with or without the presence of 
acetate (Figure 2.3). Therefore, the constructed strain would be an ideal host to produce bio-
based fuels and chemicals from red algae-derived sugar mixtures. To use lignocellulose as a 
feedstock, a yeast strain that can consume glucose and xylose efficiently and simultaneously 
needs to be engineered, which is a more challenging task. However, the COMPACTER method 
(15) developed in our lab, which allowed rapid optimization of host-specific metabolic pathways 
by fine-tuning the expression levels of multiple genes simultaneously, can be applied to construct 
an efficient xylose utilization pathway in the Pdc- strain. Simultaneous utilization of glucose and 
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xylose may be achieved in the glucose derepressed host with an optimized xylose utilization 
pathway. 
 Due to the net generation of one NADH molecule in BDO biosynthesis from glucose, 
glycerol is produced as the major byproduct (Figures 2.1 and 2.6E), especially under low oxygen 
level or anaerobic conditions. Although the deletion of GPD1 and GPD2 was able to completely 
abolish glycerol production, the host was reported to have no growth under anaerobic conditions 
because of the lack of an electron sink to re-oxidize the generated NADH molecule (45). 
Recently, acetate was proposed to be used as an electron sink in S. cerevisiae by introducing the 
E. coli mhpF gene, an acetylating NAD+-dependent acetaldehyde dehydrogenase, which converts 
acetyl-CoA to acetaldehyde then to ethanol by the endogenous ADHs (45). Compared with the 
glycerol sink, there are several advantages to use acetate as the electron acceptor. First of all, 
acetate is a cheap substrate and widely existed in biomass hydrolysates (28, 29). In addition, two 
NADH molecules will be re-oxidized per ethanol molecule produced from acetate, while only 
one NADH molecule will be re-oxidized per glycerol molecule produced from glucose.  
 Another strategy to overcome the glycerol accumulation issue is to further convert meso-
BDO to 2-butanol, whose biosynthesis from glucose is NADH neutral. Another advantage of 2-
butanol production over BDO production is the lower cost of separation from fermentation broth. 
Since BDO is miscible with water, the separation cost is one of the major challenges that hinder 
the commercialization of Bio-BDO (5). Although diol dehydratases could be functionally 
expressed in S. cerevisiae when 1,2-propanediol was supplemented as the substrate, neither B12-
dependent nor B12-independent diol dehydratases showed any activity towards meso-BDO and 
enabled 2-butanol production. As for the B12-dependent system, the capability of coenzyme B12 
uptake by yeast cells together with its high cost were the major concerns, and the construction of 
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a B12 producing yeast strain was rather desirable. As for the B12-independent system, the diol 
dehydratases were extremely sensitive to oxygen, and the whole fermentation process should be 
performed under strictly anaerobic condition. Because meso-BDO is not the natural substrate for 
diol dehydratases, protein engineering (46) must be performed for both B12-dependent and B12-
independent diol dehydratases to increase their activity and/or specificity towards BDO. 
2.4 Conclusions and Perspectives 
In summary, a pyruvate overproducing yeast strain was constructed by complete 
disruption of pyruvate decarboxylase activity, and the growth on glucose was restored by the 
overexpression of MTH1 followed by adaptive evolution. Due to the glucose-derepressed 
properties, the engineered strain enabled co-fermentation of glucose and non-glucose carbon 
sources, such as galactose and galactose/acetate. After the introduction of an R-BDO 
biosynthetic pathway, enantiopure R-BDO was produced at high titer and yield from a mixture of 
glucose and galactose. By feeding glucose and galactose continuously, more than 100 g/L R-
BDO was produced, which is the highest BDO titer ever reported in yeast. Future work will 
focus on engineering of the yeast strains to simultaneously consume sugar mixtures from other 
renewable resources, such as glucose and xylose from lignocellulosic biomass. Similarly, a yeast 
strain that could produce enantiopure meso-BDO was also constructed and its further conversion 
to MEK and 2-butanol was attempted. Currently, the diol dehydratase catalyzed reaction was the 
rate-limiting step for the production of MEK and 2-butanol, which required the involvement of 
protein engineering to improve their activity and/or specificity towards BDO. In addition, the 
pyruvate overproducing strain constructed will be a good start point for acetyl-CoA pool 
engineering, another important precursor metabolite that can be generated from pyruvate.  
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 2.5 Materials and Methods 
2.5.1 Strains, media, and cultivation conditions 
All engineered strains used in this chapter are based on S. cerevisiae CEN.PK2-1C strain. 
E. coli strain DH5α was used to maintain and amplify plasmids. Yeast strains were cultivated in 
complex medium consisting of 2% peptone and 1% yeast extract supplemented with the 
corresponding carbon source, such as glucose (YPD), galactose (YPG), and/or ethanol (YPE). 
Recombinant strains were grown on complete synthetic (SC) medium consisting of 0.17% yeast 
nitrogen base, 0.5% ammonium sulfate, and the appropriate amino acid drop out mix (CSM-HIS-
TRP-LEU-URA, MP Biomedicals, Solon, OH), supplemented with the corresponding carbon 
source. E. coli strains were cultured at 37oC in Luria-Bertani broth containing 100 μg/mL 
ampicillin. S. cerevisiae strains were cultured at 30oC and 250 rpm for aerobic growth, and 30oC 
and 100 rpm for oxygen limited fermentation. For anaerobic fermentation, anaerobic culture 
tubes with butyl rubber stoppers and aluminum seals (Chemglass Life Sciences, Vineland, NJ) 
were vacuumed and purged with nitrogen to remove the residual oxygen and 480 mg/L Tween-
80 and 10 mg/L ergosterol were supplemented as anaerobic growth factors. Coenzyme B12 was 
supplemented at a final concentration of 0.5 g/L when B12-dependent diol dehydratases were 
included. All restriction enzymes, Q5 polymerase, and the E. coli - S. cerevisiae shuttle plasmids 
were purchased from New England Biolabs (Ipswich, MA). All chemicals were purchased from 
either Sigma-Aldrich or Fisher Scientific. 
2.5.2 DNA manipulation 
The yeast homologous recombination based DNA assembler method (47) was used to 
construct the recombinant plasmids used in this chapter, which were listed in Table 2.4. Briefly, 
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DNA fragments sharing homologous regions to adjacent DNA fragments were generated via 
polymerase chain reaction (PCR). The desired DNA fragments were purified with a QIAquick 
Gel Extraction Kit (Qiagen, Valencia, CA) and co-transformed into S. cerevisiae along with the 
linearized backbone to assemble several elements in a single step manner. The MTH1 gene was 
amplified from the genomic DNA of CEN.PK2-1C strain. To construct the internal truncated 
MTH1 (MTH1T) (3), the N-terminal fragment (1-168 bp) and C-terminal fragment (394-1302 bp) 
were amplified separately and pieced together using the DNA assembler method. For the 
construction of the R-BDO pathway (Figure 2.1), the endogenous acetolactate synthase gene 
without the mitochondrial targeting sequence (cytoILV2, 271-2064 bp, predicted by MITOPROT 
(48)), the Bacillus subtilis acetolactate decarboxylase gene (BsAlsD, NCBI Accession No. 
NP_391481.1), and the endogenous butanediol dehydrogenase (BDH1) gene were PCR-
amplified from their corresponding genomic DNAs and assembled into the 2μ multiple copy 
plasmid, pRS426. Wizard Genomic DNA Purification Kit (Promega, Madison, WI) was used to 
extract the genomic DNA from both bacteria and yeast, according to the manufacturer’s protocol. 
To confirm the correct clones, yeast plasmids were isolated using a Zymoprep Yeast Plasmid 
Miniprep II Kit (Zymo Research, Irvine, CA) and re-transformed into E. coli. Plasmids were 
isolated using a QIAprep Spin Miniprep Kit (Qiagen) and confirmed using both diagnostic PCR 
and restriction digestion. A meso-BDO biosynthetic pathway (pRS416-mBDO), containing the 
acetolactate synthase gene from Bacillus licheniformis (BlBudB), the acetolactate decarboxylase 
gene from Enterobacter cloacae (EcBudA), and the meso-butanediol dehydrogenase gene from E. 
cloacae (EcBudC), was kindly provided by Dr. Mingzi Zhang (Metabolic Engineering Research 
Lab, A*STAR, Singapore). Plasmids pRS313-LrPduCDE, pUC57-LrPduGH, and pRS315-Sadh 
were a gift from Prof. Christer Larsson from Chalmers University of Technology (Gothenburg, 
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Sweden) (36). TDH3p(GPDp)-PduG PduH-ADH1t cassette in pUC57-LrPduGH, an integrative 
plasmid, was sub-cloned into pRS414 and pRS415, respectively, at the SalI and SacI sites. Yeast 
strains were transformed using the LiAc/SS carrier DNA/PEG method (49), and transformants 
were selected on the appropriate SC plates. 
2.5.3 Strain construction 
All the strains used in this chapter were listed in Table 2.5. For the construction of Pdc- 
strain, the loxP-KanMX-loxP method (21) was used for successive deletion of all three structural 
genes in the order of PDC5-PDC6-PDC1. The resultant Pdc- strain was maintained in medium 
with ethanol as the sole carbon source. After restoring the growth on glucose, the MTH1 
containing strains (Pdc-/MTH1 and Pdc-/MTH1T) were maintained on low concentration glucose 
(5 g/L). To make the strain more suitable for practical use, adaptive evolution by serial transfer 
in 20 g/L glucose was carried out to improve the glucose consumption rate. The resultant strain 
(E10) was transformed with an R-BDO or meso-BDO biosynthetic pathway to construct strain 
E10/RBDO and E10/mBDO, respectively. BDH1 and BDH2 were knocked out in E10 strain 
using the same loxP-KanMX-loxP method (21) to construct strain PB. Further disruption of 
GPD1 and GPD2 was achieved using HI-CRISPR system (50) developed in our group in a 
single step, by introducing an 8bp deletion into the desired coding sequences (392-399 deletion 
in GPD1 locus and 601-608 deletion in GPD2 locus). The introduction of the desired deletion in 
both loci of strain iGPB was confirmed by DNA sequencing (Figure 2.9). 
2.5.4 Flask and fed-batch fermentation 
The recombinant yeast strains were pre-cultured in the appropriate SC medium, washed 
twice in ddH2O, and then inoculated into YP medium supplemented with glucose and galactose 
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with an initial OD of 5, unless specified otherwise. To test the effect of acetate on the growth and 
product formation in the engineered Pdc- strain, acetate was added into the medium at the 
concentration of 5% (16.7 mM), 10% (33.3 mM), or 15% (50 mM) of total sugar, respectively. 
For the engineered strains without the heterologous pathway, cells were cultured under aerobic 
condition, while oxygen limited condition was used for BDO fermentation. 
 Fed-batch fermentation was carried out in the Multifors Multiple Benchtop Bioreactors 
(Infors-HT, Bottmingen, Switzerland) with 0.5 L working volume. The temperature was 
controlled at 30oC and the pH of the culture media was maintained at 5.5 by controlled addition 
of 4N NaOH or 4N H2SO4. The dissolved oxygen concentration in the bioreactor was maintained 
at around 10-15% by controlling the air flow rate and agitation speed. Strain E10/RBDO was 
pre-cultured in SC-His-Ura medium and inoculated into 500 mL sterile YP medium 
supplemented with 10 g/L glucose and 10 g/L galactose with an initial OD of 5. After 16 hours 
of fermentation, glucose and galactose were fed simultaneously from sugar mixture stock 
containing 200 g/L glucose and 200 g/L galactose. Sugar feeding rate was micro-adjusted based 
on the sugar consumption rate, maintaining the sugar concentration in the fermentor at around 10 
g/L. 
2.5.5 Analytical methods  
Cell growth was determined by measuring the absorbance at 600 nm using a Biotek 
Synergy 2 Multi-Mode Microplate Reader (Winooski, VT). For flask fermentation, samples were 
taken every 4 hours after inoculation. For fed-batch fermentation, samples were taken every 2-4 
hours in the early stage to monitor sugar concentration in the fermentor and every 12 hours after 
reaching steady state. Extracellular metabolites, including glucose, galactose, acetate, and 
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butanediol, were detected and quantified using Shimadzu HPLC (Columbia, MD) equipped with 
an Aminex HPX-87H column (Bio-Rad, Hercules, CA) and Shimadzu RID-10A refractive index 
detector. The column was kept at 65oC and 0.5 mM sulfuric acid solution was used as a mobile 
phase with a constant flow rate of 0.6 mL/min. Each data point represents the mean of at least 
duplicate samples. 
2-Butanol was analyzed by a Shimadzu GCMS-QP2010 Plus GC-MS equipped with an 
AOC-20i+s autosampler (Shimadzu Inc., Columbia, MD) and a DB-Wax column with a 0.25 μm 
film thickness, 0.25 mm diameter, and 30 m length (Agilent Inc., Palo Alto, CA). Samples were 
extracted using the same volume of ethyl acetate containing 10 mg/L n-butanol as the internal 
standard and the top layer was analyzed by GC-MS. Injection port and interface temperature was 
set at 250 ºC, and the ion source was set to 230 ºC. The helium carrier gas was set at a constant 
flow rate of 2 mL/min. The oven temperature program was set as the following: a) hold at 50ºC 
for 3 min, b) increase at the rate of 15ºC min-1 to 120ºC, c) increase at the rate of 50ºC min-1 to 
230ºC, d) and then hold at 230ºC for additional 2.5 min. The mass spectrometer was operated 
with a solvent cut time of 1.5 min, an event time of 0.2 s, a scan speed of 2500 from the range of 
30-500 mass to charge (m/z) ratio.  
2.5.6 Genome sequencing and single nucleotide variation (SNV) identification 
Next generation sequencing of the whole genomes of Pdc-/MTH1T, Pdc-/MTH1T-e1 
(E10), Pdc-/MTH1T-e2, and Pdc-/MTH1T-e3 was performed at the Roy J. Carver Biotechnology 
Center at the University of Illinois at Urbana-Champaign. The barcoded shotgun genomic DNA 
libraries were constructed with the TruSeq DNA Sample Preparation Kit (Illumina, San Diego, 
CA), and then quantitated by fluorometry (Qubit), a bioanalyzer (Agilent), and quantitative PCR. 
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Then the libraries were sequenced for 101 cycles from one end of the fragments (single-reads) 
for 100 nt on an Illumina HiSeq2000 using a TruSeq SBS Sequencing Kit version 3. FASTQ 
files were generated with Casava 1.8.3. 
Each sample yielded approximately 25 million reads, and the average quality scores per 
base were higher than 30. High throughout sequencing data were analyzed using CLC Genomics 
Workbench version 6.5.1. Reads were trimmed based on quality scores, which were then mapped 
to an S288C reference sequence. SNVs were identified using the Probabilistic Variant Detection 
function. Then the Filter against Control Reads tool was used to remove the variants found in 
Pdc-/MTH1T, generating the SNVs unique to Pdc-/MTH1T-e1 (E10), Pdc-/MTH1T-e2, and Pdc-
/MTH1T-e3. 
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2.7 Tables 
Table 2.1 SNVs identified in the coding sequences (CDS) of evolved strains as compared with 
Pdc-/MTH1T 
 
Non-synonymous SNVs in CDS Pdc-/MTH1T-e1 Pdc-/MTH1T-e2 Pdc-/MTH1T-e3 
YER046W (SPO73) Frame shift after Thr13 
YHR094C (HXT1) Frame shift after Pro420 
YLR412C Frame shift after Gly46 
YML088W (UFO1) Stop codon after Glu600 
YNR038W (DBP6) - - Leu605Ser 
SNVs in CDS 4 4 5 
SNVs in mitochondrial DNA 8 7 8 
Total SNVs 32 34 38 
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Table 2.2 Effect of oxygen levels on the yield and productivity of R-BDO and the major by-
products, acetoin and glycerol. The concentrations of glucose and galactose were maintained at 
the same initial level. The fermentation of E10/RBDO was carried out in SC or YP medium 
supplemented with 10 g/L glucose 10 g/L galactose under aerobic, oxygen-limited, and 
anaerobic conditions. For oxygen limited condition, different amounts of liquid media, 5 mL 
(10%v/v), 10mL (20% v/v), 15 mL (30% v/v), and 20 mL (40% v/v), were added to 50 mL 
unbaffled shake flasks. 
 
BDO Yield 
(mM/mM Sugar) 
SC YP 
R-BDO Acetoin Glycerol  R-BDO Acetoin Glycerol 
Aerobic 0.21±0.01 0.26±0.01 0±0  0.20±0.05 0.26±0.01 0.03±0.00 
 
Oxygen
-limited 
10% (v/v) N.D. N.D. N.D.  0.56±0.03 0.16±0.01 0.03±0.00 
20% (v/v) 0.60±0.01 0.02±0.00 0.27±0.02  0.71±0.05 0.02±0.00 0.12±0.01 
30% (v/v) N.D. N.D. N.D.  0.71±0.07 0±0 0.24±0.03 
40% (v/v) N.D. N.D. N.D.  0.65±0.09 0±0 0.31±0.04 
 
Anaerobic 0.46±0.01 0±0 0.42±0.01  0.58±0.01 0±0 0.61±0.01 
 
 
BDO Productivity 
(mM/h) 
SC YP 
R-BDO Acetoin Glycerol  R-BDO Acetoin Glycerol 
Aerobic 1.68±0.03 1.61±0.01 0±0  1.48±0.03 1.96±0.02 0.19±0.02 
Oxygen
-limited  
10% (v/v) N.D. N.D. N.D.  3.70±0.12 1.05±0.07 0.18±0.03 
20% (v/v) 4.00±0.51 0.08±0.00 2.09±0.01  4.59±0.02 0.13±0.00 0.82±0.02 
30% (v/v) N.D. N.D. N.D.  4.51±0.04 0±0 1.54±0.01 
40% (v/v) N.D. N.D. N.D.  4.09±0.17 0±0 1.97±0.06 
Anaerobic 0.54±0.04 0±0 0.49±0.02  1.71±0.03 0±0 1.75±0.02 
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Table 2.3 BDO yield and productivity using different sugar concentrations. The concentrations 
of glucose and galactose were maintained at the same initial level. The fermentation was carried 
out under oxygen-limited conditions. 
 
Sugar Concentration (g/L) BDO Productivity 
(mM/h) 
BDO Yield (mM 
BDO/mM Total Sugar) Glucose  Galactose 
10 10 4.63±0.15 0.67±0.02 
20 20 4.19±0.08 0.71±0.01 
30 30 3.80±0.17 0.77±0.03 
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Table 2.4 Plasmids constructed in this chapter 
 
Plasmid Features 
pRS414 CEN/ARS-based single copy plasmid with TRP1 marker 
pRS415 CEN/ARS-based single copy plasmid with LEU2 marker 
pRS423 2µ-based multi-copy plasmid with HIS3 marker 
pRS424 2µ-based multi-copy plasmid with TRP1 marker 
pRS425 2µ-based multi-copy plasmid with LEU2 marker 
pRS426 2µ-based multi-copy plasmid with URA3 marker 
pUG6 Template for loxP-KanMX-loxP gene deletion cassette 
pSH47 GAL1p-Cre with URA3 marker 
MTH1 pRS423-PGK1p-MTH1-HXT7t 
MTH1T pRS423-PGK1p-MTH1T-HXT7t 
RBDO pRS426-ENO2p-cytoILV2-PGK1t-TPI1p-BsAlsD-TPI1t-TEF1p-
BDH1-TEF1t 
mBDO pRS416-ADH1p-BlBudB-ADH1t-PGK1p-EcBudA-CYC1t-PYK1p-
EcBudC-ADH2t 
RiGdhA pD1237-GPDp-RiGdhA-CYC1t (2µ, HIS3) 
RiGdhB pD1211-TEF1p-RiGdhB-CYC1t (2µ, LEU2) 
KpPduCDE pRS426-TPI1p-KpPduC-TPI1t-TEF1p-KpPduD-TEF1t-PGK1p-
KpPduE -HXT7t 
KpPduGH pRS426-GPDp-KpPduG-CYC1t-ENO2p-KpPduH-PGK1t 
LrPduCDE  pRS313-TDH3p(GPDp)-LrPduC PduD PduE-RPL18Bt-RPS19Bp-
TEV-ADH1t (36) 
pUC57-LrPduGH  pUC57-TDH3p(GPDp)-LrPduG PduH-ADH1t (36) 
pRS414-LrPduGH pRS414-TDH3p(GPDp)-PduG PduH-ADH1t 
pRS415-LrPduGH pRS415-TDH3p(GPDp)-PduG PduH-ADH1t 
GoSadh  pRS315-TDH3p(GPDp)-GoSadh-ADH1t (36) 
AxSadh pRS424-TEF1p-AxSadh-TEF1t 
ADH4 pRS425-TEF1p-ADH4-TEF1t 
ADH5 pRS425-TEF1p-ADH5-TEF1t 
ADH6 pRS425-TEF1p-ADH6-TEF1t 
ADH7 pRS425-TEF1p-ADH7-TEF1t 
YGL157W pRS425-TEF1p-YGL157W-TEF1t 
SOR1 pRS425-TEF1p-SOR1-TEF1t 
XYL2 pRS425-TEF1p-XYL2-TEF1t 
SFA1 pRS425-TEF1p-SFA1-TEF1t 
BDH1 pRS425-TEF1p-BDH1-TEF1t 
BDH2 pRS425-TEF1p-BDH2-TEF1t 
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Table 2.4 (Cont.) 
  
Plasmid Features 
EcFucO pRS425-TEF1p-EcFucO-TEF1t 
EcEutG pRS425-TEF1p-EcEutG-TEF1t 
EcYiaY pRS425-TEF1p-EcYiaY-TEF1t 
EcYqhD pRS425-TEF1p-EcYqhD-TEF1t 
CaBdhB pRS425-TEF1p-CaBdhB -TEF1t 
ADH2 pRS425-TEF1p-ADH2-TEF1t 
ADH4s pRS425-TEF1p-ADH4s-TEF1t 
pCRCT-GPD1a-GPD2b GPD1 and GPD2 crRNAs cloned into pCRCT (50) 
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Table 2.5 Strains used in this chapter 
 
Strain Phenotype 
CEN.PK2-1C MATa ura3-52 trp1-289 leu2-3,112 his3Δ1 MAL2-8C SUC2 
Pdc- CEN.PK2-1C pdc5∆::loxP pdc6∆::loxP pdc1∆::KanMX 
Pdc-/MTH1 Pdc-/ pRS423-MTH1 
Pdc-/MTH1T Pdc-/ pRS423-MTH1T 
E10 Pdc-/MTH1T, evolved for better growth on glucose 
E10/RBDO E10/pRS426-RBDO 
E10/mBDO E10/pRS416-mBDO 
PB E10 bdh1-bdh2∆::KanMX 
PB/mBDO PB/pRS416-mBDO 
iPdc- Pdc- MTH1::MTH1T 
iE11 iPdc- evolved for better growth on glucose 
iPB iE11 bdh1-bdh2∆::KanMX 
iGPB iPB gpd1∆-gpd2∆ 
CEN/KpB2B CEN.PK2-1C/KpPduCDE+ AxSadh+ KpPduGH 
CEN/LrB2B CEN.PK2-1C/LrPduCDE+ AxSadh+ LrPduGH 
CEN/LrB2B2 CEN.PK2-1C/LrPduCDE+pRS414-LrPduGH+ GoSadh 
CEN/RiB2B CEN.PK2-1C/RiGdhA+ AxSadh+ RiGdhB 
iGPB/KpD2B iGPB/KpPduCDE+ AxSadh+ KpPduGH+ mBDO 
iGPB/LrD2B iGPB/LrPduCDE+ AxSadh+pRS415-LrPduGH+ mBDO 
iGPB/RiD2B iGPB/RiGdhA+ AxSadh+ RiGdhB+ mBDO 
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2.8 Figures 
 
 
Figure 2.1 Metabolic pathway for the synthesis of (2R,3R)-butanediol in the engineered S. 
cerevisiae strain. The dashed arrows indicate several steps of enzymatic reactions. Genes in red 
represent the endogenous genes, which lead to the synthesis of major metabolites, such as 
ethanol and glycerol, and are targets to be inactivated to redirect the fluxes to BDO. As for the 
overexpressed BDO pathway, genes in green are cloned from S. cerevisiae, while the gene in 
blue indicates the heterologous AlsD gene. 
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Figure 2.2 Construction of a Pdc- strain that can grow on glucose as the sole carbon source. A) 
Restoring the growth on glucose via the introduction of MTH1 and MTH1T. B) Engineering 
better growth of strain Pdc-/MTH1T on glucose via adaptive evolution. Yeast cells were pre-
cultured on ethanol, inoculated into SC medium containing either 5 g/L (A) or 20 g/L (B) 
glucose with an initial OD of 0.05, and cultured under aerobic condition. 
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Figure 2.3 Co-utilization of glucose and non-glucose carbon sources in the engineered Pdc- yeast 
strain. A) Simultaneous consumption of glucose and galactose. B) Co-utilization of glucose and 
galactose with the presence of acetate at the concentration of 10% of total sugar.  
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Figure 2.4 Comparison of the growth and sugar consumption of the evolved Pdc- strain with or 
without the BDO pathway. The wild-type strain (CEN.PK2), Pdc-/MTH1T strain, evolved Pdc-
/MTH1T strain (E10), and the evolved strain with the BDO pathway (E10/RBDO) were cultured 
under aerobic (A), oxygen-limited (B), and anaerobic conditions (C). The amount of glucose 
consumed at the end of fermentation under these conditions was also compared (D). Yeast cells 
were pre-cultured on ethanol and inoculated into YPD media with an initial OD around 0.05. 
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Figure 2.5 Co-fermentation of glucose and galactose for BDO production. A) BDO fermentation 
profile in shake flask with 10 g/L glucose and galactose under oxygen-limited condition. B) Fed-
batch fermentation for BDO production. A mixture of sugars consisting of the same 
concentration of glucose and galactose was continuously fed to the bioreactor.  
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Figure 2.6 Separation of acetoin, meso-BDO and R-BDO via HPLC and BDO fermentation 
profiles. Since the yeast BDH is R-specific, which reduces R-acetoin and S-acetoin 
stereospecifically to R-BDO and meso-BDO, respectively, S-BDO is not included in this study.  
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Figure 2.7 Diol dehydratase mediated 1,3-propanediol, 1-propanol, and 2-butanol production, 
with glycerol, 1,2-propanediol, and meso-BDO as the substrate, respectively. An ADH should 
also be included to reduce the corresponding aldehydes, with secondary alcohol dehydrogenase 
(Sadh) for 2-butanol production. 
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Figure 2.8 Secondary alcohol dehydrogenase (Sadh) or MEK reductase (MEKR) assay with 
MEK as the substrate. Several endogenous ADHs and ADHs from E. coli and Achromobacter 
xylosoxidans were cloned and transformed into CEN.PK2 strain to test the MEKR activities.  
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Figure 2.9 Confirmation of the disruption of both GPD1 (A) and GPD2 (B) using the HI-
CRISPR system at the desired loci by DNA sequencing. The target sequences were marked with 
arrows, the corresponding PAMs were circled, and the introduced stop codons in the disrupted 
genes were boxed. 
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Figure 2.10 Detection of n-propanol by GC-MS (A, B, C, and D) and the effect of exogenous 
SAM supplementation on n-propanol production (E). GC chromatograph of fermentation profiles 
of CEN.PK2 and CEN/RiB2B with the supplementation of 1,2-propanediol using high cell 
density fermentation under anaerobic condition. MS fragmentation pattern of target (C) and n-
propanol standard (D) were compared.  
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Chapter 3 Acetyl-CoA Pool Engineering via Synthetic Biology (I)  
3.1 Introduction 
Besides its significant role as a building block in cellular metabolism, acetyl-CoA is the 
key precursor for biological synthesis of a variety of fuel and chemical molecules, such as n-
butanol, fatty acid ethyl esters (FAEEs), alkanes, polyhydroxybutyrate (PHB), and isoprenoid-
derived drugs (1-5). However, S. cerevisiae is not optimized to synthesize acetyl-CoA, in terms 
of the titer and yield of acetyl-CoA derived molecules, if compared with those in E. coli and 
oleaginous yeasts. One explanation is the difference in acetyl-CoA metabolism. In E. coli (Figure 
3.1A), acetyl-CoA is steadily synthesized from pyruvate by either pyruvate dehydrogenase (PDH) 
under aerobic conditions (6) or pyruvate:formate lyase (PFL) under anaerobic conditions (7). In 
eukaryotes, the metabolism of acetyl-CoA is separated into several compartments, including the 
mitochondria, peroxisomes, nucleus, and cytosol (8). Acetyl-CoA is mainly generated in the 
mitochondria by PDH, however, S. cerevisiae lacks the machinery to export the mitochondrial 
acetyl-CoA to the cytosol where the synthesis of desired products generally occurs (8). In the 
cytosol of yeast (Figure 3.1B), acetyl-CoA is generated via PDH-bypass, and the activation of 
acetate is the rate-limiting step, resulting from the low activity and high energy input 
requirement of the acetyl-CoA synthetase (ACS) (2). In addition, acetaldehyde is the branch 
point to control the flux to ethanol and acetyl-CoA, and most of the metabolic fluxes are going to 
ethanol during glucose fermentation due to the Crabtree effect and the fact that aldehyde 
dehydrogenases (ALDHs) have much lower affinity towards acetaldehyde than those of ADHs. 
Therefore, the ACS-dependent acetyl-CoA biosynthesis in the cytosol of S. erevisiae suffers 
from low metabolic fluxes and low efficiencies. On the contrary, cytosolic acetyl-CoA is mainly 
generated by ATP-dependent citrate lyase (ACL) in oleaginous yeasts such as Yarrowia 
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lipolytica (Figure 3.1C), which can accumulate fatty acids and lipids to high levels. ACL 
catalyzes a reversed reaction of citrate synthase, the first step of TCA cycle for acetyl-CoA 
assimilation. In other words, ACL functions as a shuttle to export the mitochondrial PDH-
generated acetyl-CoA to the cytosol for biosynthesis.  
As mentioned in Chapter 1, PDH catalyzes the oxidative degradation of pyruvate to 
generate acetyl-CoA in an ATP-independent manner, which is the most widely existed and 
probably the most efficient route for acetyl-CoA generation in nature. PDH is a huge multi-
subunits protein complex, with TPP, FAD, NAD+, and lipoic acid used as cofactors. Since TPP, 
FAD, and NAD+ are readily available in the cytosol of yeast, the supply of lipoic acid as well as 
its attachment to PDH (lipoylation of E2 subunit) should be engineered together with the 
expression of PDH structural genes. In nature, two independent routes are probably 
synergistically used for protein lipoylation, the scavenging pathway and the de novo biosynthetic 
pathway. As for the scavenging pathway, exogenous lipoic acid will be assimilated by the host 
and attached to its protein targets by a lipoiate-protein ligase (Lpl). When exogenous lipoic acid 
is not available, it has to be synthesized de novo from octanoyl-ACP (Figure 3.2) by hijacking 
fatty acid biosynthesis. In E. coli (Figure 3.2A), where the lipoylation pathway is the most 
characterized and well-known, the de novo biosynthetic pathway proceeds by two consecutive 
reactions: in the first step the octanoyltransferase (LipB) transfers octanoyl moiety from 
endogenously produced octanoyl-ACP to the target apo-proteins; and in the second step the 
octanoyl moiety is converted to lipoic acid by the lipoyl synthase (LipA), which replaces a 
hydrogen atom on each of the octanoate C6 and C8 carbon atoms with a sulphur atom, to generate 
lipoylated proteins. In Bacillus subtilis (Figure 3.2B), a gram-positive bacterium, it is interesting 
to observe that a lipoylated protein (glycine cleavage system, GCV) is required for the 
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lipoylation of PDH E2 subunits. Later it is found that LipM is an octanoyltransferase that 
specifically transfers octanoyl moiety from octanoyl-ACP to GcvH, whereas LipL is an amido-
transferase that transfers the octanoyl moiety from GcvH to PDH (9, 10). In S. cerevisiae, the 
lipoylation pathway is less understood, which is also found to be GCV-dependent (11-13). 
Therefore, a mechanism similar to that of B. subtilis is proposed: Lip2p (octanoyltransferase) 
specifically transfers octanoyl moiety from octanoyl-ACP to Gcv3p, and then Lip3p (amido-
transferase) transfers the octanoyl moiety from Gcv3p to PDH. Currently, it is still not clear 
whether sulphur insertion (LipA or Lip5p) acts before or after octanoyl moiety transfer (LipL or 
Lip3p) from GCV (GcvH or Gcv3p). Both B. subtilis and S. cerevisiae require GCV (GcvH and 
Gcv3p) as an intermediate octanoyl moiety carrier, whereas E. coli does not (9). Notably, both 
LipM from B. subtilis and Lip3p from S. cerevisiae were characterized to have octanoyl-CoA 
transferase activity (13, 14), indicating that B. subtilis and S. cerevisiae can accept octanoyl-CoA 
as the substrate for protein lipoylation, although at a lower efficiency than that of octanoyl-ACP. 
Considering the limitations of the endogenous ACS-dependent pathway for acetyl-CoA 
generation, this chapter aims to characterize alternative biosynthetic pathways with higher 
efficiency and lower energy input requirement via synthetic biology with a focus of PDH from E. 
coli and ACL from an oleaginous yeast, while Chapter 4 focuses on the improvement of 
metabolic fluxes towards acetyl-CoA biosynthesis via metabolic engineering. Currently, several 
metabolic engineering and synthetic biology strategies have been applied to boost the availability 
of acetyl-CoA in yeast, such as the use of an ACS mutant from Salmonella enterica (SeAcsL641P) 
with increased activity (1-4) or the introduction of heterologous acetyl-CoA biosynthetic 
pathways with lower energy input requirement (5, 15). Notably, these engineering strategies 
have resulted in the improved production of isoprenoids (1, 2), polyhydroxybutyrate (PHB) (3, 5), 
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n-butanol (4), and fatty acids (15) in S. cerevisiae. Recently, functional expression of the PDH 
complex in the cytosol of yeast was achieved by co-expressing the PDH structural genes (pdhA, 
pdhB, aceF, and lpd) and the protein-lipoate ligase genes (lplA and lplA2) from Enterococcus 
faecalis. When lipoic acid was supplemented to the growth medium, a functional PDH complex 
could fully replace the endogenous ACS-dependent pathway for cytosolic acetyl-CoA synthesis 
(16). Although a growth rate similar to the wild-type yeast strain was achieved, the requirement 
of lipoic acid supplementation and its high cost hinder further application of such a system in 
industrial settings. Therefore, in this chapter, we focus more on the de novo biosynthesis and 
lipoylation pathway, besides the scavenging pathway, to reconstitute a functional PDH complex 
in the cytosol of yeast. 
3.2 Results 
3.2.1 Construction of helper plasmids to facilitate gene cloning and pathway assembly 
In order to reconstitute a functional PDH in the cytosol of yeast, many genes and 
pathways have to be cloned and assembled, such as the PDH structural genes, a lipoylation 
pathway, and a type II fatty acid synthase (FAS). Thus, six helper plasmids with the whole 
promoter or terminator as the homology region with adjacent cassettes were constructed to 
facilitate gene cloning and pathway assembly. As shown in Figure 3.3 and Table 3.1, besides the 
eGFP cassette (promoter-eGFP-terminator), there was an additional promoter sequence at the 3’ 
end of the terminator in each helper plasmid, serving as the homologous region for pathway 
assembly. Each eGFP sequence was flanked by a unique BamHI site at 5’ end and XhoI site at 3’ 
end, which allowed the cloning of desired genes by replacing the eGFP sequence. In addition, 
unique restriction enzyme sites were also introduced to flank at both ends of each cassette, which 
conferred the flexibility to remove the whole cassette by restriction digestions. As shown in 
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Figure 3.3, the whole cassettes together with the downstream homologous sequences were PCR 
amplified and co-transformed into S. cerevisiae to assemble the whole pathway via the DNA 
assembler method (17). 
3.2.2 Development of an in vivo acetyl-CoA assay system 
Although several protocols for the detection of CoAs in biological systems have been 
developed, it is still rather tedious and labor intensive to do the extractions and assays (18, 19). 
Thus, an in vivo acetyl-CoA assay system was developed by disrupting the endogenous ACS-
dependent acetyl-CoA biosynthesis. In S. cerevisiae, Acs1p and Acs2p were responsible for the 
activation of acetate at the cost of ATP consumption (ACS activities). While ACS2 was found to 
be constitutively expressed under all conditions, the expression of ACS1 was repressed by the 
presence of glucose. In other words, the disruption of ACS2 would result in a yeast strain that 
could not grow on synthetic medium with glucose as the sole carbon source (Figure 3.4A). Since 
ACS1 was expressed well under derepressed condition, the disruption of ACS2 did not have a 
significant impact on the growth on ethanol containing medium (Figure 3.4A). Therefore, the 
acetyl-CoA biosynthetic pathways could be characterized by their ability to complement the 
growth of the acs2Δ S. cerevisiae strain (Table 3.2) on glucose synthetic medium. After restoring 
the growth with alternative acetyl-CoA biosynthetic pathways, ACS1 should be further deleted to 
eliminate any possibility of host adaptation that might lead to the constitutive expression of 
ACS1 when glucose was still present. 
3.2.3 Growth complementation of the acs2Δ strain by ACL 
Comparative genomics analysis revealed that one of the biggest differences between 
oleaginous yeast and non-oleaginous yeasts were the presence of ACL (20), a route to generate 
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cytosolic acetyl-CoA from citrate. Thus, ACL genes (ACL1-ACL2) from an oleaginous yeast Y. 
lipolytica were cloned and tested in the acs2Δ S. cerevisiae strain. The introduction of ACL 
rescued the growth of the acs2Δ strain on both solid (Figure 3.4A) and liquid synthetic media 
(Figure 3.4B) with glucose as the sole carbon source, although at a lower growth rate and 
biomass yield than the wild-type strain. Further deletion of ACS1 in acs2Δ/ACL strain did not 
affect the growth significantly (data not shown), indicating that ACL from Y. lipolytica was 
functionally expressed in S. cerevisiae and could replace the endogenous pathway for acetyl-
CoA biosynthesis. 
3.2.4 Improving ACL performance via citrate supplementation and MDH and MAE co-
expression 
Although ACL could complement the growth of the Acs- strain, the growth rate and 
biomass yield were much lower than the wild-type (Acs+) strain. It was assumed that the 
cytosolic citrate concentration and/or the re-uptake of oxaloacetate by mitochondria might limit 
the activity of ACL in S. cerevisiae, especially when cultured on glucose. Therefore, citrate 
supplementation and co-expression with a malate dehydrogenase gene (MDH) and a malic 
enzyme gene (MAE) were carried out to further improve the activity of ACL. Oxaloacetate 
generated by ACL would be converted by MDH and MAE back to pyruvate, which could be 
efficiently re-assimilated by the mitochondria. While all MDHs were NADH specific, both 
NAD+ and NADP+ specific MAEs were existed in nature. Therefore, the endogenous MDH3, Y. 
lipolytica MDH2, Y. lipolytia MAE1 (NAD+ specific), and Mortierella alpine MAE1 (NADP+ 
specific) were cloned and assembled (Table 3.3). Either the mitochondrial targeting sequences or 
peroxisomal targeting sequences were removed in all MDHs and MAEs to express them in the 
cytosol of yeast. Among all ACL-MDH-MAE (AMM) systems tested, AMM2 worked the best 
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to increase the growth rate (Figures 3.5A). It was also found that the introduction of co-factor 
neutral pathways (AMM2 and AMM4) increased the ACL activity, while the pathways with 
transhydrogenase activity (AMM5 and AMM6) decreased the growth rate. Generally, citrate 
supplementation increased ACL activity, except for the wild-type strain (Figures 3.5C) and the 
AMM2 expressing strain (Figures 3.5E). The cytosolic acetyl-CoA biosynthesis was not related 
to citrate for the wide-type (Acs+) strain; while for the AMM2 expressing Acs- strain, the acetyl-
CoA biosynthesis has been already improved by co-expressing MAE-MDH. These results 
indicated that citrate supplementation and MDH-MAE co-expression might follow a same 
mechanism to increase the acetyl-CoA biosynthesis capability of ACL. Notably, although the 
introduction of co-factor imbalanced AMM systems led to lower growth rate, they might be 
useful for metabolic engineering applications with enhanced supply of NADPH. 
3.2.5 PDH with scavenging lipoylation pathway 
Although PDH was only found in the mitochondria in eukaryotes, the expression of the 
bacterial counterpart genes, due to a lack of mitochondrial targeting sequences, will relocate the 
PDH enzymes to the cytosol. If they could be functionally reconstituted in this new compartment, 
a new route to generate acetyl-CoA directly from pyruvate could be created in the cytosol of 
yeast. Therefore, PDH structural genes from E. coli (EcLpdA-EcAceE-EcAceF) and the lipoate-
protein ligase genes from E. coli (EcLplA) and Bacillus subtilis (BsLplJ) were cloned. As shown 
in Figure 3.4A, co-expression of PDH structural genes and a lipoate-protein ligase gene could 
complement the growth of the acs2Δ S. cerevisiae strain on glucose synthetic medium, when 
lipoic acid was supplemented. Interestingly, the lipoate-protein ligase from B. subtilis (BsLplJ) 
performed better than that from E. coli (EcLplA), when co-expressed with the E. coli PDH 
structural genes (Figure 3.4B). Compared with the wild-type (Acs+) strain, the growth rate and 
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biomass yield were quite similar, indicating that cytoPDH could fully replace the endogenous 
ACS-dependent pathway for acetyl-CoA biosynthesis in the cytosol of yeast. If lipoic acid was 
not supplemented to the growth medium, no cell growth could be observed (Figure 3.4A). In 
other words, the PDH containing Acs- strain was lipoic acid auxotroph.   
 The E. coli PDH was reported to be subjected to feedback inhibition by NADH, which 
led to low or lack of activity under anaerobic condition (high ratio of NADH/NAD+). Inverse 
engineering revealed a mutation in the LpdA coding sequence (E354K) resulted in an NADH 
feedback inhibition resistant PDH mutant (21). A following study on the saturation mutagenesis 
of the E354 site found more PDH mutants that were insensitive to NADH inhibition (22). In 
other words, these PDH mutants were functional under both aerobic and anaerobic conditions. 
Considering the reducing environment in the cytosol of yeast and the preference of anaerobic 
condition for industrial applications, two feedback inhibition insensitive PDH mutants with a 
mutation of E354K (PDHm1) and E354G (PDHm2), respectively, in the LpdA coding sequence 
were constructed. As shown in Figure 3.4C, no significant difference in the growth rate of the 
acs2Δ strains containing either the wild-type or the mutated PDHs was observed, indicating that 
PDH activity was not inhibited under aerobic condition. To test the advantage of using the 
NADH insensitive mutants, the PDH containing acs2Δ strains were cultured under micro-
anaerobic condition. As shown Figures 3.6A and 3.6B, there was still no significant difference in 
the fermentation performance (glucose consumption and ethanol production) between these 
strains when the glucose concentration was low (20 g/L), indicating that the NADH/NAD+ ratio 
was not high enough in the yeast cytosol to inhibit the activity of PDH or the activity of PDH 
was still high enough to provide sufficient amount of acetyl-CoA even under inhibited condition. 
Finally, fermentation with high concentration of glucose (100 g/L) was carried out under micro-
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anaerobic condition, which resulted in slightly improved fermentation performance with the 
NADH insensitive mutants (Figures 3.6C and 3.6D). The results indicated that the re-oxidation 
of NADH via ethanol and glycerol formation was able to maintain the cytosolic NADH/NAD+ 
ratio at a low level that would not inhibit the activity of PDH, even under micro-anaerobic 
condition. Nevertheless, since no significant difference between PDHwt, PDHm1, and PDHm2 
under aerobic condition and the PDH mutants might be more active under anaerobic condition, 
especially in the engineered strains with impaired glycerol and ethanol fermentation, PDHm2 
was chosen for all following studies to reconstitute the de novo lipoic acid biosynthesis and 
lipoylation machinery. 
3.2.6 Development of the lipoic acid auxotrophic strain as an in vivo acetyl-CoA assay system 
Although the acs2Δ S. cerevisiae strain has been used for in vivo acetyl-CoA assays, 
ACS1 must be further deleted to confirm the functionality of the heterologous acetyl-CoA 
biosynthetic pathways. If the heterologous pathways were not very efficient in synthesizing 
acetyl-CoA, further disruption of ACS1 in a poor growth strain could be challenging. Therefore, 
we switched to the use of the lipoic acid auxotrophic strain as the in vivo acetyl-CoA assay 
system. As shown in Figure 3.7, no cell growth was observed without lipoic acid 
supplementation, and the growth was increased gradually with higher lipoic acid concentrations. 
When the supplemented lipoic acid concentration was higher than 8 mg/L, a near wild-type 
growth rate could be achieved (Figure 3.7). Another advantage of the new acetyl-CoA assay 
system was the fast growth rate, compared with the acs2Δ S. cerevisiae strain, which had to be 
cultured on ethanol containing medium at an extremely slow growth rate. Except for the final 
step of acetyl-CoA assays, which would be carried out in lipoic acid free medium, all previous 
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steps including transformation and seed culture could be performed in a medium with lipoic acid 
supplementation. 
3.2.7 PDH with a semi-synthetic lipoylation pathway 
Although a functional PDH was reconstituted in the cytosol of yeast, its industrial 
application would still be hindered by the high cost of lipoic acid. Therefore, another goal of this 
chapter was to reconstitute the de novo lipoylation pathway. Octanoyl-ACP, an intermediate of 
fatty acid biosynthesis, was the natural substrate of lipoylation, although octanoyl-CoA was also 
reported to be acceptable at a much lower activity (13, 14). Unfortunately, the lipoylation 
enzymes had no access to octanoyl-ACP, which was constrained in the catalytic core of the type 
I FAS in the cytosol of yeast. In other words, a type II FAS should be functionally reconstituted 
in the cytosol for the de novo lipoylation machinery. To achieve this challenging goal step by 
step, a semi-synthetic lipoylation pathway was proposed and designed by taking advantage of the 
Vibrio harveyi acyl-ACP synthetase (VhAasS), a soluble enzyme that ligates free fatty acids to 
ACP to form acyl-ACPs (23). Interestingly, most of the acyl-ACP synthetases were membrane 
proteins, while VhAasS was a soluble cytosolic protein. As there is no free ACP in the cytosol of 
yeast, ACP and its activator must be included together with VhAasS. The first strategy was to 
relocate the mitochondrial proteins (encoded by ACP1 and PPT2, respectively) to the cytosol by 
removing the mitochondrial targeting sequences (cytoACP1 and cytoPPT2). Another strategy 
was to use the E. coli counterparts (encoded by acpP and acpS, respectively), which possessed 
no mitochondrial targeting sequences. To test whether octanoyl-CoA could be accepted as the 
substrate, Faa2p (24), a medium chain fatty acyl-CoA synthetase, was relocated to the cytosol by 
removing the peroxisome targeting sequences, and the resultant cytoFAA2 would be co-
expressed with the lipoylation pathways. As mentioned above, the E. coli lipoylation pathway 
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was best characterized, and the lipoylation machinery from B. subtilis and S. cerevisiae 
mitochondria were able to accept octanoyl-CoA, besides octanoyl-ACP as the lipoylation 
precursor. Therefore, the lipoylation machineries from these three systems were cloned and 
assembled, and the resultant DNA constructs were named as EcLA (EcLipA-EcLipB), BsLA 
(BsGcvH-BsLipL-BsLipM-BsLipA), and ScLA (cytoGCV3-cytoLIP2-cytoLIP3-cytoLIP5), 
respectively. As for ScLA, the mitochondrial targeting sequences were removed to relocate the 
full pathway enzymes to the cytosol of S. cerevisiae. 
 As shown in Figures 3.8A, no cell growth was observed for all strains when octanoic acid 
was missing, indicating that the activity of VhAasS and cytoFaa2p was dependent on the 
presence of octanoate. If 10 mg/L octanoic acid was supplemented to the growth medium, 
readily cell growth was observed in the Acs-/M2J strain expressing ScLA and VhEc (VhAasS-
EcAcpP-EcAcpS) or VhSc (VhAasS-cytoACP1-cytoPPT2); marginal growth was observed for 
EcLA; and no growth was observed for BsLA (Figure 3.8B). The results indicated that BsLA 
was not active; EcLA showed little activity; while ScLA was functional in the cytosol of yeast 
and could accept ACP from both E. coli and S. cerevisiae mitochondria. Under no circumstances 
would the growth of cytoFAA2 expressing strain be detected, which indicated that either 
octanoyl-CoA could not be accepted as the lipoylation precursor or the lipoylation machinery 
was not active enough to activate apo-E2 subunit of PDH (Figure 3.8B). The cell growth of Acs-
/M2J strains with semi-synthetic lipoylation pathways was further confirmed in liquid medium 
containing 10 mg/L octanoic acid, which was also compared with the strain containing a 
scavenging pathway (Figure 3.8C). In addition, octanoic acid concentration of 10-30 mg/L was 
found to be optimal for cell growth: lower concentration led to low lipoylation efficiency and 
limited acetyl-CoA biosynthesis, while higher concentration resulted in cytotoxicity (Figure 
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3.8C). Since ScLA was the most active, it was used for the following studies to reconstitute a de 
novo synthetic lipoylation pathway. 
3.2.8 PDH with a de novo synthetic lipoylation pathway 
A final goal of this chapter was to design a de novo biosynthetic lipoylation pathway, 
meaning the reconstitution of functional PDH in synthetic medium without the supplementation 
of octanoic acid or lipoic acid.  To achieve this, a type II FAS (Cem1p-Oar1p-Htd2p-Etr1p-
Acp1p-Ppt2p-Mct1p) from the mitochondria of S. cerevisiae was relocated to the cytosol by 
removing the mitochondrial targeting sequences (cytoFAS1). Unfortunately, no cell growth was 
observed with the co-expression of M2J and ScLA in the Asc- strain when cultured in synthetic 
medium with glucose as the sole carbon source, indicating a lack of enough octanoyl-ACP for 
lipoylation. One possibility lied on the poorly characterized property of Htd2p, whose 
mitochondrial targeting sequences could not be predicted by any publicly accessible program. 
Thus, the E. coli homologs, FabA and FabZ, which were confirmed to complement the htd2Δ 
strain, were included instead to construct cytoFAS2 and cytoFAS3. Unfortunately, still no 
growth was observed, indicating that the mitochondrial FAS system was not functional in the 
cytosol. Actually, the mitochondrial FAS is still not well characterized: for example, the enzyme 
and the corresponding substrate for the initial condensation step are still unknown, which is one 
major concern with this FAS system.  
 To verify whether FASs used in this chapter was functional in the cytosol of yeast, their 
activities were tested in the fas1Δ strain, whose endogenous pathway for fatty acid biosynthesis 
was disrupted. The growth of the fas1Δ strain was only possible when free fatty acid(s) was 
supplemented to the growth medium or an alternative FAS system was introduced. As shown in 
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Figure 3.9, the supplementation of C14 or C16 fatty acid could complement the growth of the 
fas1Δ strain, while the supplementation of a shorter chain fatty acid (such as C10 or C12) or the 
introduction of FAS used in this chapter (including cytoFAS1, cytoFAS2, and cytoFAS3) could 
not enable the growth in a fatty acid free medium. These results confirmed that all the FAS 
systems used in this chapter were not functional in the cytosol of S. cerevisiae. 
3.3 Discussion 
As a central metabolite, acetyl-CoA plays an important role in a series of cellular 
functions involved in enzymatic acetyl transfer reactions. Acetyl-CoA is the starting compound 
of the tricarboxylic acid (TCA) cycle, and a key precursor in the biosynthesis of sterols, fatty 
acids and lipids, amino acids, and polyketides (20, 25-29). In addition, acetyl-CoA functions as 
the donor of acetyl group for post-translational acetylation reactions of histone and non-histone 
proteins. To accommodate the cellular requirement, nature has evolved a variety of routes for 
acetyl-CoA synthesis (Fig. S1), such as the oxidative decarboxylation of pyruvate (6), the 
oxidation of long-chain fatty acids (30), and the oxidative degradation of certain amino acids 
(20). In terms of the bulk synthesis of acetyl-CoA, the most common mechanism is the direct 
conversion from pyruvate, either by pyruvate dehydrogenase (PDH) under aerobic conditions (6), 
or by pyruvate ferredoxin oxidoreductase (PFO) (31), pyruvate NADP+ oxidoreductase (PNO) 
(32), or pyruvate formate lyase (PFL) (7) under anaerobic conditions. Due to the 
compartmentalization of acetyl-CoA metabolism in eukaryotes, direct conversion of pyruvate to 
acetyl-CoA only happens in some organelles, such as mitochondria and chloroplasts. In the 
cytosol, two ATP consuming mechanisms are used to synthesize acetyl-CoA. One is PDH-
bypass (2), i.e., from pyruvate to acetaldehyde and then to acetate, which is activated to acetyl-
CoA by the acetyl-CoA synthetase (ACS) at the cost of two ATP molecules (33). PDH-bypass is 
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widely distributed in ethanogenic species, such as yeasts, filamentous fungi, and plants. The 
other is ATP-dependent citrate lyase (ACL), using a TCA cycle intermediate citrate as the 
substrate, which is enzymatically converted to acetyl-CoA and oxaloacetate at the cost of one 
ATP molecule (25). ACL is found in both ethanogenic and non-ethanogenic species such as 
fungi, plants, and animals. Notably, comparative genomics studies reveal that ACL is present in 
oleaginous yeasts such as Y. lipolytica, but not in non-oleaginous yeasts such as S. cerevisiae 
(20), indicating the significance of ACL in the supply of precursor metabolites to the 
biosynthesis of fatty acids and lipids. The phosphoketolase pathway is also reported to contribute 
to cytosolic acetyl-CoA generation in some fungal species (5). 
There is a growing interest in developing S. cerevisiae as a cell factory for the production 
of biofuels and chemicals, owing to its high tolerance to harsh industrial conditions.(1, 34). 
Besides its essential role in numerous metabolic pathways and cellular functions, acetyl-CoA is 
the building block for the biosynthesis of many products of industrial interest. However, acetyl-
CoA metabolism in yeast is rather complex and highly regulated. In addition, this precursor 
molecule is synthesized in various compartments and cannot be directly transported between 
these compartments. Due to the lack of ATP-dependent citrate lyase (ACL) and the carnitine 
shuttle when cultured in minimal medium (1), the activation of acetate is the only route to 
generate cytosolic acetyl-CoA in S. cerevisiae. This PDH-bypass route suffered from low 
enzyme activity and high energy input requirement. Therefore, the introduction of heterologous 
synthetic pathways with higher efficiency and lower energy input requirement should be able to 
enhance the availability of acetyl-CoA in the cytosol. In this chapter, PDH from E. coli and ACL 
from Y. lipolytica were characterized to enable the growth of the Acs- strain on glucose synthetic 
medium. In other words, both PDH and ACL were functional to replace the endogenous ACS-
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dependent pathway for acetyl-CoA biosynthesis. A similar strategy is to reconstruct the carnitine 
shuttle exporting mitochondrial acetyl-CoA to the cytosol in S. cerevisiae, as occurring in higher 
organisms (8). Interestingly, all components of the carnitine shuttle, such as the carnitine 
acetyltransferase and acetyl-carnitine translocase, exist in S. cerevisiae except for the de novo 
carnitine biosynthetic pathway (35). Due to the lack of carnitine in synthetic medium and its high 
cost, introducing a heterologous de novo carnitine biosynthetic pathway would be a viable option 
for industrial production of acetyl-CoA derived fuels and chemicals. 
 Considering the high cost of lipoic acid, a de novo lipoylation pathway should be 
included to construct a functional PDH in the cytosol of yeast, which was hindered by the 
challenge to reconstitute a functional type II FAS in the cytosol. Luckily, a semi-synthetic 
lipoylation pathway based on acyl-ACP synthetase (VhAasS) was constructed and could supply 
octanoyl-ACP for lipoylation when octanoic acid was supplemented to the growth medium. By 
combining with the reversed β-oxidation pathway, which was found to be able to produce 
octanoic acid when a medium chain thioesterase (CpFatB1) was co-expressed in Chapter 5, a de 
novo biosynthetic lipoylation pathway could be re-designed. As shown in Figure 3.10, octanoyl-
CoA, an intermediate of the reversed β-oxidation pathway, could be thiolyzed by CpFatB1 to 
release octanoic acid, which could then be fed to the semi-synthetic lipoylation pathway to 
construct a functional PDH in the cytosol of yeast. 
3.4 Conclusion and Future Work 
Acetyl-CoA biosynthetic pathways from E. coli (PDH) and Y. lipolytica (ACL) were 
introduced into the cytosol of S. cerevisiae via synthetic biology approaches. Both ACL and 
PDH could replace the endogenous ACS-dependent pathway for acetyl-CoA biosynthesis. To 
construct a functional PDH in the cytosol of yeast, different lipoylation pathways were 
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introduced. Besides the naturally existing scavenging pathway and de novo biosynthetic pathway, 
we also designed a semi-synthetic lipoylation pathway based on the acyl-ACP synthetase (AasS). 
The scavenging pathway resulted in a functional PDH that enabled the growth of Acs- strain to a 
similar level of the wild-type strain. While the de novo biosynthetic lipoylation pathway was 
hindered by the difficulty in reconstituting a functional type II FAS in the cytosol, the semi-
synthetic lipoylation pathway could rescue the growth with octanoic acid supplementation 
although at a much lower growth rate and biomass yield. A new de novo biosynthetic lipoylation 
pathway was designed and proposed to combine the semi-synthetic lipoylation pathway and the 
reversed β-oxidation pathway. The next chapter will focus on the use of these alternative acetyl-
CoA pathways for metabolic engineering applications: to increase the intracellular acetyl-CoA 
level with a goal to increase the titer and productivity of n-butanol and other value-added 
compounds.   
3.5 Materials and Methods 
3.5.1. Strains, media, and cultivation conditions 
E. coli strain DH5α was used to maintain and amplify plasmids. S. cerevisiae CEN.PK2-
1C was used as the host for homologous recombination based cloning, heterologous gene 
expression, and growth assays. Yeast strains were cultivated in complex medium consisting of 2% 
peptone and 1% yeast extract supplemented with either 2% glucose (YPD) or 2% ethanol (YPE). 
Recombinant strains were grown on synthetic complete (SC) medium consisting of 0.17% yeast 
nitrogen base, 0.5% ammonium sulfate, and 0.07% amino acid drop out mix (CSM-HIS-TRP-
LEU-URA, MP Biomedicals, Solon, OH), supplemented with 2% glucose (SCD) or 2% ethanol 
(SCE). E. coli strains were cultured at 37oC in Luria-Bertani broth containing 100 μg/mL 
ampicillin. S. cerevisiae strains were cultured at 30oC and 250 rpm for aerobic growth, and 30oC 
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and 100 rpm in un-baffled shaker flasks for oxygen limited fermentation. To select for antibiotic 
resistant S. cerevisiae strains, G418 was supplemented at a final concentration of 200 μg/mL. 
When necessary, lipoic acid was supplemented to the growth medium at a final concentration of 
100 μg/L, unless specifically mentioned. All restriction enzymes, Q5 High Fidelity DNA 
polymerase, and the E. coli - S. cerevisiae shuttle vectors were purchased from New England 
Biolabs (Ipswich, MA). All chemicals were purchased from either Sigma-Aldrich or Fisher 
Scientific. 
3.5.2 DNA manipulation 
The yeast homologous recombination based DNA assembler method (17) was used to 
construct the helper plasmids, clone candidate genes and assemble the multiple-gene pathways. 
Recombinant plasmids constructed in this chapter were listed in Table 3.1. Briefly, polymerase 
chain reaction (PCR) was used to generate DNA fragments with homology arms at both ends, 
which were purified with a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) and co-
transformed along with the linearized backbone into S. cerevisiae. All genetic elements, 
including promoters, coding sequences, and terminators, were PCR-amplified from their 
corresponding genomic DNAs. Wizard Genomic DNA Purification Kit (Promega, Madison, WI) 
was used to extract the genomic DNAs from both bacteria and yeasts, according to the 
manufacturer’s protocol. To confirm the correct clones, yeast plasmids were isolated using a 
Zymoprep Yeast Plasmid Miniprep II Kit (Zymo Research, Irvine, CA) and re-transformed into 
E. coli DH5α or NEB Turbo competent cells. To construct NADH insensitive PDH mutants 
(PDHm1 and PDHm2), mutation at the E354 site of LpdA (E354K or E354G) was introduced by 
overlapped extension PCR and the resultant DNA fragment was cloned into the AfeI and PacI 
sites of PDHwt. To construct cytoPDH and M2J, BsLplJ cassette (TEF1p-BsLplJ-TEF1t) was 
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cloned into the SalI site of PDHwt and PDHm2, respectively, by the Gibson assembly method 
(New England Biolabs). To construct cytoFASs, cytoFAS0 was constructed first using the helper 
plasmid based DNA assembler method, then the HTD2 cassette (HXT7p-cytoHTD2-HXT7t), the 
EcFabA cassette (HXT7p-EcFabA-HXT7t), and the EcFabZ cassette (HXT7p-EcFabZ-HXT7t) 
was cloned into the StuI site of cytoFAS0 to construct cytoFAS1, cytoFAS2, and cytoFAS3, 
respectively. MaMAE was synthesized by two gBLOCKs (Integrated DNA Technologies, 
Coralville, Iowa) and cloned into pH5. pYFJ84, the VhAasS containing plasmid, was kindly 
provided by Prof. John Cronan from the University of Illinois at Urbana-Champaign (36). 
Plasmids were isolated using a QIAprep Spin Miniprep Kit (Qiagen) and confirmed using both 
diagnostic PCRs and restriction digestions. Yeast strains were transformed using the LiAc/SS 
carrier DNA/PEG method (37), and transformants were selected on the appropriate SC plates. 
3.5.3 Strain construction 
All the strains used in this chapter were based on CEN.PK2-1C and listed in Table 3.2. 
The Cre-loxP method (38) was used to construct all knock-out strains. For the construction of 
acs2Δ strain, the loxP-KlURA3-loxP cassette was PCR amplified with pUG73 as the template to 
include 40bp homology arms at both ends, and transformed into CEN.PK2-1C strain. The 
transformants were screened on SCE-URA plates and the resultant acs2Δ strain was maintained 
in medium with ethanol as the sole carbon source. After restoring the growth on glucose by ACL 
or PDH, ACS1 was further deleted by transforming the loxP-KanMX-loxP cassette and selection 
on YPD plates supplemented with 200 mg/L G418. The resultant Acs- strains (acs1Δ acs2Δ) 
containing alternative acetyl-CoA pathways were maintained on glucose medium and used as an 
in vivo reporter of acetyl-CoA levels in the cytosol. The same method was used to knock out 
FAS1, encoding the β-subunit of fatty acid synthase, which was selected on YPD plates 
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containing 200 mg/L G418 and 0.05% C14 fatty acid. The resultant fas1Δ strain was maintained 
on glucose and free fatty acid containing medium and used as an in vivo reporter of fatty acid 
biosynthesis capabilities. The selection marker in the engineered strains was rescued by 
transforming the Cre expressing plasmid (pSH47, pSH62, or pSH63). 
3.5.4 Growth assays 
To test yeast cell growth on agar plates by spotting assays, acs2Δ yeast strains were pre-
grown in the appropriate synthetic medium with 2% ethanol as the carbon source for about 5 
days. Then yeast cells were collected by centrifugation, washed three times in sterile ddH2O, and 
cells with appropriate dilutions (104, 103, 102, and 101 cells, assuming 107 cells/mL equivalent to 
OD600 of 1.0) were spotted into synthetic medium agar plates containing 2% ethanol, 2% glucose, 
and 2% glucose supplemented with 100 µg/L lipoic acid, respectively. Strains on glucose with 
lipoic acid plates were incubated at 30°C for 3 days, while those on ethanol and glucose plates 
were incubated at 30°C for 5 days. Liquid growth assays were performed using a Bioscreen C 
(Growth Curves USA, Piscataway, NJ) in four replicates. 4 µL of fully grown seeds were 
inoculated into 200 µL of the corresponding selection medium with an initial OD around 0.05. 
Tween80 or Brij58 was supplemented at a final concentration of 0.05%. The experiment was run 
at 30°C for 5 days with continuous shaking and sampling every 1h. 
3.5.5 Prediction of the mitochondrial and peroxisomal targeting sequences  
The mitochondrial targeting sequences of the candidate proteins were predicted using the 
MITOPROT online tool (http://ihg.gsf.de/ihg/mitoprot.html) (39). The peroxisomal targeting 
sequences were predicted using the PTSs predictor from PeroxisomeDB 2.0 
(http://www.peroxisomedb.org/Target_signal.php) (40).   
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3.7 Tables 
Table 3.1 Plasmids constructed in this chapter 
 
Plasmid Construct 
pH1 pRS425-StuI-PDC1p-BamHI-eGFP-XhoI-ADH1t-AvrII-PYK1p 
pH11 pRS425-StuI-GPM1p-BamHI-eGFP-XhoI-ADH1t-AvrII-PYK1p 
pH2 pRS425-AvrII-PYK1p-BamHI-eGFP-XhoI-CYC1t-SbfI-ENO2p 
pH22 pRS425-AvrII-ADH1t-GPDp-BamHI-eGFP-XhoI-CYC1t-SbfI-ENO2p 
pH3 pRS425-SbfI-ENO2p-BamHI-eGFP-XhoI-PGK1t-NotI-TPI1p 
pH4 pRS425-NotI-TPI1p-BamHI-eGFP-XhoI-TPI1t-SacII-TEFK1p 
pH5 pRS425-SacII-TEF1p-BamHI-eGFP-XhoI-TEF1t-XmaI 
pH6 pRS425-TEF1t-PGK1p-BamHI-eGFP-HindIII-HXT7t 
pUG6 PCR template for loxP-KanMX-loxP 
pUG73 PCR template for loxP-KlURA3-loxP 
pSH47 GAL1p-Cre-CYC1t containing plasmid with URA3 marker 
pSH62 GAL1p-Cre-CYC1t containing plasmid with HIS3 marker 
pSH63 GAL1p-Cre-CYC1t containing plasmid with TRP1 marker 
YlACL pRS423-TPI1p-YlACL1-TPI1t-TEF1p-YlACL2-TEF1t 
MM2 pRS425-TPI1p-cytoMDH3-TPI1t-TEF1p-cytoYlMAE1-TEF1t 
MM4 pRS425-TPI1p-cytoYlMDH2-TPI1t-TEF1p-cytoYlMAE1-TEF1t 
MM5 pRS425-TPI1p-cytoMDH3-TPI1t-TEF1p-cytoMaMAE1-TEF1t 
MM6 pRS425-TPI1p-cytoYlMDH2-TPI1t-TEF1p-cytoMaMAE1-TEF1t 
PDHwt pRS414-TEF1p-EcLpdA-PGK1t-TPI1p-EcAceE-GPDt-ENO2p-EcAceF-TEF1t 
PDHm1 PDHwt with the mutation E354K of EcLpdA 
PDHm2 PDHwt with the mutation E354G of EcLpdA 
BsLplJ pH5-BsLplJ 
EcLplA pH5-EcLplA 
cytoPDH PDHwt-TEF1p-BsLplJ-TEF1t 
M2J PDHm2-TEF1p-BsLplJ-TEF1t 
BsLA pRS425-ENO2p-BsGcvH-PGK1t-TPI1p-BsLipA-TPI1t-TEF1p- BsLipM-TEF1t-
PGK1p- BsLipL-HXT7t 
EcLA pRS425-TPI1p-EcLipA-TPI1t-TEF1p-EcLipB-TEF1t 
ScLA pRS425-ENO2p-cytoGCV3-PGK1t-TPI1p-cytoLIP5-TPI1t-TEF1p-cytoLIP3-
TEF1t-PGK1p-cytoLIP2-HXT7t 
cytoFAA2 pRS423-TEF1p-cytoFAA2-TEF1t 
cytoFAS0 pRS413-GPM1p-cytoCEM1-ADH1t-PYK1p-cytoOAR1-CYC1t-ENO2p-
cytoETR1-PGK1t-TPI1p-cytoACP1-TPI1t-TEF1p-cytoPPT2-TEF1t-PGK1p-
cytoMCT1-HXT7t 
cytoFAS1 cytoFAS0-HXT7p-cytoHTD2-HXT7t 
cytoFAS2 cytoFAS0-HXT7p-EcFabA-HXT7t 
cytoFAS3 cytoFAS0-HXT7p-EcFabZ-HXT7t 
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Table 3.1 (cont.) 
  
Plasmid Construct 
pYFJ84 pET16b-VhAasS (36) 
VhEc pRS413-TPI1p-EcAcpP-TPI1t-TEF1p-EcAcpS-TEF1t-PGK1p-VhAasS-HXT7t 
VhSc pRS413-TPI1p-cytoACP1-TPI1t-TEF1p-cytoPPT2-TEF1t-PGK1p-VhAasS-
HXT7t 
 
*Bs, Baillus subtilis; Ec, Escherichia coli; Ma, Mortierella alpine; Yl, Yarrowia lipolytica; Vh, 
Vibrio harveyi;  
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Table 3.2 Strains used in this chapter 
 
Strain Phenotype 
CEN.PK2-1C MATa ura3-52 trp1-289 leu2-3,112 his3Δ1 MAL2-8C SUC2 
acs2∆ CEN.PK2-1C acs2∆::URA3 
acs2∆/ACL CEN.PK2-1C acs2∆::URA3/YlACL 
Acs-/ACL CEN.PK2-1C acs2∆::URA3 acs1∆::KanMX/YlACL 
acs2∆/M2J CEN.PK2-1C acs2∆::URA3/M2J 
Acs-/M2J CEN.PK2-1C acs2∆::URA3 acs1∆::KanMX/M2J 
Acs-K/M2J CEN.PK2-1C acs2∆::loxP acs1∆::KanMX/M2J 
fas1∆ CEN.PK2-1C fas1∆::KanMX 
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Table 3.3 Co-factor specificities of MDHs and MAEs used in this chapter 
 
 cytoYlMAE1 cytoMaMAE 
cytoMDH3 AMM2 (NADH-NAD+) AMM5 (NADH-NADP+) 
cytoYlMDH2 AMM4 (NADH-NAD+) AMM6 (NADH-NADP+) 
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3.8 Figures 
 
 
Figure 3.1 Acetyl-CoA biosynthesis in E. coli (A), S. cerevisiae (B), and Y. lipolytica (C).  
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Figure 3.2 De novo lipoylation machineries in E. coli (A), B. subtilis (B), and S. cerevisiae (B, 
boxed). A functional PDH in the cytosol of yeast was designed and engineered with different 
lipoylation mechanisms, including the scavenging pathway, the semi-synthetic pathway, and the 
de novo biosynthetic pathway (C). 
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Figure 3.3 Schemes of gene cloning and pathway construction via DNA assembler using six 
helper plasmids. 
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Figure 3.4 Complementation of the cell growth of acs2Δ yeast strain by introducing alternative 
acetyl-CoA biosynthesis, including ATP-dependent citrate lyase (ACL) and pyruvate 
dehydrogenase (PDH). The cell growth was determined by either spotting assays (A) on 
synthetic medium agar plates containing ethanol, glucose, and glucose with lipoic acid, 
respectively, or growth curves (B and C) in the corresponding liquid media (acs2Δ/ACL and 
CEN.PK2 on SCD, while all other strains on SCD supplemented with 100 µg/L lipoic acid) 
using the Bioscreen C. 
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Figure 3.5 Improving the performance of ACL by citrate supplementation and MDH-MAE co-
expression. 
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Figure 3.6 Fermentation performance of acs2Δ yeast strains containing PDH mutants with low 
(A and B) and high (C and D) glucose concentrations under micro-anaerobic condition. 
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Figure 3.7 Growth dependence of Acs-/M2J on lipoic acid concentration. Acs-/M2J strain was 
pre-grown in SCD-WU medium supplemented with 100 µg/L lipoic acid until saturation and 
inoculated into fresh SCD-WU medium supplemented with lipoic acid at the indicated 
concentrations at an initial OD of 0.05. The growth of CEN.PK2 (WT) was measured under the 
same condition and included for comparison. 
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Figure 3.8 Reconstitution of a functional PDH by the semi-synthetic lipoylation pathway. 
Recombinant yeast strains were pre-cultured on SCD-HWLU medium supplemented with 100 
µg/L lipoic acid, collected by centrifugation, washed three times in ddH2O, and inoculated into 
fresh SCD-HWLU medium without (A) or with (B) the supplementation of 10 mg/L octanoic 
acid. Cell densities were measured 5 days after inoculation. The concentration of octanoic acid 
was optimized for the growth of Acs-/M2J+ScLA+VhSc strain in SCD-HWLU medium (C). The 
growth of Acs-/M2J+ScLA+VhSc strain in SCD-HWLU medium supplemented with 100 µg/L 
lipoic acid was included as a positive control.  
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Figure 3.9 Growth complementation of fas1Δ strain by either introducing a type II FAS 
(cytoFAS1, cytoFAS2, cytoFAS3, and EcFAS1H) or supplementing free fatty acid (C10, C12, C14, 
and C16). Recombinant yeast strains were pre-grown in SCD-HIS medium supplemented with 
200 mg/L G418 and 0.05% C14 fatty acid until saturation and then inoculated into fresh SCD-
HIS (A) or YPD (B) medium supplemented with 200 mg/L G418 at an initial OD of 0.05. To test 
the growth complementation by free fatty acid supplementation, 0.05% fatty acid with the 
specifically mentioned chain length was added to the growth media. 
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Figure 3.10 Re-designed de novo lipoylation pathway for functional PDH in the cytosol of yeast. 
Other than the use of a type II FAS, the semi-synthetic lipoylation pathway was combined with 
the reversed β-oxidation pathway to supply the lipoylation precursor, octanoyl-ACP. 
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Chapter 4 Acetyl-CoA Pool Engineering via Metabolic Engineering (II) 
4.1 Introduction 
In the previous chapter, the acetyl-CoA biosynthetic pathways from Escherichia coli 
(pyruvate dehydrogenase, PDH) and Yarrowia lipolytica (ATP-dependent citrate lyase, ACL), 
which showed higher catalytic activity and energetic benefits, were found to be functionally 
expressed in yeast and be able to replace the endogenous acetyl-CoA synthetase (ACS)-
dependent system for acetyl-CoA biosynthesis in the cytosol. Although the expression of these 
two heterologous pathways as well as those reported in other studies (1, 2) complemented the 
growth of the Acs- strain (acs1Δ acs2Δ), the use of these pathways to improve the production of 
acetyl-CoA derived value-added compounds has not been demonstrated yet, which was one of 
the major goals of this thesis. Therefore, this chapter mainly focuses on the application of these 
alternative acetyl-CoA biosynthetic pathways to improve the production of acetyl-CoA derived 
fuels and chemicals especially in the context of metabolic engineering. 
Currently, most of the efforts on acetyl-CoA pool engineering in yeast were focused on 
the introduction of heterologous pathways, especially the PDH-bypass pathway with the ACS 
mutant (3-6). Due to its central role in cellular metabolism, acetyl-CoA is used as the substrate 
for a variety of enzymatic reactions. Therefore, host engineering to redirect the metabolic flux to 
acetyl-CoA can be as important as the introduction of heterologous acetyl-CoA biosynthetic 
pathways. As shown in Figure 4.1, acetaldehyde is the branch point to control the flux to ethanol 
and acetyl-CoA, and most of the metabolic fluxes are going to ethanol during glucose 
fermentation due to the Crabtree effect and much lower affinity of aldehyde dehydrogenases 
(ALDHs) towards acetaldehyde than that of alcohol dehydrogenases (ADHs). Thus the 
inactivation of ADHs would direct the flux to acetyl-CoA. However, previous reports indicated 
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that decreased ADH activity would lead to increased production of another major product 
glycerol (7), which also serves as one of the major electron sinks in S. cerevisiae. Therefore, 
simultaneous disruption of the glycerol pathway and the ethanol pathway would be necessary to 
enhance the acetyl-CoA levels. In S. cerevisiae, the transport of acetyl-CoA between different 
compartments is carried out by the glyoxylate shunt (8, 9), with several organic acids as the 
intermediates, such as citrate, malate, succinate, and oxaloacetate. The disruption of the 
glyoxylate shunt by knocking out CIT2 or MLS1, encoding peroxisomal citrate synthase and 
cytosolic malate synthase, respectively, may enhance the levels of acetyl-CoA in the cytosol. The 
combined “push” and “pull” engineering may work synergistically to increase the cytosolic 
acetyl-CoA levels in yeast. 
In this chapter, systematic evaluation of various metabolic engineering strategies for 
enhancing acetyl-CoA availability was carried out, including the disruption of competing 
pathways and the introduction of heterologous biosynthetic pathways with higher catalytic 
efficiency and lower energy input requirement. By inactivating the glycerol pathway and major 
ADHs involved in ethanol production, the metabolic flux was redirected to acetyl-CoA and the 
production of n-butanol was increased by 3-4 fold. Subsequent introduction of heterologous 
acetyl-CoA biosynthetic pathways, including the PDH-bypass pathways, cytosolic localized 
PDH (cytoPDH), and ACLs, into the engineered host further increased the production of n-
butanol. Among these strategies, the cytoPDH worked the best, which increased the production 
of n-butanol by additional 3-4 fold. By combining the most effective acetyl-CoA pathways, n-
butanol titer of as high as 100 mg/L could be achieved under high cell density fermentation, 
which is the highest n-butanol titer ever reported in S. cerevisiae using the CoA dependent 
pathway. Considering some limitations of the ADH (partially) deficient yeast strain, engineering 
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of acetyl-CoA levels in the Pdc- strain was also attempted. The acetyl-CoA overproducing strains 
constructed in this work would be useful for efficient production of a wide range of acetyl-CoA 
derived products. Note that a major part of this chapter is adapted from one of my research 
articles published in Metabolic Engineering (10). 
4.2 Results 
4.2.1 Construction of a n-butanol pathway as the reporter of cytosolic acetyl-CoA levels 
Although several protocols for the detection of CoAs in biological systems have been 
developed, it is still rather tedious and labor intensive to do the extractions and assays (11, 12). 
Thus, the acetyl-CoA dependent n-butanol pathway from Clostridium was chosen as a model to 
study the effects of various metabolic engineering strategies on the acetyl-CoA pool in the 
cytosol of yeast. Thus, a pathway (HZ1982, Figure 4.2A) with the Clostridium acetobutyrium 
thiolase (CaThl), C. acetobutyrium β-hydroxybutyryl-CoA dehydrogenase (CaHbd), Clostridium 
beijerinckii crotonase (CaCrt), Treponema denticola trans-2-enoyl-CoA reductase (TdTer), C. 
beijerinckii butyraldehyde dehydrogenase (CbBad), and C. acetobutyrium butanol 
dehydrogenase B (CaBdhB) was constructed. However, no n-butanol production could be 
detected. Enzyme activity assay indicated the lack of Bad activity, while all other activities 
including Thl, Hbd, Crt, Ter, and Bdh were detected (Figure 4.2B). To have a functional n-
butanol pathway, candidate genes with either putative Bad activity or bifunctional 
aldehyde/alcohol dehydrogenase (AdhE/Aad) activity were cloned from various organisms. 
Indeed, complementing HZ1982 with a functional Bad, such as MhpF, EutE, and AdhE from E. 
coli and Aad from C. beijerinckii, allowed the production of a small amount of n-butanol in yeast 
(Figure 4.2C). Among all the Bad or AdhE/Aad enzymes tested, EutE from E. coli gave the 
highest n-butanol production, which was cloned to replace the nonfunctional CbBad in HZ1982. 
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The resultant n-butanol pathway (BuPa28) was used as the reporter of the cytosolic acetyl-CoA 
levels. In the wild-type yeast strain with BuPa28, 2-3 mg/L n-butanol could be produced, a titer 
similar to those in previous reports (3, 12).  
4.2.2 Host engineering to direct metabolic flux to acetyl-CoA 
To redirect the glycolytic flux to acetyl-CoA, ethanol and glycerol biosynthetic pathways 
were partially or completely inactivated. In S. cerevisiae, glycerol-3-phosphate dehydrogenase 
was the rate-limiting enzyme for glycerol formation (Figure 4.1). Thus both of the structural 
genes, GPD1 and GPD2, were deleted to eliminate glycerol production. As for the ethanol 
production, several alcohol dehydrogenases (ADHs), including but are not limited to Adh1p, 
Adh2p, Adh3p, Adh4p, Adh5p, Adh6p, and Adh7p, catalyze the NAD(P)H dependent reduction 
of acetaldehyde to ethanol (7), which directly compete with acetyl-CoA biosynthesis in the 
cytosol. Since Adh2p was glucose repressed at the transcription level, Adh3p and Adh5p were 
mainly localized in the mitochondrion, Adh6p and Adh7p were determined to be specific for 
medium chain and branched chain substrates, Adh1p and Adh4p were chosen as the targets to 
decrease ethanol production and redirect the flux to acetyl-CoA when cultured on glucose. The 
growth and sugar utilization were dramatically decreased when cultured the ΔGGAA (gpd1Δ 
gpd2Δ adh1Δ adh4Δ) strain on glucose, although no significant difference was observed for 
galactose fermentation (Figure 4.3). In addition, both acetaldehyde and acetate, the precursor for 
cytosolic acetyl-CoA, were accumulated to high levels after the inactivation of ADH1 and ADH4. 
Accordingly, n-butanol titer was increased by more than 4 fold, compared with that in the wild-
type strain (Figure 4.4). The productivity of n-butanol was only increased by about 2 fold, 
because of the impaired cell growth and sugar utilization. 
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The disruption of the competing acetyl-CoA consuming pathways, such as the glyoxylate 
shunt, was also carried out to enhance the availability of acetyl-CoA. As shown in Figure 4.4, n-
butanol titer was increased by 2 fold by inactivating CIT2 or MLS1 in the wild-type strain. 
However, further deletion of CIT2 or MLS1 in the ΔGGAA strain led to decreased n-butanol 
production, probably caused by the accumulation of acetate to cytotoxicity levels (Figure 4.5). 
Therefore, ΔGGAA was chosen as the host for subsequent introduction of acetyl-CoA 
biosynthetic pathways. 
4.2.3 Introduction of various acetyl-CoA biosynthetic pathways into the engineered host  
4.2.3.1 Engineered PDH-bypass pathways 
Concerning the low efficiency of the endogenous PDH-bypass pathway, heterologous 
acetyl-CoA biosynthetic pathways with higher efficiency and/or lower energy input requirement 
would be desirable. The most straightforward strategy was to overexpress the PDH-bypass 
pathway including the ACS mutant with much higher activity. However, the overexpression of 
the whole PDH-bypass pathway, which was demonstrated to improve the production of a series 
of acetyl-CoA derived molecules in wild-type yeast (3-6), nearly blocked the production of n-
butanol in the engineered host (Figure 4.6A). Later it was found that low n-butanol production 
was accompanied with the accumulation of a large amount of acetate (Figure 4.5). To figure out 
the reason for low n-butanol production, additional recombinant plasmids containing ALD6-
SeAcsL641P or only SeAcsL641P were constructed by gradually removing the upstream genes. 
Interestingly, the production of n-butanol was increased, with the highest titer produced by the 
engineered strain containing only ACS*. After codon optimization of this ACS mutant, the titer 
of n-butanol was further improved to about 20 mg/L. In contrast with the overexpression of the 
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SeAcs mutant, the overexpression of the endogenous ACS1 and ACS2 did not improve the 
production of n-butanol (Figure 4.6A), probably due to the low enzymatic activity or the post-
translational deactivation. 
4.2.3.2 Functional PDH in the cytosol (cytoPDH) 
Although PDH was only found in the mitochondria of eukaryotes, the expression of the 
bacterial PDH genes, which lacked the mitochondrial targeting sequences, would create a new 
route to generate acetyl-CoA directly from pyruvate in the cytosol (cytoPDH). As demonstrated 
in the previous chapter of this thesis, cytoPDH containing the PDH structural genes from E. coli 
(EcLpdA-EcAceE-EcAceF) and the lipoate-protein ligase gene from Bacillus subtilis (BsLplJ) 
could fully replace the endogenous system for acetyl-CoA biosynthesis. Therefore, cytoPDH was 
also introduced into the engineered host (ΔGGAA), which resulted in additional three fold 
increase in n-butanol titer, a total of more than 12 fold improvement (Figure 4.6A). 
4.2.3.3 ATP-dependent citrate lyase (ACL) 
Comparative genomics analysis revealed that one of the biggest differences between 
oleaginous yeast and non-oleaginous yeasts were the presence of ACL (13), a route to generate 
cytosolic acetyl-CoA from citrate. Thus, ACL genes from an oleaginous yeast Y. lipolytica and 
the model plant Arabidopsis thaliana were cloned and introduced into the engineered S. 
cerevisiae strain. As shown in Figure 4.6A, the introduction of ACL from Y. lipolytica could 
increase the n-butanol titer by approximately two fold in the engineered host, while ACL from A. 
thaliana had no effect on improving the n-butanol titer, which was resulted from the low activity 
and/or poor expression of the plant genes in yeast (data not shown).  
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4.2.3.4 Function of the heterologous pathways in synthesizing cytosolic acetyl-CoA 
To verify that the introduced acetyl-CoA pathways were functional and the increased n-
butanol production was resulted from enhanced acetyl-CoA levels, acetyl-CoA concentration in 
various strains was determined using an Acetyl-CoA Assay Kit. As shown in Figure 4.6B, the 
deletion of GPD1, GPD2, ADH1, and ADH4 increased the acetyl-CoA level by approximately 2 
fold, and the introduction of heterologous acetyl-CoA pathways could further increase the acetyl-
CoA level in S. cerevisiae. Although acetyl-CoA concentration was similar for the engineered 
strain with different acetyl-CoA pathways (Figure 4.6C), the amount of n-butanol produced was 
higher in the strain with cytoPDH than those with ACL or ACS. Since the activities of ACL and 
ACS are coupled to ATP consumption and PDH is ATP-independent, the increased n-butanol 
production might result from the energetic benefits of cytoPDH. In other words, the increased 
acetyl-CoA level and reduced energy input requirement lead to the highest n-butanol titer 
achieved in the cytoPDH harboring strain (Table 4.1). Another explanation lies on the fact that 
acetyl-CoA concentration in S. cerevisiae might be limited by the total CoA pool as well. 
4.2.3.5 Combining the most effective Acetyl-CoA biosynthetic pathways 
After verifying the activity of the acetyl-CoA biosynthetic pathways, we decided to 
combine the most effective and independent pathways in order to achieve maximal acetyl-CoA 
availability in the cytosol. As shown in Figure 4.7A, cytoPDH with ACS*Opt was the best 
combination, and could increase the titer of n-butanol by approximately six fold, compared with 
the engineered host with empty vectors. However, the total n-butanol titer was not significantly 
improved compared with the strain containing cytoPDH only, probably due to the burden of 
maintaining several plasmids, which was confirmed by the decreased n-butanol titer in the 
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control strain. Interestingly, the combination of ACS and ACL failed to increase the production 
of n-butanol, which might result from the energy input requirement for both enzymes. Thus, the 
combination of cytoPDH, ACL, and ACS was further attempted for n-butanol fermentation. To 
eliminate the plasmid burden issue, high cell density fermentation was carried out and the 
highest n-butanol titer over 100 mg/L could be achieved (Figure 4.7B). 
4.2.3 Acetyl-CoA pool engineering in the unevolved Pdc- strain 
Considering the accumulation of acetaldehyde and acetate in the Adh- strain, the 
inactivation of the upstream enzymes, the pyruvate decarboxylases (PDCs), was proposed to be a 
better strategy for efficient production of fuels and chemicals (14, 15). As mentioned in Chapter 
2, the Pdc- strain was incapable of growing on glucose as the sole carbon source and required C2 
supplementation to provide cytosolic acetyl-CoA (16). As an alternative to C2 supplementation, 
introduction of acetyl-CoA biosynthetic pathways, such as cytoPDH and ACL, might enable the 
Pdc- strain to grow on glucose as the sole carbon source. 
Similar to the Acs- strain lacking a route to generate cytosolic acetyl-CoA, the Pdc- strain 
could be an ideal selection/screening platform to test the activity of the cytosolic acetyl-CoA 
pathways as well. As expected, the introduction of alternative acetyl-CoA pathways rescued the 
growth of the Pdc- strain on low concentration glucose (5 g/L) as the sole carbon source (Figure 
4.8A). Although the growth was still rather poor, protein engineering, pathway engineering, and 
even adaptive evolutionary engineering strategies (17) could be carried out to increase the 
activity of these pathways. Since the growth rate of the Pdc- strain was the direct readout of 
acetyl-CoA levels in the cytosol, a high throughput selection/screening platform could be readily 
developed. As a proof of concept, adaptive evolution was carried out for the Pdc- strain 
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containing cytoPDH by serial transfers in synthetic medium with 20 g/L glucose as the sole 
carbon source. After ten rounds of adaptive evolution, the growth rate of the evolved strain (Pdc-
/cytoPDHe) was quite similar to E10 (Figure 4.8B), an evolved Pdc- strain containing MTH1T. 
Unfortunately, no n-butanol production could be detected after introducing the n-butanol 
biosynthetic pathway (data not shown), indicating that the acetyl-CoA level was still rather low 
in the evolved strain. To figure out the mechanisms of improved phenotype, the whole genomes 
of the evolved strains (Pdc-/cytoPDH-e1 and Pdc-/cytoPDH-e2) were sequenced (Table 4.1). 
Interestingly, a mutation in the Mth1p coding sequence (Ala81Pro) was observed in both of the 
evolved strains, indicating that the improved growth rate might result from alleviated glucose 
repression rather than enhanced acetyl-CoA supply. Notably, a previous study done by another 
group on the evolution of Pdc- strain on glucose found the same mutation in Mth1p (Ala81Pro) 
(18). Recently, the similar study performed by a third group found a mutation at the same site of 
Mth1p (Ala81Asp) that contributed to the improved phenotype in synthetic medium with glucose 
as the sole carbon source (19). Since the mutation at the same site of Mth1p (Ala81) was 
obtained by several independent studies by different groups, it was confirmed that Ala81 
contributed significantly to the activity or stability of Mth1p.   
4.2.4 Acetyl-CoA pool engineering in the evolved Pdc- strain 
As the engineering of acetyl-CoA pool in the unevolved Pdc- strain was unsuccessful, the 
evolved Pdc- strain (iE11 constructed in Chapter 2) instead was used as the host, to eliminate the 
effects of host adaptation on acetyl-CoA pool engineering. Interestingly, a shift on the metabolite 
profiles was observed: alcohol fermentation (iso-butanol, n-butanol, 3-methyl-1-butanol) in Pdc+ 
strain rather than acid fermentation (iso-butyrate, n-butyrate, 3-methyl-1-butyrate) in Pdc- strain 
(Figure 4.9). Since the reduction of aldehydes to alcohols consumed one NADH molecule while 
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the oxidation to acids generated one NADPH molecule, it inferred a lack of NADPH and/or 
NADH in the Pdc- yeast strain. By introducing the cytoPDH and n-butanol biosynthetic pathway 
into iE11, the production of butyrate, instead of n-butanol, was detected by GC-MS, even 
without the supplementation of lipoic acid. Neither butyrate nor n-butanol was produced in iE11 
strain containing only the n-butanol pathway, indicating that the PDH from E. coli possessed 
some background activity without lipoylation. When lipoic acid was supplemented to the 
fermentation medium, which would activate cytoPDH to generate more acetyl-CoA as well as 
NADH, the fermentation profiles shifted gradually back to alcohols. As shown in Figure 4.9, 
with the increasing concentration of lipoic acid, iso-butanol and 3-methyl-1-butanol were shifted 
from their acid form first and then n-butanol was generated. Different from iso-butanol and 3-
methyl-1-butanol, only limited amount of n-butyrate was shifted to n-butanol, indicating that 
intracellular NADPH and/or NADH level was still rather low. Anyway, this was the first time to 
detect the production of n-butanol in the Pdc- yeast strain.  
 To investigate the effect of enhanced NADPH supply on fermentation performance of the 
iE11/cytoPDH strain to produce acetyl-CoA derived value added compounds, n-butanol in this 
case, three different strategies to boost NADPH level in yeast were tested. The first strategy 
(Figure 4.10A) was to overexpress gapN, encoding a non-phosphorylating glyceraldehyde-3-
phosphate (G-3-P) dehydrogenase. Different from the G-3-P dehydrogenase in the glycolysis 
pathway, GAPN catalyzed an NADPH-dependent reaction. The second strategy (Figure 4.10B) 
was to overexpress ZWF1, encoding an enzyme that controls the entry point of the oxidative 
pentose phosphate pathway, which was the major source of NADPH in S. cerevisiae. The third 
strategy was to combine cytoPDH with the ACL-MDH-MAE system (Figure 4.10C), which not 
only functioned as an acetyl-CoA shuttle but also an NADH-NADPH shunt. Unfortunately, none 
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of these NADPH engineering strategies significantly changed the fermentation profiles and 
increased n-butanol production in the Pdc- Strain. 
4.2.5 Further exploring ACL-MDH-MAE for metabolic engineering applications 
As mentioned in Chapter 3, ACL-MDH-MAE system not only functions as an acetyl-
CoA shuttle but also an NADH-NADPH shunt. In other words, ACL-MDH-MAE will not only 
provide acetyl-CoA but also NADPH, both of which are used as precursors by a wide range of 
biosynthetic pathways, such as fatty acid biosynthesis and 3-HP production. Besides biosynthetic 
pathways, ACL-MDH-MAE also has potential applications in catabolic pathways, such as xylose 
utilization. It is well known that the fungal redox pathway, which was generally introduced to S. 
cerevisiae to enable xylose utilization, suffers from co-factor imbalance problems, meaning 
NADPH consumption in the first step catalyzed by xylose reductase and NADH generation in 
the following step catalyzed by xylitol dehydrogenase (XDH). To demonstrate the application of 
the ACL-MDH-MAE system in both anabolic and catabolic pathways, xylose-based fatty alcohol 
production was carried out, based on an engineered yeast strain constructed in our previous study 
to produce fatty alcohol efficiently from glucose (20).  
The introduction of an NADH-NADPH shunt into L34 (21), a xylose utilizing yeast 
strain constructed in our previous study, increased both the growth rate (Figure 4.11A) and 
xylose consumption rate (Figure 4.11B). Similarly, the enhanced supply of NADPH in XF3 (20), 
a fatty alcohol overproducing yeast strain constructed in our previous study, also further 
increased the production of fatty alcohol around 1.5 fold, with a final concentration of about 350 
mg/L from 20 g/L glucose (Figure 4.11C). Notably, the titer of the control strain was not as high 
as that reported previously, probably due to the metabolic burden of introducing another multi-
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copy plasmid. To investigate the potential synergy between catabolic and anabolic pathways, 
ACL-MDH-MAE was applied for xylose-based fatty alcohol production (Figure 4.11E and F). 
Although the consumption of xylose and the titer of fatty alcohols were both increased, the yield 
(g fatty alcohol per g xylose) was rather similar (Figure 4.11D), indicating that the increased 
fatty alcohol production was resulted from improved xylose utilization. In other words, we 
observed competition rather than synergy between the co-factor imbalanced (NADPH requiring) 
anabolic and catabolic pathways, with catabolism as the winner of the NADPH competition.  
4.3 Discussions 
There is a growing interest in developing S. cerevisiae as a cell factory for the production 
of biofuels and chemicals, owing to its high tolerance to harsh industrial conditions (3, 22). 
Besides its essential role in numerous metabolic pathways and cellular functions, acetyl-CoA is 
the building block for the biosynthesis of many products of industrial interest. However, acetyl-
CoA metabolism in yeast is rather complex and highly regulated. In addition, this precursor 
molecule is synthesized in various compartments and cannot be directly transported between 
these compartments. In this chapter, the acetyl-CoA metabolism was engineered in S. cerevisiae 
to enhance the availability of this precursor metabolite in the cytosol. 
Due to the lack of ATP-dependent citrate lyase (ACL) and the carnitine shuttle when 
cultured in minimal medium (3), the activation of acetate is the only route to generate cytosolic 
acetyl-CoA in S. cerevisiae. This PDH-bypass route suffered from low enzyme activity and high 
energy input requirement. Therefore, heterologous synthetic pathways with higher efficiency and 
lower energy input requirement were introduced to enhance the availability of acetyl-CoA in the 
cytosol. Among all acetyl-CoA pathways tested, cytoPDH from E. coli and ACL from Y. 
lipolytica worked the best to increase the production of n-butanol. In addition, although n-
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butanol titer was different, acetyl-CoA concentration in the engineered strain containing 
ACS*Opt, cytoPDH, or YlACL was nearly the same, indicating that the synthesis of acetyl-CoA 
may also be limited by the total CoA pool. Engineering of CoA biosynthesis (23), especially the 
rate-limiting step catalyzed by pantothenate kinase, would further improve the concentration of 
acetyl-CoA in yeast. In terms of the compartmentalization of acetyl-CoA metabolism, the whole 
n-butanol pathway can be relocated to the same compartment as the precursor metabolite. 
Besides the enhanced availability of the precursor molecule, compartmentalization engineering 
was also found to have higher efficiency, as a result of increased local enzyme concentration and 
fewer competing pathways (24, 25).  
Since most of the glycolytic flux goes to ethanol formation even under respiration 
conditions (the Crabtree effect), the flux towards acetyl-CoA is very limited. To redirect the 
metabolic flux towards acetyl-CoA, the synthesis of ethanol was decreased by deleting two 
major ADHs (ADH1 and ADH4) in the cytosol, which was confirmed in part by the 
accumulation of acetaldehyde in the yeast cells. However, ethanol was still the major product, 
indicating the presence of other genes encoding enzymes with ADH activity in the yeast genome. 
Further disruption of an acetyl-CoA consuming pathway (the glyoxylate shunt) by the 
inactivation of CIT2 or MLS1 led to decreased n-butanol production, which was inconsistent with 
the results obtained in the wild-type yeast strain (Figure 4.4). This discrepancy might result from 
the effect of ADH deletion on acetate metabolism. In the wild-type strain, only a small amount of 
acetate was produced (Figure 4.3), which was considered as one of the rate-limiting factors for 
acetyl-CoA biosynthesis (4). Thus the disruption of the glyoxylate shunt would result in more 
acetate in the cytosol for acetyl-CoA biosynthesis (Figure 4.1). On the contrary, acetate was 
already accumulated to relative high levels in the ΔGGAA strain (Figures 4.3 and 4.5), and the 
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activity of ACS or the supply of ATP was rate-limiting for acetyl-CoA biosynthesis. Further 
disruption of the glyoxylate shunt in the ΔGGAA strain resulted in the accumulation of acetate to 
cytotoxic levels. The difference in acetate metabolism could also explain the observation that 
overexpression of the whole PDH-bypass pathway led to increased acetyl-CoA level in the wild-
type strain while impaired the synthesis of acetyl-CoA derived products in the ΔGGAA strain.  
Considering the accumulation of acetaldehyde and acetate in the Adh- strain, the 
inactivation of the upstream enzymes, pyruvate decarboxylases (PDCs), was proposed to be a 
better strategy for efficient production of fuels and chemicals (14, 15). However, the Pdc- strain 
was notorious for its inability to grow with glucose as the sole carbon source and required C2 
supplementation to provide cytosolic acetyl-CoA (16). As an alternative to C2 supplementation, 
introduction of acetyl-CoA biosynthetic pathways, such as cytoPDH and ACL, was found to be 
able to rescue the growth on low concentrations of glucose (Figure 4.8A), which was similar to 
the work shown in Chapter 3 that these alternative acetyl-CoA biosynthetic pathways were able 
to complement the growth of an Acs- (acs1Δ acs2Δ) S. cerevisiae strain. As ethanol production 
was completely eliminated and pyruvate was accumulated to high levels, the Pdc- strain could be 
used as a good start point for acetyl-CoA pool engineering, especially for the cytoPDH. Since the 
growth was still rather poor and the growth rate of the Pdc- strain was the direct readout of 
acetyl-CoA levels in the cytosol, a high throughput selection/screening platform based on growth 
rate could be readily developed. Unfortunately, the adaptive evolution results indicated the 
improved growth rate was resulted from glucose derepression (MTH1 mutation) rather than 
enhanced acetyl-CoA levels. Then, we switched to engineer acetyl-CoA pool in the well evolved 
Pdc- strain, as mentioned in chapter 2. Interestingly, a redistribution of the metabolic profiles was 
observed (Figure 4.9), from alcohol fermentation of the wild-type strain to acid fermentation of 
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Pdc- strain, which might indicate a cellular status lacking NADPH and/or NADH. Metabolic 
engineering efforts to combine NADPH engineering with acetyl-CoA engineering led to limited 
success. Therefore, a systematic understanding of the metabolism of the Pdc- strain would be 
required for the design and construction of an acetyl-CoA overproducing strain.  
4.4 Conclusions and Perspectives 
In summary, combined strategies of disrupting competing pathways to redirect the flux 
towards acetyl-CoA and introducing heterologous acetyl-CoA pathways with higher activity and 
lower energy input requirement were carried out to enhance the availability of acetyl-CoA in 
yeast. The yeast host was engineered to eliminate or decrease the formation of glycerol and 
ethanol and redirect the glycolytic flux to acetyl-CoA biosynthesis. Subsequent introduction of 
three independent acetyl-CoA biosynthetic pathways, with acetate (PDH-bypass), pyruvate 
(cytoPDH), and citrate (ACL) as the substrate, respectively, into the host increased the 
concentration of acetyl-CoA by approximately 3 fold. In terms of the accumulation of high level 
pyruvate and the function of cytoPDH to convert pyruvate to acetyl-CoA, the introduction of 
functional cytoPDHs into the Pdc- strain was also attempted to try to construct an acetyl-CoA 
overproducing yeast strain. 
4.5 Materials and Methods 
4.5.1 Strains, media, and cultivation conditions 
All engineered strains used in this chapter are based on S. cerevisiae CEN.PK2-1C strain. 
E. coli strain DH5α was used to maintain and amplify plasmids, and recombinant strains were 
cultured at 37°C in Luria-Bertani (LB) broth containing 100 μg/mL ampicillin. Yeast strains 
were cultivated in complex medium consisting of 2% peptone and 1% yeast extract 
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supplemented with 2% glucose (YPD) or galactose (YPG). Recombinant strains were grown on 
synthetic complete medium consisting of 0.17% yeast nitrogen base, 0.5% ammonium sulfate, 
and the appropriate amino acid drop out mix, supplemented with 2% glucose (SCD) or galactose 
(SCG). The adh1-adh4- yeast strains were pre-cultured in galactose medium under aerobic 
conditions (30oC and 250 rpm) and inoculated to glucose medium for n-butanol fermentation 
under oxygen-limited conditions (30°C and 100 rpm). All restriction enzymes, Q5 polymerase, 
and the E. coli-S. cerevisiae shuttle vectors were purchased from New England Biolabs (Ipswich, 
MA). All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
specified. 
4.5.2 DNA manipulation 
The yeast homologous recombination based DNA assembler method was used to 
construct the recombinant plasmids (26). Briefly, DNA fragments sharing homologous regions to 
adjacent DNA fragments were co-transformed into S. cerevisiae along with the linearized 
backbone to assemble several elements in a single step. All recombinant plasmids constructed in 
this chapter are listed in Table 4.3. Wizard Genomic DNA Purification Kit (Promega, Madison, 
WI) was used to extract the genomic DNA from both bacteria and yeasts, according to the 
manufacturer’s protocol. All acetyl-CoA biosynthetic pathways were first cloned into pRS424 or 
pRS414. In order to combine the overexpression of complementary acetyl-CoA pathways, PDH-
bypass pathways were subcloned into pRS425, and ACLs were subcloned into pRS423. The 
acetyl-CoA and NADPH boosting plasmids, pIYC08 (3) and pJC2 (27), were kindly provided by 
Prof. Jens Nielsen from the Chalmers University of Technology. To confirm the correct clones, 
yeast plasmids were isolated using a Zymoprep Yeast Plasmid Miniprep II Kit (Zymo Research, 
Irvine, CA) and amplified in E. coli for verification.  
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4.5.3 Strain construction 
All the strains used in this chapter are listed in Table 4.4. For the construction of gpd1Δ, 
gpd2Δ, adh1Δ, adh4Δ, cit2Δ, and/or mls1Δ strains, the loxP-KanMX-loxP method (28) was used 
for consecutive deletion of these genes. The Pdc- strain was constructed chapter 2. The deletion 
of each gene was verified by diagnostic PCR. Yeast strains were transformed using the LiAc/SS 
carrier DNA/PEG method (29), and transformants were selected on the appropriate SCD or SCG 
plates. To construct the trp1 deficient yeast strain, trp1-289 was amplified from CEN.PK2 
genome by PCR and then transformed into XF3. By counter selection on SCD plate 
supplemented with 0.5 g/L 5-fluoroanthranilic acid (5-FAA), the resultant strain (XF3w) was 
trp1 deficient and could be transformed with pRS424 based recombinant plasmids. 
4.5.4 n-Butanol fermentation and detection 
A single colony from the newly transformed plate was inoculated into 3 mL of the 
appropriate SCD or SCG medium, and cultured under aerobic conditions for 36 h. Then 200 μL 
of seed culture was transferred into 10 mL of the corresponding SCD medium in a 50 mL 
unbaffled flask at an initial OD600 of about 0.05, and cultured under oxygen-limited conditions. 
Samples were taken every 24 h after inoculation until no further increase in n-butanol production 
was observed, and the highest titer detected was used to compare the effects of different 
metabolic engineering strategies on n-butanol production. 
 Samples were centrifuged at 14,000 rpm for 10 min and the resulting supernatant was 
analyzed using a Shimadzu GCMS-QP2010 Plus GC-MS equipped with an AOC-20i+s 
autosampler and a DB-Wax column with a 0.25 μm film thickness, 0.25 mm diameter, and 30 m 
length (Agilent Inc., Palo Alto, CA). Injection port and interface temperature was set at 250 °C, 
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and the ion source set to 230 °C. The helium carrier gas was set at a constant flow rate of 2 
mL/min. The oven temperature program was set as the following: a) 3 min isothermal heating at 
50 °C, b) increase at the rate of 15 °C min-1 to 120 °C, c) increase at the rate of 50 °C min-1 to 
230 °C, d) and then isothermal heating at 230 °C for an additional 2.5 min. The mass 
spectrometer was operated with a solvent cut time of 1.5 min, an event time of 0.2 s, and a scan 
speed of 2500 from the range of 30-500 mass to charge (m/z) ratio. Concentrations were 
determined using standard curves, with 50 mg/L methanol as the internal standard. Each data 
point of the n-butanol titer represents the average of at least duplicates. 
4.5.5 Acetyl-CoA assay 
Yeast cells were pre-cultured, inoculated, and cultured under the same conditions as n-
butanol fermentation. After growing to the mid-log phase, cell metabolism was quenched by 
adding 8 mL cells into 40 mL pre-chilled (-80 °C) methanol, and cells were harvested by 
centrifugation at 4,000 g for 5 min. Then 2 mL boiling ethanol was added to the cell pellets, 
followed by boiling for an additional 15 min to release intracellular metabolites. After 
centrifugation, the supernatant was vacuum dried and resuspended into 200 µL ddH2O. The 
resultant solution containing acetyl-CoA was analyzed by the acetyl-Coenzyme A Assay Kit 
(Sigma-Aldrich). The concentration of acetyl-CoA was the average of biological duplicates and 
normalized by the dry cell weight. 
4.5.6 Fatty alcohol fermentation and detection 
A single colony from the fresh plate was inoculated into 5 mL appropriate SCD medium 
and cultured under aerobic conditions for 48 h. Then cells were collected, washed, and 
transferred into 5 mL the same SCD medium topped with 10% n-dodecane overlay in a 20 mL 
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glass tube at an initial OD600 of about 3. Fatty alcohol fermentation was performed under aerobic 
conditions for 48 h. The top n-dodecane layer was collected, diluted 100 fold in ethyl acetate 
containing 1 mg/L n-tridecane as an internal standard, and analyzed using the same GC-MS 
settings as mentioned above. The oven temperature program was set as the following: a) hold at 
50ºC for 2 min isothermal heating, b) increase at the rate of 50ºC min-1 to 230ºC, c) and then 
hold at 230ºC for additional 15 min.  
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4.7 Tables 
Table 4.1 Comparison of different acetyl-CoA biosynthetic pathways on the generation of 
energy (ATP) and co-factors (NADH/NADPH), as well as the n-butanol productivity and yield.  
 
 Theoretical value/glucosea Glucose 
consumption 
rate (g/L-h) 
n-Butanol 
productivity 
(mg/L-h) 
n-Butanol 
yield (mg/g 
glucose) 
 ATP NADH NADPH 
NC 0 2 2 0.23±0.01 0.11±0.01 0.51±0.02 
ACS*Opt 0 2 2 0.19±0.02 0.18±0.01 0.85±0.08 
EcPDH 2 4 0 0.22±0.01 0.42±0.02 1.58±0.09 
YlACL 1 4 0 0.20±0.02 0.26±0.04 1.23±0.18 
 
aThe numbers are the theoretical values for the heterologous acetyl-CoA biosynthetic pathways 
generated from one glucose molecule. A combination of the endogenous system and the 
heterologous system was used in the n-butanol fermentation process.  
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Table 4.2 SNVs identified in the coding sequences (CDS) of the evolved Pdc-/cytoPDH strains 
 
Non-synonymous SNVs in CDS Pdc-/cytoPDH-e1 Pdc-/cytoPDH-e2 
EIW11482.1 (Mth1p) Ala81Pro 
EIW10966.1 (Rph1p) Gln715Lys 
EIW07758.1 (Pdr10p) Phe1381Ser 
EIW12312.1 (Gem1p) - Ser489fs 
EIW11030.1 (Unknown) - Val373fs 
Total SNVs in CDS 4 5 
Total SNVs 42 36 
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Table 4.3 Plasmids constructed in this chapter. 
Plasmids Description 
pRS414 Single copy plasmid in S. cerevisiae with TRP1 marker 
pRS416 Single copy plasmid in S. cerevisiae with URA3 marker 
pRS423 Multiple copy plasmid in S. cerevisiae with HIS3 marker 
pRS424 Multiple copy plasmid in S. cerevisiae with TRP1 marker 
pRS425 Multiple copy plasmid in S. cerevisiae with LEU2 marker 
pRS426 Multiple copy plasmid in S. cerevisiae with URA3 marker 
pUG6 Template plasmid containing loxP-KanMX-loxP elements 
pSH47 Cre containing plasmid for loxP-KanMX-loxP cassette recycle 
HZ1982 pRS416-CaThl-CaHbd-CbCrt-TdTer-CbBad-CaBdhB 
EcMhpF pRS425-EcMhpF 
EcEutE pRS425-EcEutE 
EcAdhE pRS425-EcAdhE 
CaAad pRS423-CaAad 
CaAdhE2 pRS423-CaAdhE2 
CbAad pRS423-CbAad 
CnBad pRS423-CnBad 
TeAad pRS423-TeAad 
GlAad pRS424-GlAad 
BuPa28 pRS426-CaThl-CaHbd-CbCrt-TdTer-EcEutE-CaBdhB 
HZ1983 pRS424-PDC1-ALD6-SeAcsL641P 
HZ2000 pRS424-ALD6-SeAcsL641P 
pIYC08 pRS423-ADH2- ALD6-SeAcsL641POpt-ERG10 (3) 
ACS1 pRS424-ACS1 
ACS2 pRS424-ACS2 
ACS* pRS424-SeAcsL641P 
ACS*Opt pRS424-SeAcsL641POpt 
ACS*Opt-L pRS425-SeAcsL641POpt 
cytoPDH pRS414-EcLpdA-EcAceE-EcAceF-BsLplJ (Chapter 3) 
YlACL pRS424-YlACL1-YlACL2 
YlACL-H pRS423-YlACL1-YlACL2 (Chapter 3) 
AtACL pRS423-AtACL1-AtACL2 
pJC2 pIYC04-gapN (27) 
pJC2Z pIYC04-gapN-ZWF1 
MM5 pRS424-cytoMDH3-cytoMaMAE (Chapter 3) 
MM6 pRS424-cytoYlMDH2-cytoMaMAE (Chapter 3) 
TaFAR pRS425-TaFAR (20) 
psXP pRS416-PsXR-PsXDH-PsXDH (30) 
 
* At, Arabidopsis thaliana; Bs, Bacillus subtilis; Ca, Clostridium acetobutylicum; Cb, 
Clostridium beijerinckii; Cn, Cupriavidus necator; Ec, Escherichia coli; Gl, Giardia lamblia; Ps, 
Pichia stiptis; Se, Salmonella enterica; Td, Treponema denticola; Te, Thermoanaerobacter 
ethanolicus; Yl, Yarrowia lipolytica; Opt, codon optimized for expression in S. cerevisiae. 
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Table 4.4 Yeast strains used in this chapter. 
Strains Genotypes 
CEN.PK2-1C MATa; ura3-52; trp1-289; leu2-3,112; his3Δ1; MAL2-8C; SUC2 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
ΔGGAA CEN.PK2-1C gpd1Δ gpd2Δ adh1Δ adh4Δ 
ΔCIT2 CEN.PK2-1C cit2Δ 
ΔMLS1 CEN.PK2-1C mls1Δ 
ΔGGAAC ΔGGAA cit2Δ 
ΔGGAAM ΔGGAA mls1Δ 
Pdc- CEN.PK2-1C pdc1Δ pdc5Δ pdc6Δ 
E10 Pdc-/MTH1T, evolved for better growth on glucose 
iE11 Pdc-/MTH1::MTH1T, evolved for better growth on glucose 
L34 L2612-ura3::URA3-psXR-psXDH-psXKS (21) 
XF3 BY4741 rpd3Δ/ACC1+TaFAR 
XF3w XF3 trp1-289 
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4.8 Figures 
 
Figure 4.1 Overview of acetyl-CoA metabolism in S. cerevisiae, which happens in several 
compartments, including the mitochondria (green), peroxisomes (yellow), nucleus (not shown), 
and cytosol (red). Genes involved in the endogenous glycerol and ethanol pathways and the 
acetyl-CoA consuming glyoxylate shunt are shown in blue and chosen as the targets for deletion. 
The organic acids involved in the transport of acetyl-CoA in different compartments are 
underlined. The heterologous acetyl-CoA biosynthetic pathways tested in this study, including 
cytoPDH, ACS*, and ACL, are shown in red.  
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Figure 4.2 Construction of a CoA-dependent n-butanol pathway as the acetyl-CoA reporter. The 
Clostridia n-butanol biosynthetic pathway HZ1982 was constructed in our previous study (A) 
and the corresponding enzyme activity of each step in the pathway was determined by comparing 
with the control strain with an empty vector (B). The production of n-butanol by 
CEN.PK2/HZ1982 could be complementated by co-expressing a funtional Bad or AdhE/Aad (C). 
Candidate Bad or AdhE/Aad genes were cloned from various organisms, and transformed into 
ΔGGAA strain to test n-butanol production. Arrows indicated the peak for n-butanol.   
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Figure 4.3 Fermentation performance of the wild-type (A and C) and the ΔGGAA (B and D) 
strains on glucose (A and B) and galactose (C and D) under oxygen-limited condition. The 
glucose consumption (blue), acetate production (green), ethanol formation (yellow), and cell 
growth (pink) were compared. 
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Figure 4.4 Host engineering to increase cytosolic acetyl-CoA levels in S. cerevisiae. GPD1 and 
GPD2 responsible for glycerol formation and ADH1 and ADH4 involved in ethanol production 
were inactivated to redirect the glycolytic flux to acetyl-CoA. CIT2 and MLS1 were deleted to 
disrupt the glyoxylate shunt contributing to the consumption of acetyl-CoA in the cytosol of 
yeast.  
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Figure 4.5 Fermentation profiles of the engineered yeast strains, analyzed by GC-MS. Peaks 1, 2, 
3, 4, and 5 were acetaldehyde, methanol (internal standard), ethanol, n-butanol, and acetate, 
respectively.  
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Figure 4.6 Enhancing acetyl-CoA levels via metabolic engineering, as demonstrated by 
increased n-butanol production (A) and increased acetyl-CoA concentration (B). Three series of 
complementary pathways, including the PDH-bypass, cytoPDH, and ACL, were introduced into 
the ΔGGAA S. cerevisiae strain to improve n-butanol production. The amount of n-butanol 
produced was plotted against the measured acetyl-CoA concentration. 
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Figure 4.7 (A) Combination of the most effective and independent acetyl-CoA biosynthetic 
pathways for n-butanol production in the engineered yeast strains under oxygen-limited 
condition. (B) High cell density fermentation for n-butanol production with the combined acetyl-
CoA pathways. The combination of EcPDH and ACS*Opt was found to be the most effective to 
boost acetyl-CoA levels in the engineered yeast strain. 
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Figure 4.8 A) Restoring the growth of Pdc- strain on synthetic medium with low concentration 
glucose (5 g/L) as the sole carbon source via the introduction of alternative acetyl-CoA 
biosynthetic pathways. Pdc-/MTH1 and Pdc-/MTH1T constructed in Chapter 2 were included for 
comparison. B) Engineering better growth of strain Pdc-/cytoPDH on glucose via adaptive 
evolution.  
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Figure 4.9 Redistribution of metabolic profiles in the evolved Pdc- yeast strain. Peaks 1, 2, 3, 4, 
5, and 6 represented iso-butanol, n-butanol, 3-methyl-1-butanol, iso-butyrate, n-butyrate, and 3-
methyl-1-butyrate, respectively.  
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Figure 4.10 Strategies to enhance NADPH levels in S. cerevisiae investigated in this study. The 
first strategy (A) was to overexpress gapN, encoding a non-phosphorylating glyceraldehyde-3-
phosphate (G-3-P) dehydrogenase. The second strategy (B) was to overexpress ZWF1, encoding 
an enzyme that control the entry point of oxidative pentose phosphate pathway. The third 
strategy was to use the ACL-MDH-MAE system, which showed (potential) metabolic 
engineering applications both anabolic and catabolic pathways. 
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Figure 4.11 Metabolic engineering applications of the ACL-MDH-MAE system for both 
catabolic (xylose utilization, A, B, and F) and anabolic pathways (fatty alcohol biosynthesis, C 
and E). Xylose-based fatty alcohol production (E and F) was carried out to investigate the 
relationship between catabolic and anabolic pathways, and the yield of fatty alcohol per sugar 
consumed was compared as well (D). 
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Chapter 5 Acyl-CoAs Pool Engineering via Functional Reversal of the β-
Oxidation Cycle in Saccharomyces cerevisiae  
5.1 Introduction 
Biological conversion of plant-derived lignocellulosic materials into biofuels has been 
intensively investigated due to increasing concerns on energy security, sustainability and global 
climate change (1-3). Although commercial production of bioethanol has been achieved, ethanol 
has its intrinsic shortcomings such as low energy density, high corrosivity, and hydroscopicity. 
Thus, increasing effort has been devoted to produce advanced biofuels, such as n-butanol, long-
chain alcohols, fatty acid ethyl esters (FAEEs or biodiesels), and alkanes, which have similar 
properties to current transportation fuels (4-6). Notably, most of the “drop-in” fuels are derived 
from fatty acids (fatty acyl-CoAs or fatty acyl-ACPs), which can be produced by the endogenous 
fatty acid biosynthetic pathways (FAB) (5). However, classic FAB suffers from high energy 
input and complicated regulation, which significantly hinders efficient and cost-effective 
production of advanced biofuels. Generally, FABs use malonyl-CoA which is activated from 
acetyl-CoA at the cost of ATP consumption as the starter unit, ACP as the acyl activation group, 
and NADPH as the reducing force (7-9). Interestingly, the fatty acid degradation pathway, i.e. 
so-called β-oxidation cycle, which happens in the opposite direction as that of FAB, proceeds in 
a much more efficient manner, as no ATP consuming reaction is involved and CoA and NADH 
are used as co-factors (10, 11).  
 To overcome the major limitation of FAB, a recent report demonstrated that the fatty acid 
degradation enzymes were functional in both degradative and synthetic directions and the 
Escherichia coli β-oxidation cycle could be functionally reversed to synthesize a series of 
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advanced fuels and chemicals, including short-, medium-, and long- chain alcohols and fatty 
acids (12, 13). Compared with the other engineering strategies, this novel platform has several 
advantages for advanced biofuel production, such as the high efficiency by avoiding the energy 
consuming and rate-limiting step to generate malonyl-CoA and the flexibility to produce 
alcohols and fatty acids with different carbon chain lengths. Although E. coli is currently the 
most popular host for metabolic engineering and synthetic biology studies, Saccharomyces 
cerevisiae has several advantages for industrial applications, such as the high tolerance to 
lignocellulose hydrolysate inhibitors and toxic products, the capability of high density 
fermentation, and the absence of phage contamination (1, 2). Although the reversal of β-
oxidation for efficient fuel and chemical synthesis was firstly demonstrated in E. coli (12, 13), it 
might be extended to this eukaryotic system as well, owing to the ubiquitous nature of the β-
oxidation process (10, 11). Therefore, we aimed to develop a new platform, based on the 
reversed β-oxidation pathway, to synthesize a wide variety of fuels and chemicals efficiently and 
cost-effectively in S. cerevisiae, including but not limited to fatty acids, fatty alcohols, FAEEs, 
alkanes, and even waxes (Figure 5.1).  
Although the biochemistry is rather similar, the β-oxidation process in eukaryotes is more 
complicated than that in prokaryotes, mainly due to the compartmentalization of cellular 
metabolisms. Generally, eukaryotic β-oxidation of fatty acids happens in peroxisomes and/or 
mitochondria (14). In S. cerevisiae, peroxisomes are the only cellular compartment responsible 
for the complete degradation of medium- and long- chain fatty acids (10, 11). Due to the 
dependence on fatty acids for optimal activities and the lack of precursors and cofactors for 
biosynthesis, peroxisomes may be not a good location to reverse the β-oxidation cycle. Thus, we 
chose to construct the reversed β-oxidation pathway in the cytosol. To identify functional 
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pathway enzymes, a number of β-oxidation enzymes were cloned from various species and 
expressed in the cytosol of S. cerevisiae. As proof of concept, n-butanol was chosen as a reporter 
molecule because its synthesis requires the reversal of only one β-oxidation cycle. The ability to 
reverse the β-oxidation cycle for multiple times was then demonstrated by the synthesis of 
medium-chain fatty acids (MCFAs) and medium-chain fatty acid ethyl esters (MCFAEEs) in S. 
cerevisiae. To the best of our knowledge, this is the first report on the reversal of the β-oxidation 
cycle in a eukaryote. Note that most contents of this chapter are adapted from one of my research 
articles published in ACS Synthetic Biology (15). 
5.2 Results  
5.2.1 Cloning of Functional β-Oxidation Enzymes Expressed in the Cytosol of S. cerevisiae 
To construct a reversed β-oxidation cycle in S. cerevisiae, a number of genes encoding 
the β-oxidation pathway from various species were cloned. The corresponding enzymes included: 
1) E. coli and yeast β-oxidation enzymes (10, 11, 16, 17); 2) proteins sharing high homology 
with the E. coli reversed β-oxidation pathway enzymes (12); 3) putative enzymes that are 
predicted to have the desired functions or similar activities. Gene cloning and pathway assembly 
were performed using the helper plasmids (pH11, pH22, pH3, pH4, pH5, and pH6) constructed 
in Chapter 3, with the whole promoter or terminator as the homology arm between two adjacent 
cassettes.  
Due to the availability of the commercial CoA substrates, enzyme activity assays were 
performed using C4-CoAs, including acetoacetyl-CoA, β-hydroxybutyryl-CoA, and crotonoyl-
CoA (trans-2-butenoyl-CoA). Considering the broad specificity of the β-oxidation enzymes, the 
enzyme assays using C4-CoAs should be sufficient to represent the β-oxidation activities (18). 
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Since β-oxidation enzymes were localized either in the mitochondria and/or the peroxisomes in 
eukaryotes, the targeting sequences were predicted using the on-line tools (MITOPROT (19) for 
the mitochondrial targeting sequences and PeroxisomeDB 2.0 (20) for the peroxisomal targeting 
sequences) and removed in order to express the proteins in the cytosol of S. cerevisiae. 
5.2.1.1 β-Ketoacyl-CoA synthase (KS) 
The β-ketoacyl-CoA synthase (KS) activity was carried out in the thiolysis direction 
using acetoacetyl-CoA as the substrate. Several KS candidate genes were cloned from both S. 
cerevisiae and E. coli (Table 5.1). The thiolase from Clostridium acetobutylicum (CaThl), which 
is involved in the fermentative production of n-butanol (21), was used as the positive control. 
Both acetyl-transferase (Erg10p, EcAtoB and EcYqeF) and acyl-transferase (cytoFox3p and 
EcFadA) were included for analysis, which showed short-chain specificity (22) and broad 
specificity (17), respectively. As shown in Figure 5.2A, Erg10p showed the highest activity 
towards acetoacetyl-CoA among all enzymes tested, which was consistent with a previous report 
that Erg10p was optimal for n-butanol production in yeast (23). Unfortunately, none of the 
enzymes cloned from E. coli was functional. By removing the peroxisomal targeting sequences, 
Fox3p was relocalized to the cytosol and functionally expressed. Although the activity of 
cytoFox3p was lower than that of Erg10p, this β-oxidation enzyme was expected to exhibit broad 
specificity towards different chain length substrates (10, 11). Therefore, cytoFOX3 was chosen 
to construct the reversed β-oxidation pathways. 
5.2.1.2 β-Ketoacyl-CoA reductase (KR) and β-hydroxyacyl-CoA dehydratase (HTD) 
The second and third steps of β-oxidation were carried out by a multi-functional enzyme, 
FadB in E. coli (16) and Fox2p in S. cerevisiae (17). Unfortunately, neither of them could be 
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functionally expressed in the cytosol of S. cerevisiae (Figure 5.2B). Therefore, more FOX2 
homologs were identified by BLAST search and cloned (Table 5.1). Unfortunately, although 
more than 20 candidate enzymes from different species were tested, none was found to possess 
either KR or HTD activities, towards acetoacetyl-CoA and crotonoyl-CoA, respectively. The 
difference of the protein folding environments between cytosol and peroxisomes might prevent 
all the FOX2 homologs from being functionally expressed in the cytosol of S. cerevisiae. 
Different from S. cerevisiae, some oleaginous yeasts were found to have another set of β-
oxidation system in the mitochondria in addition to the classic system in the peroxisomes (24). 
Therefore, the mitochondrial β-oxidation enzymes were cloned from Yarrowia lipolytica. The β-
hydroxybutyryl-CoA dehydrogenase from C. acetobutylium (CaHbd) and crotonase from C. 
beijerinckii (CbCrt) (21, 25) were included as positive controls. There are two separate enzymes 
in the mitochondrial β-oxidation system to possess KR and HTD activities, encoded by 
YALI0C08811 and YALI0B10406, respectively (24). This is different from the peroxisomal 
system, in which a multifunctional enzyme can catalyze the second and third steps of β-oxidation. 
As shown in Figure 5.2C, both of the mitochondrial β-oxidation enzymes could be functionally 
expressed in the cytosol of yeast, which showed comparable enzymatic activities with the 
clostridial equivalents. Thus, these two enzymes were chosen to construct the reversed β-
oxidation pathways. 
5.2.1.3 Trans-2-enoyl-CoA reductase (TER) 
The first step of β-oxidation is the only irreversible step and carried out by fatty acid 
oxidase with the involvement of an oxygen molecule (10, 11). Instead, trans-2-enoyl-CoA 
reductases (TERs), which are involved in fatty acid biosynthesis (FAB) and only catalyze the 
reaction in the reduction direction, were included as the last step of the reversed β-oxidation 
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pathways. Several TERs, such as those from Euglena gracilis (EgTer) and Treponema denticola 
(TdTer), have been characterized (26-28) and determined to significantly improve the production 
of n-butanol (29, 30) and short-chain fatty acids (13) in E. coli. Therefore, TERs from E. coli, S. 
cerevisiae, E. gracilis and T. denticola and some homologs that shared high homology were 
cloned (Table 5.1). As shown in Figure 5.2D, several candidates involved in the biosynthesis of 
fatty acids, such as the endogenous Etr1p (cytoEtr1p), FabI from E. coli (EcFabI), TER from E. 
gracilis (EgTer), and TER from T. denticola (TdTer), were determined to possess the TER 
activity. Consistent with the previous work (26, 27), TdTer was found to have the highest 
activity when crotonoyl-CoA was used as the substrate. Therefore, cytoETR1 and TdTer were 
chosen to construct the reversed β-oxidation pathways. 
5.2.2 n-Butanol Biosynthesis as Proof-of-concept 
After intensive cloning and screening by enzyme activity assays, several candidates were 
found to be functionally expressed in the cytosol of yeast with the desired activities, with at least 
one functional enzyme in each step of the β-oxidation cycle. Therefore, using the DNA 
assembler method (31, 32), a reversed β-oxidation pathway could be readily constructed. As a 
proof of concept, n-butanol biosynthesis that requires only one cycle reversal of β-oxidation was 
selected. Reversed β-oxidation pathways were constructed using ERG10/cytoFOX3-cytoYlKR-
cytoYlHTD-TdTer/cytoETR1, based on the enzyme activity assay results. To synthesize n-
butanol from butyryl-CoA, the CoA-acylating aldehyde dehydrogenase from E. coli (EcEutE) 
(33, 34) and butanol dehydrogenase from C. acetobutylium (CaBdhB) (21) were included in the 
reversed β-oxidation pathways. As shown in Figure 5.3, n-butanol, although at a very low titer, 
could be detected using the strains containing the reversed β-oxidation pathways, including rP31, 
rP32, rP34, and rP35. Currently, rP34 produced the highest amount of n-butanol, with a titer as 
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high as 20 mg/L in the wild-type yeast strain. Although the titer of n-butanol was still rather low 
compared with that in clostridia (25) and E. coli (12, 29, 30), it was approximately 10 fold higher 
than previous reports using the clostridial n-butanol fermentative pathway in yeast (23, 35), 
highlighting the high efficiency of the reversed β-oxidation pathways.  
The assembled pathways containing functional β-oxidation enzymes could produce a 
small amount of n-butanol, indicating the successful reversal of the β-oxidation cycle. To ensure 
that the detected n-butanol was produced via the reversed β-oxidation pathway, pathway deletion 
and complementation were carried out (Figure 5.3). No n-butanol production was observed if 
cytoYlKR was replaced with eGFP (rP37 and rP38). Co-expression of cytoYlKR together with 
the “incomplete pathways” (rP37c and rP38c) could complement the production of n-butanol. In 
other words, the production of n-butanol was dependent on the presence of a functional reversed 
β-oxidation pathway in yeast. 
5.2.3 Medium-chain Fatty Acids (MCFAs) Production 
To show the reversal of more than one β-oxidation cycle, the production of alcohols with 
longer carbon chains, such as n-hexanol and n-octanol, should be achieved. Unfortunately, the 
CoA acylating aldehyde dehydrogenases or acyl-CoA reductases, which could reduce acyl-CoAs 
to the corresponding aldehydes, with the desired specificities were not available. On the contrary, 
thioesterases (TEs), catalyzing the release of free fatty acids from fatty acyl-CoAs, were well 
characterized and showed broad diversity, ranging from long-chain (C14-C18) and medium-chain 
(C8-C12) to short-chain (C4-C6) specificity.(36) In the present work, CpFatB1, encoding a plant 
thioesterase with medium-chain specificity (37), was included in the reversed β-oxidation 
pathway. Using a modified protocol, all short- and medium- chain fatty acids could be readily 
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separated and detected by GC-MS (Figure 5.4B). In the control strain expressing the thioesterase 
(CpFatB1) with a nonfunctional reversed β-oxidation pathway (rP38), only tiny amount of 
hexanoic acid (C6) and octanoic acid (C8) were detected (Figures 5.4C and 5.6A). The 
introduction of a functional reversed β-oxidation pathway (rP35) resulted in 6.1-fold 
improvement of octanoic acid production, with hexanoic acid production increased slightly as 
well (Figures 5.4D and 5.6A). Since acetyl-CoA served as both the starter and extender units for 
the reversed β-oxidation pathway, the same plasmids (rP35 and CpFatB1) were introduced into 
an acetyl-CoA overproducing host (ΔGGAA/ACS*) constructed in Chapter 4. The cellular 
acetyl-CoA level was increased by simultaneous disruption of the competing pathways (GPD1 
and GPD2 for glycerol biosynthesis and ADH1 and ADH4 for ethanol formation) and 
overexpression of a feedback inhibition insensitive acetyl-CoA synthetase mutant from 
Salmonella enterica (SeAcsL641P). In this acetyl-CoA overproducing strain, additional 3.2-fold in 
octanoic acid production was achieved (Figures 5.4E and 5.6A). In addition, the enhanced 
acetyl-CoA supply led to the production of decanoic acid (C10), whose concentration was too low 
to be detected in the wild-type yeast strain (Figures 5.4 and 5.6A). On the other hand, these 
results indicated that acetyl-CoA was the rate-limiting factor for the efficiency of the reversed β-
oxidation pathway. 
The ability of the reversed β-oxidation pathway to accept odd-chain acyl-CoAs as 
substrates was demonstrated by supplementing propanoic acid to the medium. In S. cerevisiae, 
ACSs, encoded by ACS1 and ACS2, contributed to the activation of propanoate to form 
propionyl-CoA,(38) which might be incorporated into the reversed β-oxidation cycle as well. As 
shown in Figure 5.4F, besides octanoic acid and decanoic acid, nonanoic acid (C9) was also 
detected with propanoic acid supplementation. Interestingly, the production of heptanoic aicd (C7) 
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was nearly un-detectable, probably due to the substrate specificity of the thioesterase used. Our 
current work demonstrated that the β-oxidation cycle was reversed at least 4 times to synthesize 
decanoyl-CoA and the reversed pathway could accept both even- and odd- chain substrates for 
carbon chain initiation and elongation. 
5.2.4 Increased Production of Medium-chain Fatty Acid Ethyl Esters (MCFAEEs) 
During sugar fermentation, S. cerevisiae produces a broad range of aroma-active 
substances, including ethyl octanoate and ethyl decanoate. The formation of MCFAEEs is 
catalyzed by acyl-CoA:ethanol O-acyltransferases, encoded by EEB1 and EHT1 (39, 40). 
Previous work indicated that the supply of MCFAs precursors was the rate-limiting factor for 
MCFAEEs biosynthesis (39, 40). Thus, it was assumed that the production of MCFAEEs would 
be increased if the β-oxidation cycle could be functionally reversed to provide more acyl-CoAs 
precursors. As expected, increased production of ethyl octanoate and ethyl decanoate was 
observed in the strain with a functional reversed β-oxidation pathway. The detection and 
quantification of ethyl octanoate and ethyl decanoate were achieved by GC-MS. As shown in 
Figure 5.5, the production of ethyl octanoate and ethyl decanoate was increased by 2.8- and 2.1-
fold, respectively. Interestingly, although co-expressing EEB1 or EHT1 with the reversed β-
oxidation pathway did not further increase the production of MCFAEEs (Figure 5.6B), the ratio 
of ethyl octanoate and ethyl decanoate was changed from 2:1 to around 1:1. These results might 
be caused by the dual functions of Eeb1p and Eht1p, with both acyltransferase (FAEE synthesis) 
and esterase activity (FAEE hydrolysis) (40). In addition, Eeb1p and Eht1p showed higher 
esterase activity towards octanoate ester than decanoate ester (40), whose overexpression might 
result in the hydrolysis of ethyl octanoate at a higher rate than that of ethyl decanoate. The 
production of FAEEs with alkyl chains longer than 10 was not detected under all conditions, 
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probably due to the specificity of the acyltransferases in S. cerevisiae (Eeb1p, Eht1p, and other 
unknown ones). These results also demonstrated that the β-oxidation cycle was reversed by at 
least 4 turns. 
5.3 Discussions 
The reversal of β-oxidation was confirmed by the production of n-butanol, MCFAs, and 
MCFAEEs in S. cerevisiae. The yeast β-oxidation enzymes show broad specificity towards 
short-, medium-, and long- chain substrates (10, 11), which represents a promising versatile 
platform for synthesis of a wide variety of fuel and chemical molecules with different chain 
lengths. Meanwhile, we also encountered the challenges to control the chain lengths of the final 
products. Currently, the chain lengths of the products were mainly controlled by the specificity 
of the terminal enzymes, such as the thioesterases and acyltransferases. Future work will be 
focused on protein engineering strategies to design the terminal enzymes with the desired 
product specificity (41). 
The present study demonstrated that the β-oxidation cycle could be reversed by 4 times to 
synthesize decanoyl-CoA derived molecules, such as decanoic acid and ethyl decanoate. FAEEs 
with alkyl chain longer than 10 were not detected and no significant difference in the production 
of dodecanoic acid (C12), tetradecanoic acid (C14), and hexadecanoic acid (C16) was observed 
between the strains with or without the reversed β-oxidation pathway (data not shown). These 
findings could result from the substrate specificities of the terminal enzymes used in this study 
and/or the efficiency of the β-oxidation cycle to be reversed by more than 4 times. The CoA 
acylating aldehyde dehydrogenase (EcEutE) showed short-chain specificity and only ethanol and 
n-butanol could be synthesized. The thioesterase (CpFatB1) showed medium-chain specificity 
and C6-C10 fatty acids could be produced. There are no acyltransferases in S. cerevisiae that were 
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reported to be active towards the acyl chains longer than 10. In previous work, both system-level 
engineering approach and synthetic biology approach were applied to construct the functionally 
reversed β-oxidation pathways in E. coli. In the system-level engineering approach, several 
global transcriptional regulators were manipulated to enable the constitutive expression of all β-
oxidation enzymes under anaerobic conditions with the absence of fatty acids and presence of 
glucose. The resultant strain could fully reverse the β-oxidation cycle to produce C16 and C18 
fatty acids at a titer higher than 6 g/L (12). In the synthetic biology approach, all the structural 
genes of the β-oxidation cycle were overexpressed, without any manipulation on the 
transcriptional factors. Interestingly, overexpression of the structural genes only enabled the 
reversal of the β-oxidation cycle up to 5 turns to produce dodecanoic acid (C12), whose titer was 
lower than 5 mg/L (13). The decreased number of reversed turns and the dramatically decreased 
titer for long-chain products indicated some limitations using the synthetic biology approach. 
Since the synthetic biology approach was used in the present study, we might encounter the same 
problems as the E. coli system. Alternatively, a similar system-level engineering approach can be 
applied to this eukaryotic system by manipulating the equivalent global regulators.  
 The high efficiency of the reversed β-oxidation pathway was characterized by its 
energetic benefits of the malonyl-CoA independence and the use of CoA and NADH instead of 
ACP and NADPH as cofactors (12). However, compared with the high efficiency of the reversed 
β-oxidation pathway in E. coli, this system seemed to not work well in yeast, as shown by the 
relatively low n-butanol and fatty acid productivity. One explanation for this observation is the 
difference in acetyl-CoA biosynthesis. In E. coli, acetyl-CoA is steadily synthesized from 
pyruvate by either pyruvate dehydrogenase (PDH) under aerobic conditions (42) and pyruvate-
formate lyase (PFL) under anaerobic conditions (43). While in S. cerevisiae, acetyl-CoA is 
160 
 
mainly generated in the mitochondria, and the reversed β-oxidation pathway enzymes are 
localized in the cytosol. S. cerevisiae lacks the machinery to export the mitochondrial acetyl-
CoA to the cytosol (44), making the situation even worse. Thus, due to the compartmentalization 
of acetyl-CoA metabolism, there is not enough driving force for the reversed β-oxidation 
pathway. In the cytosol of S. cerevisiae, acetyl-CoA is generated via the PDH-bypass pathway, 
from pyruvate to acetaldehyde and then to acetate, which is activated to acetyl-CoA by ACS at 
the cost of two ATP molecules (45). The activation of acetate is rate-limiting, due to the low 
activity of ACS and high energy input requirement. Several metabolic engineering strategies 
have been carried out to boost the availability of acetyl-CoA in yeast, such as the use of an ACS 
mutant with higher activity (35, 46-48) and the introduction of heterologous acetyl-CoA 
biosynthetic pathways with less energy input (49, 50). Notably, these strategies have been 
applied to improve the production of isoprenoids (46, 47), polyhydroxybutyrate (48, 49), n-
butanol (35), and fatty acids (50) in S. cerevisiae. In the acetyl-CoA overproducing host, the 
production of octanoic acid was increased by 3.2-fold and the synthesis of decanoic acid was 
detected, indicating that the cellular acetyl-CoA level was indeed the rate-limiting factor of the 
reversed β-oxidation pathway. Therefore, the construction of an acetyl-CoA overproducing yeast 
may significantly enhance the efficiency of the reversed β-oxidation pathway for advanced 
biofuel production, not only increasing the titer but also diversifying the chain lengths of the 
final products. Considering the compartmentalization of acetyl-CoA metabolism, an alternative 
strategy is to relocate the reversed β-oxidation pathway to the same compartment as the 
precursor metabolite. By fusion with mitochondrial targeting sequences at N-termini, the 
engineered enzymes can be imported to the mitochondria (51, 52). Since the major β-oxidation 
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enzymes used in the present study originated from the mitochondria of Y. lipolytica, they should 
be functional in the mitochondria of S. cerevisiae.  
5.4 Conclusions 
To construct a functional reversed β-oxidation pathway, approximately 40 enzyme 
homologs were cloned from various species and at least one functional enzyme was obtained for 
each catalytic step. The production of n-butanol, MCFAs, and MCFAEEs indicated that the β-
oxidation cycle was functionally reversed. More work should be done to further increase the 
intracellular acetyl-CoA level to push the β-oxidation cycle to be reversed more efficiently.  
5.5 Methods 
5.5.1 Strains, media, and cultivation conditions 
E. coli strain DH5α was used to maintain and amplify plasmids. S. cerevisiae CEN.PK2-
1C (MATa ura3-52 trp1-289 leu2-3,112 his3Δ1 MAL2-8C SUC2, EUROSCARF) was used as the 
host for gene cloning and n-butanol, MCFAs, and MCFAEEs fermentation. Yeast strains were 
cultivated in complex medium consisting of 2% peptone and 1% yeast extract supplemented with 
2% glucose (YPD). Recombinant strains were grown on synthetic complete medium consisting 
of 0.17% yeast nitrogen base, 0.5% ammonium sulfate, and 0.07% amino acid drop out mix 
without leucine and/or uracil (MP Biomedicals, Solon, OH), supplemented with 2% glucose 
(SCD-LEU, SCD-URA, OR SCD-LEU-URA). E. coli strains were cultured at 37oC in Luria-
Bertani broth containing 100 μg/mL ampicillin. S. cerevisiae strains were cultured at 30oC and 
250 rpm for aerobic growth, and 30oC and 100 rpm in un-baffled shaker flasks for oxygen 
limited fermentation. All restriction enzymes, Q5 High Fidelity DNA polymerase, and the E. coli 
- S. cerevisiae shuttle vectors, including pRS425 and pRS426, were purchased from New 
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England Biolabs (Ipswich, MA). All chemicals were purchased from either Sigma-Aldrich (St. 
Louis, MO) or Fisher Scientific (Pittsburgh, PA). 
5.5.2 DNA manipulation 
The yeast homologous recombination based DNA assembler method (31, 32) was used to 
construct the helper plasmids, clone candidate genes and assemble the reversed β-oxidation 
pathways (Table 5.1). Briefly, polymerase chain reaction (PCR) was used to generate DNA 
fragments with homology arms at both ends, which were purified with a QIAquick Gel 
Extraction Kit (Qiagen, Valencia, CA) and co-transformed along with the linearized backbone 
into S. cerevisiae. All genetic elements including promoters, coding sequences, and terminators 
were PCR-amplified from their corresponding genomic DNAs. Wizard Genomic DNA 
Purification Kit (Promega, Madison, WI) was used to extract the genomic DNAs from both E. 
coli and various yeast species, according to the manufacturer’s protocol. The sequence encoding 
the medium-chain thioesterase from Cuphea palustris (CpFatB1) was synthesized by two gBlock 
fragments and cloned into pH5 via the DNA assembler method. To confirm the correct clones, 
yeast plasmids were isolated using a Zymoprep Yeast Plasmid Miniprep II Kit (Zymo Research, 
Irvine, CA) and re-transformed into E. coli DH5α competent cells. Plasmids were isolated using 
a QIAprep Spin Miniprep Kit (Qiagen) and confirmed by DNA sequencing. Yeast strains were 
transformed using the LiAc/SS carrier DNA/PEG (53) method, and transformants were selected 
on either SCD-LEU, SCD-URA, or SCD-LEU-URA plates. 
5.5.3 Enzyme activity assays 
To measure the activity of enzymes expressed in yeast, a single colony was inoculated 
into 5 mL SCD-LEU medium, and cultured under aerobic conditions for about 36 h. Then cells 
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were collected by centrifugation at 4,000 g for 5 min at 4oC, washed twice with pre-chilled water, 
and resuspended in 250 μL Yeast Protein Extraction Reagent (YPER). After incubation at 25oC 
with 700 rpm shaking in a thermomixer for 20 minutes, the supernatant containing all soluble 
proteins were separated by centrifugation at 14,000g for 10 min at 4oC and ready for enzyme 
activity assays. All the assays were performed in 96-well microplates at 30oC and the 
spectrophotometric changes were monitored using the Biotek Synergy 2 Multi-Mode Microplate 
Reader (Winooski, VT). The reaction was initiated by the addition of 10-20 μL cell extract, to a 
total volume of 200 μL. Enzyme activity was calculated using the initial reaction rate and 
normalized to the total protein concentration determined by the Bradford assay. 
 The KS activity was measured by monitoring the disappearance of acetoacetyl-CoA, 
corresponding to the thiolysis direction of the enzymatic reaction, which was monitored by the 
decrease in absorbance at 303 nm. The reaction mixture contained 100 mM Tris-HCl (pH 8.0), 
10 mM MgSO4, 200 μM acetoacetyl-CoA, and 200 μM free CoA.  
 The KR activity was measured by monitoring the decrease of absorption at 340 nm, 
corresponding to the consumption of NADH in the reducing direction of the reaction. The 
reaction mixture contained 100 mM potassium phosphate buffer (pH 7.3), 200 μM NADH, and 
200 μM acetoacetyl-CoA.  
 The HTD activity was measured by the decrease of absorption at 263nm, corresponding 
to the disruption of the carbon-carbon double bond of crotonoyl-CoA. The assay mixture 
contained 100 mM Tris-HCl (pH 7.6) and 100 μM crotonoyl-CoA.  
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 The TER activity was measured at 340 nm, corresponding to the consumption of NADH 
to reduce crotonoyl-CoA. The reaction mixture contained 100 mM potassium phosphate buffer 
(pH 6.2), 200 μM NADH, and 200 μM crotonoyl-CoA.  
5.5.4 n-Butanol fermentation and detection 
A single colony with the reversed β-oxidation pathway from the newly transformed plate 
was inoculated into 3 mL SCD-URA medium, and cultured under aerobic conditions for 36 h. 
Then 200 μL seed culture was transferred into 10 mL fresh SCD-URA medium in a 50 mL 
unbaffled shaker flask at an initial OD600 of about 0.05, and cultured under oxygen-limited 
conditions for n-butanol fermentation. Samples were taken every 24 h after inoculation until no 
further increase in n-butanol production was observed. The production of n-butanol was detected 
and quantified by GC-MS as described in section 4.5.4. 
5.5.5 MCFAs fermentation and detection 
A single colony with the reversed β-oxidation pathway and CpFatB1 was inoculated into 
3 mL SCD-LEU-URA medium, and cultured under aerobic conditions for 36 h. Then 400 μL 
seed culture was transferred into 20 mL fresh SCD-LEU-URA medium in a 125 mL baffled 
shaker flask at an initial OD600 of about 0.05, and cultured under aerobic conditions for MCFAs 
fermentation for 48 h. 
 Fatty acids were analyzed using a previously described protocol with some modifications 
(37). A previous report indicated that the short- and medium- chain fatty acid methyl esters were 
rather volatile, leading to increased variability of the fatty acid analysis (37). Thus, N-(t-
butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) was used to derivatize short- and 
medium- chain fatty acids in the present study (Figure 5.4A). The fatty acid t-butyldimethylsilyl 
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esters were less volatile, which would make the derivatization process more reproducible. 5 
mg/L heptanoic acid was added as an internal standard. Extracellular fatty acids were extracted 
from 20 mL culture supernatant by adding 2 mL 1M HCl and 5 mL of a 2:1 
chloroform:methanol mixture. The solution was vortexed and then centrifuged for 5 min at 4,000 
rpm. The lower chloroform layer was recovered and evaporated in the chemical hood overnight. 
For derivatization, 100 μL MTBSTFA and 100 μL tetrahydrofuran (THF) were added to the 
dried sample, which was then incubated at 70ºC for 1 h. The THF layer was diluted 10-100 fold 
into THF and analyzed by a Shimadzu GCMS-QP2010 Plus GC-MS equipped with an AOC-
20i+s autosampler (Shimadzu Inc., Columbia, MD) and a DB-Wax column with a 0.25 μm film 
thickness, 0.25 mm diameter, and 30 m length (Agilent Inc., Palo Alto, CA). Injection port and 
interface temperature was set at 250 ºC, and the ion source was set to 230 ºC. The helium carrier 
gas was set at a constant flow rate of 2 mL/min. The oven temperature program was set as the 
following: a) hold at 50ºC for 3 min, b) increase at the rate of 5ºC min-1 to 120ºC, c) increase at 
the rate of 50ºC min-1 to 230ºC, d) and then isothermal heating at 230ºC for additional 3 min.  
5.5.6 MCFAEEs fermentation and detection 
A single colony with the reversed β-oxidation pathway from the fresh plate was 
inoculated into 3 mL SCD-URA medium, and cultured under aerobic conditions for 36 h. Then 
100 μL seed culture was transferred into 5 mL fresh SCD-URA medium topped with 10% n-
dodecane overlay in a 20 mL glass tube at an initial OD600 of about 0.05, and cultured under 
aerobic conditions for MCFAEEs fermentation for 48 h. 
 The top n-dodecane layer was collected, diluted 100 fold in ethyl acetate containing 1 
mg/L n-decanol as an internal standard, and analyzed using the same GC-MS settings as 
166 
 
mentioned above. The oven temperature program was set as the following: a) hold at 50ºC for 2 
min isothermal heating, b) increase at the rate of 50ºC min-1 to 230ºC, c) and then hold at 230ºC 
for additional 15 min.  
5.5.7 Prediction of the mitochondrial and peroxisomal targeting sequences  
The mitochondrial targeting sequences of the candidate proteins were predicted using the 
MITOPROT online tool (http://ihg.gsf.de/ihg/mitoprot.html) (19). The peroxisomal targeting 
sequences were predicted using the PTSs predictor from PeroxisomeDB 2.0 
(http://www.peroxisomedb.org/Target_signal.php) (20).  
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5.7 Tables 
Table 5.1 List of plasmids constructed in this chapter. 
Plasmid Constructs 
p426 pRS426, multi-copy plasmid with URA3 marker 
pH11 p425-GPM1p-BamHI-eGFP-XhoI-ADH1t 
pH22 p425-ADH1t-GPDp-BamHI-eGFP-XhoI-CYC1t 
pH3 p425-ENO2p-BamHI-eGFP-XhoI-PGK1t 
pH4 p425-TPI1p-BamHI-eGFP-XhoI-TPI1t 
pH5 p425-TEF1p-BamHI-eGFP-XhoI-TEF1t 
pH66 pR25-TEF1t-PGK1p-BamHI-eGFP-HindIII-HXT7t 
CaThl pH11-CaThl 
ERG10 pH11-ERG10 
cytoFox3 pH11-cytoFox3 
EcAtoB pH11-EcAtoB 
EcYqeF pH11-EcYqeF 
EcFadA pH11-EcFadA 
cytoFOX2 pH22-cytoFOX2 
EcFadB pH22-EcFadB 
cytoTdeFOX2 pH22-cytoTdeFOX2 
cytoCgFOX2 pH22-cytoCgFOX2 
cytoNdFOX2 pH22-cytoNdFOX2 
cytoVpFOX2 pH22-cytoVpFOX2 
cytoNcFOX2 pH22-cytoNcFOX2 
cytoKlFOX2 pH22-cytoKlFOX2 
cytoTpFOX2 pH22-cytoTpFOX2 
cytoZrFOX2 pH22-cytoZrFOX2 
cytoAgFOX2 pH22-cytoAgFOX2 
cytoPpFOX2 pH22-cytoPpFOX2 
cytoPfFOX2 pH22-cytoPfFOX2 
cytoHpFOX2 pH22-cytoHpFOX2 
cytoCpFOX2 pH22-cytoCpFOX2 
cytoPgFOX2 pH22-cytoPgFOX2 
cytoCdFOX2 pH22-cytoCdFOX2 
cytoCtrFOX2 pH22-cytoCtrFOX2 
cytoSsFOX2 pH22-cytoSsFOX2 
cytoLeFOX2 pH22-cytoLeFOX2 
cytoCteFOX2 pH22-cytoCteFOX2 
cytoYlFOX2 pH22-cytoYlFOX2 
CaHbd pH22-CaHbd 
cytoYlKR pH22-cytoYALI0C08811g 
CbCrt pH6-CbCrt 
cytoYlHTD pH66-cytoYALI0B10406g 
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Table 5.1 (cont.)  
  
Plasmid Constructs 
cytoETR1 pH3-cytoETR1 
ZTA1 pH3-ZTA1 
cytoSPS19 pH3-cytoSPS19 
YNL134C pH3-YNL134C 
YLR460C pH3-YLR460C 
YCR102C pH3-YCR102C 
EcYdiO pH3-EcYdiO 
EcFabI pH3-EcFabI 
EgTer pH3-EgTer 
TdTer pH3-TdTer 
EcEutE pH4-EcEutE 
CaBdhB pH5-CaBdhB 
CpFatB1 pH5-CpFatB1 
EEB1 pH5-EEB1 
EHT1 pH5-EHT1 
rP31 p426-ERG10-cytoYlKR-cytoYlHTD-TdTer-EcEutE-CaBdhB 
rP32 p426-cytoFOX3-cytoYlKR-cytoYlHTD-TdTer-EcEutE-CaBdhB 
rP34 p426-ERG10-cytoYlKR-cytoYlHTD-cytoETR1-EcEutE-CaBdhB 
rP35 p426-cytoFOX3-cytoYlKR-cytoYlHTD-cytoETR1-EcEutE-CaBdhB 
rP37 p426-ERG10-eGFP-cytoYlHTD-TdTer-EcEutE-CaBdhB 
rP38 p426-cytoFOX3-eGFP-cytoYlHTD-TdTer-EcEutE-CaBdhB 
 
*Ag, Ashbya gossypii; Ca, Clostridium acetobutylicum; Cb, Clostridium beijerinckii; Cd, 
Candida dubliniensis; Cg, Candida glabrata; Cp, Candida parapsilosis; Cte, Candida tenuis; Ctr, 
Candida tropicalis; Ec, Escherichia coli; Eg, Euglena gracilis; Hp, Hansenula polymorpha; Kl, 
Kluyveromyces lactis; Le, Lodderomyces elongisporus; Nc, Naumovozyma castellii; Nd, 
Naumovozyma dairenensis; Pf, Pichia farinose; Pg, Pichia guilliermondii; Pp, Pichia pastoris; 
Ss, Scheffersomyces stipites; Td, Treponema denticola; Tde, Torulaspora delbrueckii; Tp, 
Tetrapisispora phaffii; Vp, Vanderwaltozyma polyspora; Yl, Yarrowia lipolytica; Zr, 
Zygosaccharomyces rouxii. 
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5.8 Figures 
 
 
 
Figure 5.1 Overview of the synthesis of advanced biofuels by reversing the β-oxidation cycle in 
Saccharomyces cerevisiae. Reversed β-oxidation pathways were constructed via constitutive 
overexpression of the β-oxidation structural genes in the cytosol of yeast. To increase the 
cytosolic acetyl-CoA level, competing pathways for acetyl-CoA biosynthesis were inactivated 
and an acetyl-CoA synthetase mutant (ACS) free of feedback inhibition was overexpressed. KS, 
β-ketoacyl-CoA synthase; KR, β-ketoacyl-CoA reductase; HTD, β-hydroxyacyl-CoA 
dehydratase; TER, trans-2-enoyl-CoA reductase; CpFatB1, thioesterase from Cuphea palustris; 
EcEutE, CoA-acylating aldehyde dehydrogenase from Escherichia coli; CaBdhB, butanol 
dehydrogenase from Clostridium acetobutylium; EEB1/EHT1, acyl-CoA:ethanol O-
acyltransferases; ADH, alcohol dehydrogenase; FAEE, fatty acid ethyl ester. 
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Figure 5.2 Enzyme activity assays of the reversed β-oxidation pathway enzymes, including KS 
(A), KR (B), HTD (C), and TER (D). The CoA-dependent n-butanol biosynthetic pathway 
enzymes including CaThl, CaHbd, CbCrt, and TdTer were used as positive controls for KS, KR, 
HTD, and TER activity assays, respectively.  
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Figure 5.3 Detection and confirmation of n-butanol synthesis by the reversed β-oxidation 
pathways. The production of n-butanol could only be detected when a fully functional reversed 
β-oxidation pathway was present (rP31, rP32, rP34, and rP35). The failure of the control strains 
with either an empty vector (p426) or a nonfunctional pathway (rP37 and rP37) indicated the 
dependence of n-butanol production on the reversed β-oxidation pathways in S. cerevisiae. The 
production of n-butanol could be complemented by co-expressing cytoYlKR together with the 
incomplete pathway (rP37c and rP38c). 
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Figure 5.4 Production of MCFAs by the reversed β-oxidation pathway. (A) A protocol to 
derivatize and detect short-chain fatty acids by GC-MS was developed. MTBSTFA was chosen 
as the derivatiation reagents, since the derived fatty acid t-butyldimethylsilyl esters were less 
volatile and could be more accurately measured. (B) Using the developed GC-MS program, all 
short- and medium-chain fatty acids could be well separated and detected. (C) Extracellular fatty 
acid profiles of the wild-type strain expressing the thioesterase with an incomplete reversed β-
oxidation pathway.  (D) Extracellular fatty acid profiles of the wild-type strain expressing the 
thioesterase with a functional reversed β-oxidation pathway. (E) Extracellular fatty acid profiles 
of an acetyl-CoA overproducing strain expressing the thioesterase with a functional reversed β-
oxidation pathway. (F) Production of odd-chain fatty acids with the supplementation of 0.1 g/L 
propanoic acid. 5 mg/L heptanoic acid was included as an internal standard (C, D, and E), except 
for D to show the full profiles of MCFAs produced by the engineered yeast strain.  
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Figure 5.5 Increased production of MCFAEEs by the reversed β-oxidation pathway. Production 
of ethyl octanoate and ethyl decanoate was compared between the strains expressing either an 
incomplete (A) or a functional (B) reversed β-oxidation pathway. 1 mg/L n-decanol was included 
as an internal standard. The MS fragments of ethyl octanoate (C, D) and ethyl decanoate (E, F) 
were compared between the samples (C, E) and the standards (D, F).   
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Figure 5.6 Distribution of medium-chain fatty acids (A) and medium-chain fatty acid ethyl 
esters (B) produced by yeast strains with or without the reversed β-oxidation pathway.   
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Chapter 6 Modular Pathway Optimization at DNA Level: Induced Pathway 
Optimization by Antibiotic Doses  
6.1 Introduction 
Increasing attention has been drawn to convert renewable feedstocks into fuels, chemicals, 
and other value-added compounds, using microbial fermentation at large scales (1, 2). The 
introduction of biosynthetic pathways containing several heterologous genes is generally the first 
step to achieve microbial synthesis. In order to enable commercially viable production of these 
compounds, metabolic fluxes or protein levels in the heterologous multi-gene pathways must be 
carefully fine-tuned and balanced to maximize product titers, yields, and productivities (3, 4). 
The optimization of a multi-gene pathway can be achieved at DNA level (copy number (5, 6)), 
transcription and mRNA level (promoter engineering (7-9), intergenic region engineering (10), 
and terminator engineering (11)), translation and protein level (ribosome binding site engineering 
(12) and protein co-localization (13)), and metabolite level (dynamic control (14-16)). Notably, 
most of these synthetic biology tools are well developed for Escherichia coli. While in 
Saccharomyces cerevisiae, a preferred host for industrial applications, the development of these 
pathway optimization tools is far behind due to the complexity as a eukaryotic cell factory and 
limited to a few examples, such as the use of promoters (9, 17) and terminators (11) with 
different strength. Recently, RNA interference (RNAi) was also reconstituted in this eukaryotic 
host to modulate gene expression levels (18-20) and showed (potential) applications in metabolic 
engineering and synthetic biology. However, the use of RNAi for multi-gene pathway 
optimization has not been explored yet. Notably, gene expression levels and metabolic fluxes are 
mainly fine-tuned at the transcription and mRNA level, which was usually reported to have a 
limited dynamic range (~10 fold) (21). What is worse, lower expression or knock-down is 
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generally obtained using either promoter engineering or RNAi, while to achieve much higher 
expression level is more challenging (7, 9). Therefore, this work aimed to develop new synthetic 
biology tools to fine-tune protein expression levels and metabolic fluxes at DNA level, in the 
hope of further expanding the dynamic range of pathway optimization tools in S. cerevisiae. 
Plasmids have been extensively used for both fundamental studies and metabolic 
engineering and synthetic biology applications, since they have the advantages of convenience 
and ease of use, flexibility of transferring to different hosts, high copy number to allow strong 
gene expression, and high transformation efficiency for library construction and high throughput 
screening (9, 11, 22).  In S. cerevisiae, two sets of episomal plasmids have been developed, the 
so-called CEN/ARS-based low-copy plasmids (1-4 copies per cell) and 2µ-based high-copy 
plasmids (20-30 copies per cell with auxotrophic markers and 4-6 copies with antibiotic markers). 
These plasmids are constructed using a series of auxotrophic selection markers (such as HIS3, 
TRP1, LEU2, and URA3) and dominant antibiotic markers (such as KanMX, HygB, and Ble). 
Although widely used, the current system suffers from low copy numbers and a lack of dynamic 
range, making them rather limited for multi-gene pathway optimization. Previously, it was found 
that plasmid copy number (PCN) could be enhanced by weakening the expression of the 
selection marker genes (such as the use of heterologous or truncated promoters) (23-26) and 
destabilizing the marker proteins (such as fusion with a degradation tag) (22). This study aims to 
construct a series of 2µ-based plasmids with step-wise increased copy numbers, which can be 
used for modular optimization of multi-gene pathways. Assuming that promoter length may 
control the expression level of the marker gene, plasmids with different copy numbers can be 
obtained by truncating the promoter to different degrees in S. cerevisiae. 
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In the present study, the promoters driving the expression of selection marker genes, 
including HIS3, TRP1, LEU2, URA3, KanMX, and HygB, were truncated to different degrees 
and their effects on PCNs were systematically evaluated. By simply performing promoter 
truncation, plasmids with different copy numbers (as high as 100 copies per cell) were 
constructed, and a dynamic range of around 20 folds were achieved for engineered plasmids with 
KanMX and HygB markers, which endowed G418 and hygromycin resistance, respectively. 
More importantly, the copy number of the plasmids with engineered dominant markers (5-100 
copies per cell) showed a positive correlation with the concentration of antibiotics supplemented 
to the growth media. Therefore, a simple method named iPOAD (induced pathway optimization 
by antibiotic doses) was developed for modular optimization of multi-gene pathways by different 
combination of antibiotic concentrations. The applications of iPOAD were demonstrated by 
modular optimization of the lycopene and n-butanol biosynthetic pathways, with the production 
of lycopene and n-butanol increased by 10- and 100-fold, respectively. Considering the strain 
stability and the requirement of antibiotic supplementation, the pathway optimized by iPOAD 
was integrated into chromosomes using delta integration. Multiplex double cross-over based 
integration at different loci of delta sequences was achieved by combining iPOAD and the 
CRISPR-Cas9 technology. 
6.2 Results 
6.2.1 Enhanced plasmid copy number via truncation of marker gene promoters 
Previously it was found that the use of truncated promoters or partially defective 
promoters driving the expression of the marker genes (LEU2 and URA3) led to significantly 
enhanced copy numbers of the 2µ-based plasmids (23, 24). Therefore, this simple strategy was 
also applied to other markers commonly used in S. cerevisiae, especially for those with dominant 
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antibiotic markers, which were reported to have very low PCNs (4-6 copies per cell) even though 
the 2µ-based backbone was used (11). Since plasmids with step-wise increased copy numbers 
are rather desirable for pathway optimization at DNA levels, promoter truncation at different 
levels (TP5, TP4, TP3, TP2, and TP1 corresponded to the use of 15 bp, 20 bp, 30 bp, 50 bp, and 
100 bp sequences upstream of the start codon as the partially defective promoters, respectively) 
were performed for four auxotrophic markers (HIS3, TRP1, LEU2, and URA3) and two 
dominant markers (KanMX and HygB). The effects of promoter truncation on PCNs were 
systematically evaluated by using eGFP as a reporter (Figure 6.1). Using the dual marker system, 
all recombinant yeast strains were pre-cultured in SCD-LEU (non-selective media, except for 
those with LEU2 marker) to have a similar start point and then transferred to the corresponding 
selective media to study the effects of promoter truncation on PCNs. As shown in Figure 6.2A, 
no significant difference in eGFP fluorescence intensity was observed in non-selective media, 
which was gradually increased with a higher degree of promoter truncation in the corresponding 
selective media. For TRP1 and LEU2, PCNs were only slightly enhanced with partially defective 
promoters, while promoter truncation resulted in a step-wise increase of PCNs for HIS3, URA3, 
KanMX, and HygB, which showed a dynamic range around 5-10 fold (Figure 6.2B). By 
measuring PCNs with qPCR, it was found that PCNs followed the same pattern as those of eGFP 
intensity, and a strong linear correlation (R2=0.87) between PCNs and eGFP intensities could be 
constructed (Figures 6.2C and 6.2D), indicating that eGFP intensity could be used as a reporter 
of PCNs in S. cerevisiae. Notably, dominant markers with full-length promoters (wild-type 
markers) showed rather low PCNs (lower than 5 copies per cell), even though the 2µ origin of 
replication was used, which agreed well with previous studies (11). Through promoter truncation, 
PCNs as high as 80 copies per cell could be achieved with either 200 mg/L G418 or hygromycin 
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supplemented to the growth media, which represented a 20-fold enhancement in PCNs. If 
mCherry was cloned instead of eGFP, the effects of promoter truncation could even be seen by 
naked eyes (Figure 6.2E). In addition, flow cytometry indicated that the enhanced PCNs were 
resulted from the redistribution of plasmids with different copy numbers (Figure 6.2F). Promoter 
truncation provided a selection pressure for plasmids with higher copy numbers and cells with 
higher PCNs would be enriched. Compared with those containing wild-type promoters which 
showed two peaks of eGFP fluorescence by flow cytometry, a single peak was observed for 
those with truncated promoters (engineered markers) (Figure 6.2F). In other words, besides the 
enhanced PCNs, the yeast population containing the engineered markers was more homogenous, 
which is another important feature useful for metabolic engineering and synthetic biology 
applications.   
6.2.2 Dependence of PCNs on antibiotic concentrations 
Since dominant markers with truncated promoters showed much higher PCNs, it was 
assumed that plasmids with these engineered markers might be more sensitive to the 
concentration of antibiotics. To prove this, G418 or hygromycin was supplemented to the growth 
media at different concentrations. Interestingly, as the antibiotic concentration increased, 
although PCNs were constant with the wild-type markers, a nice step-wise increase in PCNs 
could be obtained when engineered markers were used (Figure 6.3), especially for Kan20 (TP4) 
and Hyg30 (TP3). In other words, PCNs with engineered markers were antibiotic dose-
dependent. Generally, PCNs were more sensitive to antibiotic concentrations with shorter 
promoters (higher degrees of truncation), leading to a larger dynamic range of PCNs. However, 
it was also found that the dynamic range of PCNs was lost if the promoter was truncated too 
much, such as the case with Hyg20 (TP4). Therefore, the promoter driving the expression of the 
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selection marker gene must be carefully engineered to achieve the best performance, such as the 
largest dynamic range for pathway optimization in this study. By combining promoter 
engineering and the optimal antibiotic concentration, PCNs as high as 120 copies per cell were 
achieved for both engineered KanMX and HygB markers.  
6.2.3 Modular pathway optimization using plasmids with different copy numbers 
Since a series of plasmids with step-wise increased copy numbers were obtained via 
promoter truncation, it was desirable to test whether they could be used to fine-tune the 
metabolic fluxes of a biosynthetic pathway at the DNA level. As a proof of concept, two 
fluorescent proteins (eGFP and mCherry) were cloned into HIS3 (HIS-CEN, HIS-WT, HIS100, 
HIS50, HIS30, and HIS15) and URA3 (URA-CEN, URA-WT, URA100, URA50, URA30, and 
URA15) based plasmids, respectively. As shown in Figures 6.4A and 6.4B, the eGFP and 
mCherry signals were almost distributed as expected, with eGFP mainly determined by HIS3 
plasmids and mCherry by URA3 plasmids. Indeed, some interactions between the two series of 
plasmids were observed. For example, both eGFP and mCherry signals were significantly 
decreased when both were cloned into the plasmids with high copy numbers, probably due to the 
competition between these 2µ-based plasmids. 
To further test whether antibiotic concentrations could be modulated to fine tune 
metabolic fluxes, eGFP and mCherry were cloned into Hyg30 and Kan20, respectively. Similarly, 
a nice distribution of eGFP and mCherry signals was obtained, with eGFP mainly determined by 
the concentration of hygromycin and mCherry by the concentration of G418, albeit not following 
a completely independent manner (Figures 6.4C and 6.4D). 
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Based on these results, plasmids with different copy numbers obtained by either promoter 
truncation at different levels or modulating antibiotic concentration could be used for pathway 
optimization at the DNA level. Especially for the latter, metabolic fluxes could be fine-tuned by 
simply modulating antibiotic concentration, representing a simplest strategy for pathway 
optimization. This method was named induced pathway optimization via antibiotic doses 
(iPOAD) for pathway optimization at the DNA level. 
6.2.4 Increased lycopene production via iPOAD 
To demonstrate that iPOAD could be applied for the optimization of multi-gene pathways, 
lycopene biosynthesis was chosen as the first example. The whole pathway involved more than 
10 genes from acetyl-CoA was divided into two modules at the farnesyl diphosphate (FPP) 
branch, the FPP module with Hyg30 marker and Lyc module with Kan20 marker (Figure 6.5A). 
The FPP module contained several endogenous genes (ERG10-ERG13-tHMGR-ERG12-ERG8-
ERG20) whose overexpression was confirmed to enable higher fluxes from acetyl-CoA to FPP 
(27), and the lycopene module contained genes (CrtE-CrtB-CrtI) that were responsible for the 
conversion of FPP to lycopene (28). By testing different combinations of G418 and hygromycin 
concentrations, it was found that lycopene production was increased at higher concentration of 
hygromycin, while G418 concentration had no effect (Figure 6.5B), indicating that the FPP 
module was the rate-limiting factor. Therefore, hygromycin was supplemented at higher 
concentration to further increase the metabolic fluxes towards FPP. Indeed, lycopene production 
continued to be improved as the hygromycin concentration was increased (Figure 6.5C). 
Compared with the system containing wild-type promoters, the production of lycopene was 
increased about 3 fold by promoter truncation and additional 3 fold by iPOAD, resulting in a 
total of around 10 fold improvement (Figure 6.5D). 
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6.2.5 Improved n-butanol fermentation via iPOAD 
Although significant improvement in lycopene production was achieved, the balancing of 
metabolic fluxes at the DNA level was not clearly demonstrated, since the FPP module was rate-
limiting. Therefore, another multi-gene pathway leading to the biosynthesis of n-butanol was 
tested. The whole pathway was divided into two modules at the butyryl-CoA branch, the 
upstream module (Thl-Hbd-Crt-Ter, from acetyl-CoA to butyryl-CoA) with Hyg30 marker and 
downstream module (Bad-Bdh, from butyryl-CoA to n-butanol) with Kan20 marker (Figure 
6.6A). By testing different combinations of G418 and hygromycin concentrations, it was found 
that the optimal condition for n-butanol production was 800 mg/L of hygromycin and 400 mg/L 
of G418 (Figure 6.6B). Higher concentration of hygromycin before reaching the optimal level 
was better for n-butanol production, since the overall fluxes were controlled by the upstream 
module. The optimal G418 concentration was dependent on the upstream module, since the 
downstream module functioned to balance the overall fluxes. In other words, the concentration 
of hygromyin and G418 should be carefully adjusted to fine-tune the metabolic fluxes of both 
modules, since higher concentration would lead to cellular burdens and lower concentration 
would result in limited (upstream module) or unbalanced (downstream module) metabolic fluxes. 
Compared with the system containing wild-type promoters, the production of n-butanol was 
increased about 10 fold by promoter truncation (due to enhanced PCNs) and additional 10 fold 
by iPOAD (due to balanced metabolic fluxes), resulting in a total of around 100 fold 
improvement (Figure 6.6C). 
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6.2.6 Multiplex pathway integration via CRISPR-Cas9 
Although iPOAD enabled the optimization of a multi-gene pathway at the DNA level by 
simply modulating the antibiotic concentration, its practical or industrial applications would be 
limited by the requirement for high concentration of antibiotics. Therefore, a final goal of this 
work was to transfer the iPOAD optimized pathway to chromosomes, since genome integrated 
strains were reported to have much higher stability and might eliminate the requirement of 
antibiotic supplementation to maintain the plasmids with high copy numbers. Assuming the 
engineered markers could control the copy numbers of plasmids, they might be able to control 
the copy numbers in the genome as well. To test this hypothesis, Kan20 with a 40 bp homology 
arm at both ends was integrated into delta sequences and the resultant strains were screened on 
plates with different G418 concentrations. As shown in Table 6.1, all the clones tested had only 
one copy integration at lower selection pressure, while delta integration with more than 30 copies 
could be achieved at higher G418 concentrations, indicating that the integration copy numbers 
were also follow a similar dose-dependent manner. Unfortunately, no colonies could be obtained 
if a large biosynthetic pathway was included together with the engineered marker, probably due 
to the lower transformation and/or integration efficiency of large DNA fragments. The 
introduction of a double strand break on the chromosome was reported to boost the efficiency of 
homologous recombination (HR) to a much higher level, with an improvement of at least 1000 
fold (29). Therefore, the newly developed CRISPR-Cas9 system was employed to achieve 
multiplex delta integration (Di-CRISPR, Figure 6.7). 
First of all, mCherry was cloned into the donor plasmid with Kan20 marker to optimize 
Di-CRISPR. As shown in Figure 6.8, the optimal condition to achieve highest delta integration 
efficiency is to place the CRISPR-Cas9 system on a super-high copy plasmid and three serial 
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transfers on integration medium and one transfer in plasmid rescue medium. Combined with 
counter selection, all donor plasmids were removed from the system, as confirmed by the 
inability of the 24 randomly picked up colonies to grow on SCD-URA (data not shown). After 
screening colonies on SCD plates containing different concentrations of G418, the fluorescence 
was found to be dependent on the selection pressure (higher antibiotic concentration resulted in 
more intensive fluorescence), confirming our assumption that the engineered markers were able 
to control the copy numbers of integrated cassettes on chromosome (Figure 6.9A). 
Then the upstream module and downstream module of n-butanol biosynthetic pathway 
were cloned together with Hyg30 and Kan20, respectively, into the helper plasmids to construct 
two donor plasmids for Di-CRISPR. Using the optimal conditions for n-butanol production, 16 
colonies were randomly picked up from the plates containing antibiotics with either non-optimal 
(Hyg200Kan200) or optimized conditions (Hyg800Kan400) and characterized for their ability to 
produce n-butanol. As shown in Figures 6.9B and 6.9C, higher n-butanol production was 
achieved with higher selection pressure (optimal condition), further confirming that the 
engineered markers could control the copy numbers of both plasmids and chromosomally 
integrated cassettes. Compared with the plasmid system, we found significant clonal variations in 
n-butanol production, which was commonly observed for delta integration (30-32), probably due 
to the difference in copy numbers and/or loci dependent pathway activities. As for the best 
performing strain (INT3), the production of n-butanol reached about 70% of the value achieved 
using the plasmid system. Then the copy numbers of the upstream module and downstream 
module in the four best performing strains (INT1, INT2, INT3, and INT4, respectively) were 
quantified by qPCR and compared with the strain containing plasmids, which were obtained 
under the same selection pressure (Figure 6.9D). Interestingly, although the exact copy numbers 
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were not the same, the ratio of the copy numbers of the upstream module and the downstream 
module was rather similar (~1:2.4 in the plasmid containing strain v.s. ~1:2.9 in the integration 
strains). These results indicated that the n-butanol biosynthesis pathway was also optimized in 
the integration strains through the use of the engineered markers. In other words, we were able to 
transfer the optimized pathway to the chromosome by combining iPOAD and CRISPR-Cas9 
technologies. 
Finally, the stability of the integration strain (INT3) was tested in media without 
antibiotics supplementation. After more than 20 rounds of cell division without selection 
pressure, the integrated strain still produced about 80% of the amount of n-butanol when 
antibiotics were supplemented, which was nearly undetectable in the plasmid based system 
(Figure 6.9E). Therefore, although the n-butanol titer was not as high as the plasmid containing 
strain, the integration strain demonstrated much higher stability without antibiotics 
supplementation, which promised potential applications of Di-CRISPR to construct yeast cell 
factories for industrial production of fuels and chemicals. 
6.3 Discussion 
Biological conversion of renewable feedstock into fuels and chemicals has been 
intensively investigated due to increasing concerns on sustainability and global climate change 
(1). Many chemicals, such as lactic acid, succinic acid, and iso-butanol, used to be produced by 
chemical processes are synthesized biologically with microbial fermentation. Microorganisms 
are able to convert a wide range of substrates, such as plant biomass and agricultural waste, to 
value-added chemicals and fuels, promising a low carbon economy and sustainable future. 
Biofuels and chemicals are preferred to be produced at large scales using industrially friendly 
hosts such as E. coli and S. cerevisiae. Besides these two model microorganisms, cyanobacteria 
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(33) and oleaginous yeasts (34) have also been explored as cell factories. Compared with its 
counterparts, S. cerevisiae is more industrially relevant thanks to the well-studied genetic and 
physiological background, the availability of a large collection of genetic tools, the compatibility 
of high-density and large-scale fermentation, the resistance to phage infection, and the high 
tolerance against toxic inhibitors and products (2). Therefore, S. cerevisiae is the most popular 
cell factory and has been successfully used in modern fermentation industry to produce a wide 
variety of products including but not limited to ethanol, organic acids, amino acids, enzymes, and 
therapeutic proteins (1, 2). 
The development of microbial cell factory generally starts with the introduction of a 
biosynthetic pathway containing several heterologous genes, followed by optimization of the 
multi-gene pathway by balancing metabolic fluxes to maximize product titers, yields, and 
productivities (3, 4). The most powerful and well-developed method to achieve pathway 
optimization in S. cerevisiae is to use different promoters or promoter mutants with step-wise 
increased strengths. A method named COMPACTER using promoter mutants was developed in 
our previous studies to fine-tune the metabolic fluxes of multi-gene pathways. Although 
promoter mutants with different strengths could be generated by error-prone PCR, this method 
tended to generate promoter mutants with lower activities rather than higher ones and the 
dynamic range was very limited (~10 fold). Therefore, development of new tools at different 
levels of control (such as DNA level) was required to optimize multi-gene pathways. In this 
study, 2µ-based high copy plasmids were engineered to have different copy numbers through the 
use of partial defective promoters to drive the expression of both auxotrophic and dominant 
markers. Notably, promoter mutants used in COMPACTER tended to have lower activity than 
the wild-type, while the engineered marker containing plasmids tend to have higher copy 
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numbers than the traditional 2µ-based plasmids. Therefore, iPOAD and COMPACTER could be 
combined to further develop pathway optimization tools with expanded dynamic range in S. 
cerevisiae. From another perspective, the number of genes in a biosynthetic pathway could be 
optimized was limited by the library transformation efficiency. For example, assuming a 
transformation efficiency of 105 and 10 promoter mutants with step-wise increased strengths, a 
maximal of 5 genes could be optimized. This dramatically limited the application of 
COMPACTER to improve the production of many value-added compounds, whose biosynthetic 
pathways may generally involve more than 10 genes. Another advantage of combining iPOAD 
and COMPACTER is the possibility to divide a long synthetic pathway into different modules. 
In this case, each module containing around 5 genes could be optimized using COMPACTER 
(local or partial optimization), and further balancing the metabolic fluxes between different 
modules could be achieved using iPOAD (global or complete optimization) (Figure 6.10). 
Although the optimization of only two modules was demonstrated in this study, more engineered 
dominant markers such as Ble (bleomycin resistance) and Nat (natamycin resistance) could be 
achieved by following a similar strategy and included for the optimization of multi-module 
pathways. 
Although plasmids possess the advantages mentioned above, they suffer from genetic 
instability due to segregational instability, structural instability, and allele segregation (32, 35). 
Clonal variations and PCN change at different growth stages are also associated with the 
plasmid-based expression systems. Therefore, genome integration to maintain the heterologous 
pathways during the long-time culture without selection pressure is preferred for industrial 
applications. A major challenge is to integrate several copies of the desired genes or pathways 
into the chromosome, especially for multi-gene pathways. In E. coli, a process named CIChE 
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(chemical induced chromosome evolution) was developed to evolve a chromosome with ~40 
consecutive copies of a recombinant pathway (35). In S. cerevisiae, integration into the delta 
sequences (delta integration), which are positioned throughout the genome as the long terminal 
repeats of Ty retrotransposons, is generally used to construct genomic integrated yeast strains 
with multiple copies (30, 31). Interestingly, it was found that delta mediated integration tended to 
achieve high copy number integration by tandem (single cross-over) integration into the same 
locus rather than single (double cross-over) integration at different loci of delta sequences. One 
problem with genes in tandem repeat is their genetic instability, as shown in the CIChE 
engineered strains that the high copies could only be maintained under selection pressure or in a 
homologous recombination deficient strain (35). Recently, another study designed double cross-
over based delta integration and only 6 copy integration was achieved, even hough the process 
was repeated several times with gradually increased selection pressures with a final antibiotic 
concentration as high as 20 g/L (32). In this study, much higher copy number integration was 
achieved at a lower antibiotic concentration, 200 mg/L of G418 to achieve 30 copies of 
integration (Table 6.1). In addition, by taking advantage of the CRISPR-Cas9 technology, we 
were able to integrate much larger DNA fragments (>10 kb) with high copy numbers into the 
chromosome. More importantly, by using the engineered markers, the copy numbers of the 
integrated cassettes could be controlled by the antibiotic concentrations, making the transfer of 
the iPOAD optimized pathway to chromosomes possible. In addition, although the production of 
n-butanol was slightly lower compared with the plasmid containing strain, the engineered strain 
obtained by Di-CRISPR showed much higher stability when antibiotics were not supplemented, 
an important feature for industrial applications. If even higher copies of integration were desired, 
Di-CRISPR could be repeated several cycles with gradually increased selection pressure as well. 
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The stability of the engineered strains obtained by Di-CRISPR that contained the same pathway 
at different loci should be further evaluated even without the supplementation of antibiotics.  
6.4 Conclusions 
Saccharomyces cerevisiae has increasingly been engineered as a cell factory for efficient 
and economic production of fuels and chemicals from renewable resources. We develop a new 
and simplest synthetic biology approach, named induced pathway optimization by antibiotic 
doses (iPOAD), to improve the performance of multi-gene biosynthetic pathways in S. cerevisiae. 
First of all, plasmids with step-wise increased copy numbers were constructed by engineering the 
expression level of selection marker proteins, including both auxotrophic and dominant markers. 
More importantly, the copy number of the plasmids with engineered dominant markers (5-100 
copies per cell) showed a positive correlation with the concentration of antibiotics supplemented 
to the growth media. Based on this finding, iPOAD was developed for modular optimization of 
multi-gene pathways by different combinations of antibiotic concentrations. To demonstrate this 
approach, iPOAD was applied to optimize the lycopene and n-butanol biosynthetic pathways, 
with the production of lycopene and n-butanol increased by 10- and 100-fold, respectively. 
Finally, the pathway optimized by iPOAD was transferred to the chromosomes to increase the 
strain stability and eliminate the requirement of antibiotic supplementation, by taking advantage 
of iPOAD and the CRISPR-Cas9 technology for multiplex pathway integration. 
6.5 Materials and Methods 
6.5.1 Strains, media, and cultivation conditions 
E. coli strain DH5α was used to maintain and amplify plasmids, and recombinant strains 
were cultured at 37°C in Luria-Bertani (LB) broth containing 100 μg/mL ampicillin. S. 
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cerevisiae INVSc1 strain (Life Technologies) was used as the host for homologous 
recombination based cloning and lycopene production. ΔGGAA strain constructed in Chapter 4 
was used for n-butanol fermentation. Yeast strains were cultivated in complex medium 
consisting of 2% peptone and 1% yeast extract supplemented with 2% glucose (YPD) or 
galactose (YPG). Recombinant strains were grown on synthetic complete medium consisting of 
0.17% yeast nitrogen base, 0.5% ammonium sulfate, and the appropriate amino acid drop out 
mix, supplemented with 2% glucose (SCD) or galactose (SCG). ΔGGAA derived recombinant 
yeast strains were pre-cultured in galactose medium under aerobic conditions (30oC and 250 rpm) 
and inoculated to glucose medium for n-butanol fermentation under oxygen-limited conditions 
(30°C and 100 rpm) or micro-aerobic conditions (30oC and 250 rpm with the top tightly capped). 
G418 (KSE Scientific, Durham, NC) and hygromycin (Roche, Indianapolis, IN) were 
supplemented to the growth media at specifically mentioned concentration. All restriction 
enzymes, Q5 polymerase, and the E. coli-S. cerevisiae shuttle vectors were purchased from New 
England Biolabs (Ipswich, MA). All chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO) unless otherwise specified. 
6.5.2 DNA manipulation 
The yeast homologous recombination based DNA assembler method was used to 
construct the recombinant plasmids (28). Briefly, DNA fragments sharing homologous regions to 
adjacent DNA fragments were co-transformed into S. cerevisiae along with the linearized 
backbone to assemble several elements in a single step. All the recombinant plasmids 
constructed in this chapter are listed in Table 6.2. Wizard Genomic DNA Purification Kit 
(Promega, Madison, WI) was used to extract the genomic DNAs, according to the 
manufacturer’s protocol. HIS3, TRP1, LEU2, URA3, KanMX, and HygB expression cassettes 
194 
 
with variable length of promoters were amplified from pRS423, pRS424, pRS425, pRS426, 
pUG6, and pXZ5, respectively, and then cloned into pH5 linearized by Tth111I (Figure 6.1). The 
lycopene biosynthetic pathway (CrtE-CrtB-CrtI) was amplified from pRS426-Zea, constructed 
in our previous study (28). Genes of the FPP module (ERG10-ERG13-ERG8-tHMGR-ERG20-
ERG12) were amplified from S. cerevisiae CEN.PK2-1C genome. Upstream (rPu containing 
ERG10, cytoYlKR, cytoYlHTD, and cytoETR1) and downstream (rPd containing EcEutE and 
CaBdhB) n-butanol biosynthetic pathways were amplified from rP34, constructed in Chapter 5. 
To confirm the correct clones, yeast plasmids were isolated using a Zymoprep Yeast Plasmid 
Miniprep II Kit (Zymo Research, Irvine, CA) and amplified in E. coli for verification.  
6.5.3 Fluorescence intensity measurement 
eGFP and mCherry fluorescence signals were measured at 488 nm-520 nm and 580 nm-
620 nm, respectively, using a Biotek Synergy 2 Multi-Mode Microplate Reader (Winooski, VT). 
The fluorescence intensity was normalized to cell density that was determined by measuring the 
absorbance at 600 nm using the same microplate reader. 
6.5.4 Plasmid copy number assays 
Plasmid copy numbers were determined by quantitative PCR (qPCR) using the yeast total 
DNA extracts. As to the extraction process, 2 OD600 units of mid-log phase yeast culture were 
harvested by centrifuging at 15000 rpm for 1 min. After resuspending in 200 μL of lysis buffer 
(20 mM phosphate buffer at pH7.2, 1.2 M sorbitol, and 15 U Zymolase), the cells were incubated 
at 37°C for 20 minutes. Total DNAs were extracted from yeast cells by boiling the samples for 
15 minutes, freezing at -80°C for 15 minutes, and then boiling again for another 15 minutes. 
After spinning at 15000 rpm for 5 min, the resulting supernatant containing the total DNA was 
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diluted by 10- to 100-fold and used for qPCR analysis. The ampicillin resistance gene (Ampr) on 
the plasmids and ALG9 gene on the chromosome were chosen as the target and reference genes, 
respectively. As for the quantification of PCNs of yeast strains containing more than one plasmid 
and the copy numbers of the integrated cassettes, the KanMX or HygB gene and ALG9 gene were 
chosen as the target genes and reference gene, respectively. The copy numbers were quantified 
by comparing the Cq values of the target genes and the reference gene. qPCR was performed 
using LightCycler 480 SYBR Green Master on a Roche Light Cycler® 480 System (Roche).  
6.5.5 Lycopene production and quantification 
Lycopene producing strains were pre-cultured in SCD-HIS-URA medium for around 2 
days and inoculated into SCD medium supplemented with different concentrations of 
hygromycin and G418 with an initial OD600 of 0.05. After growing into the stationary phase 
under aerobic conditions, 1 mL of yeast cells were collected by centrifuge at 15,000 rpm for 1 
min and cell precipitates were resuspended in 1 mL of 3N HCl, boiled for 5 min, and then cooled 
in an ice-bath for 5 min. The cracked cells were washed with ddH2O and resuspended in 400 μL 
acetone to extract lycopene. The cell debris was removed by centrifuge and the lycopene 
containing supernatant was analyzed for its absorbance at 472 nm using a Biotek Synergy 2 
Multi-Mode Microplate Reader. Lycopene concentrations were determined by the standard curve 
method and normalized to cell density (dry cell weight). 
6.5.6 n-Butanol fermentation and quantification 
n-Butanol producing strains were precultured in  SCG-LEU-URA medium under aerobic 
conditions for 2 days. For n-butanol fermentation under oxygen-limited condition, 200 μL seed 
culture was transferred into 10 mL fresh SCD medium supplemented with different 
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concentrations of hygromycin and G418 in a 50 mL unbaffled shaker flask; while for micro-
aerobic fermentation, 200 μL seed culture was transferred into 5 mL fresh SCD medium 
supplemented with hygromycin and G418 in a 14 mL BD Falcon round bottom tube with the top 
tightly capped. Samples were taken every 24 h after inoculation until no further increase in n-
butanol production was observed. Samples were extracted using the same volume of ethyl 
acetate and the top layer was analyzed by GC-MS as described in Section 4.5.4, except for the 
use of 100 mg/L of 2-butanol as the internal standard.  
6.5.7 Di-CRISPR 
Considering the significant role of HR donors in delta integration, plasmid based donors 
which could be stably maintained under selection condition were designed for Di-CRISPR. To 
facilitate the construction of donor plasmids, two helper plasmids containing the left half (δ1) 
and the right half (δ2) of delta sequence with multi-cloning sites (MCSs) inserted in between (as 
shown in Figure 6.7B) were constructed. Then pathway of interest (rPu, rPd, or mCherry) and 
the engineered marker (Hyg30 or Kan20) were cloned into MCSs. The donor plasmids were 
based on pRS424 (TRP1 marker) and pRS426 (URA3 marker), which allowed counter-selection 
on 5-fluoroanthranilic acid (FAA) and 5-fluoroorotic acid (FOA) plates, respectively, to 
completely eliminate the donor plasmids from yeast cells. In addition, suicide sites were 
designed to flank the two halves of delta sequence on donor plasmids. Besides the delta 
sequences, crRNA arrays were designed to target the suicide sites on the donor plasmid as well. 
Therefore, the donor plasmids could be stably maintained during integration stage, and will be 
degraded and completely kicked out from the cell under non-selective and counter-selective 
conditions. A general protocol of Di-CRISPR was shown in Figure 6.11.  
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6.7 Tables 
Table 6.1 Copy numbers of Kan20 cassette integrated to the chromosome under different 
selection pressure (G418 concentrations). 
 25 mg/L 100 mg/L 400 mg/L 
Clone 1 0.86 1.10 33.13 
Clone 2 1.02 14.83 28.25 
Clone 3 0.96 1.06 28.47 
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Table 6.2 Plasmids constructed in this chapter 
Plasmids Description 
pRS413 HIS3 marker with CEN/ARS4 origin 
pRS416 URA3 marker with CEN/ARS4 origin 
pRS423 HIS3 marker with 2 Micron origin 
pRS424 TRP1 marker with 2 Micron origin 
pRS425 LEU2 marker with 2 Micron origin 
pRS426 URA3 marker with 2 Micron origin 
pH5 pRS425-TEF1p-eGFP-TEF1t 
HIS-CEN pRS413-TEF1p-eGFP-TEF1t 
HIS-WT pH5-HIS3(WT)p-HIS3-HIS3t 
HIS100 pH5-HIS3(100bp)p-HIS3-HIS3t 
HIS50 pH5-HIS3(50 bp)p-HIS3-HIS3t 
HIS30 pH5-HIS3(30 bp)p-HIS3-HIS3t 
HIS20 pH5-HIS3(20 bp)p-HIS3-HIS3t 
TRP-WT pH5-TRP1(WT)p-TRP1-TRP1t 
TRP100 pH5-TRP1(100 bp)p-TRP1-TRP1t 
TRP50 pH5-TRP1(50 bp)p-TRP1-TRP1t 
TRP30 pH5-TRP1(30 bp)p-TRP1-TRP1t 
TRP20 pH5-TRP1(20 bp)p-TRP1-TRP1t 
LEU-WT (pH5) pLEU2(WT)p-LEU2-LEU2t-TEF1p-eGFP-TEF1t 
LEU100 pLEU2(100 bp)p-LEU2-LEU2t-TEF1p-eGFP-TEF1t 
LEU50 pLEU2(50 bp)p-LEU2-LEU2t-TEF1p-eGFP-TEF1t 
LEU30 pLEU2(30 bp)p-LEU2-LEU2t-TEF1p-eGFP-TEF1t 
URA-WT pH5-URA3(WT)p-URA3-URA3t 
URA100 pH5-URA3(100 bp)p-URA3-URA3t 
URA50 pH5-URA3(50 bp)p-URA3-URA3t 
URA30 pH5-URA3(30 bp)p-URA3-URA3t 
URA15 pH5-URA3(15 bp)p-URA3-URA3t 
URA-CEN-R pRS416-TEF1p-mCherry-TEF1t 
URA-WT-R URA-WT with eGFP replaced by mCherry 
URA100-R URA100 with eGFP replaced by mCherry 
URA50-R URA50 with eGFP replaced by mCherry 
URA30-R URA30 with eGFP replaced by mCherry 
URA15-R URA15 with eGFP replaced by mCherry 
KanWT pH5-AgTEF1(WT)p-KanMX-AgTEF1t 
Kan100 pH5-AgTEF1(100 bp)p-KanMX-AgTEF1t 
Kan50 pH5-AgTEF1(50 bp)p-KanMX-AgTEF1t 
Kan30 pH5-AgTEF1(30 bp)p-KanMX-AgTEF1t 
Kan20 pH5-AgTEF1(20 bp)p-KanMX-AgTEF1t 
HygWT pH5-HXT7(WT)p-HygB-FBA1t 
Hyg100 pH5-HXT7(100 bp)p-HygB-FBA1t 
Hyg50 pH5-HXT7(50 bp)p-HygB-FBA1t 
Hyg30 pH5-HXT7(30 bp)p-HygB-FBA1t 
Hyg20 pH5-HXT7(20 bp)p-HygB-FBA1t 
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Table 6.2 (cont.) 
  
Plasmids Description 
Kan20-R Kan20 with eGFP replaced by mCherry 
pRS426-Zea pRS426-CrtE-CrtB-CrtI-CrtY-CrtZ 
FPP pRS423-Hyg30-ERG10-ERG13-ERG8-tHMGR-ERG20-ERG12 
Lyc pRS426-Kan20-CrtE-CrtB-CrtI 
rP34 pRS426-ERG10-cytoYlKR-cytoETR1-cytoYlHTD-EcEutE-CaBdhB 
rPu pRS426-Hyg30-ERG10-cytoYlKR-cytoETR1-cytoYlHTD 
rPd pRS425-Kan20-EcEutE-CaBdhB 
DiH1 pRS424-suicide1-δ1-MCS-δ2-suicide2 
DiH2 pRS426-suicide1-δ1-MCS-δ2-suicide2 
Di-rPu pRS424-δ1-Hyg30-ERG10-cytoYlKR-cytoETR1-cytoYlHTD-δ2 
Di-rPd pRS426-δ1-Kan20-EcEutE-CaBdhB-δ2 
pCRCT pURA3(47bp)p-URA3-SNR52p-crRNA-TEF1p-iCas9-RPR1p-tracrRNA 
pLH-CRCT pCRCT with URA3 marker replaced with LEU2 and HIS30 
Di-CRISPR crRNA(delta)-crRNA(suicide) inserted into pLH-CRCT 
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6.8 Figures  
 
 
Figure 6.1 Development of an eGFP reporter system for quantification of plasmid copy numbers 
(PCNs). HIS3, TRP1, LEU2, URA3, KanMX, and HygB expression cassettes with variable length 
of promoters were inserted into the Tth111I site via DNA assembler. 
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Figure 6.2 Systematic evaluation of promoter truncations on PCNs. Fluorescence intensity of 
plasmids with different level of promoter truncations cultured in non-selective media (cloning 
media, A) and selective media (B).PCNs of the engineered plasmids on selective media was 
quantified by qPCR (C). The use of eGFP as a reporter of PCNs was confirmed by their strong 
linear correlation (D). The effects of promoter truncation on PCNs could be seen by naked eyes 
(E) and flow cytometry (F). 
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Figure 6.3 Dose dependence of PCNs with KanMX (A and B) and HygB (C and D) markers. 
Plasmids with different levels of truncation showed variable sensitivity to antibiotic 
concentration (A and C). TP4 and TP3 worked the best for KanMX and HygB, respectively, 
whose PCNs were quantified by qPCR (B and D).  
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Figure 6.4 Demonstration of iPOAD using fluorescent proteins. iPOAD could be achieved by 
using either multi plasmids containing auxotrophic markers with different degrees of promoter 
truncations (A and B) or a single plasmid containing dominant markers with different antibiotic 
concentrations (C and D). The fluorescence intensities of eGFP (A and C) and mCheery (B and 
D) were distributed as expected. 
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Figure 6.5 iPOAD for lycopene biosynthesis. A) The multi-gene lycopene biosynthesis pathway 
was divided into two modules, the FPP module (blue) and Lyc module (red). B) Optimization of 
lycopene production by testing combination of G418 and hygromycin concentrations. C) Further 
improvement of lycopene production by increasing the concentration of hygromycin. D) A 
summary of the engineering efforts to increase lycopene production.  
 
  
207 
 
 
 
Figure 6.6 iPOAD for n-butanol production. A) The multi-gene n-butanol biosynthesis pathway 
was divided into two modules, the upstream module (blue) and the downstream module (red). B) 
Optimization of n-butanol production by testing combination of G418 and hygromycin 
concentrations. C) A summary of the engineering efforts to increase lycopene production. 
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Figure 6.7 Design of Di-CRISPR. A) Multiplex pathway integration into the delta sites was 
achieved by taking advantage of the CRISPR-Cas9 technology to introduce a double strand 
break on the chromosome. To supply the HR donors for delta integration continuously, plasmid-
based donors were designed, which allowed to be completely removed from yeast cells by Cas9 
cutting and counter selection. B) The design of helper plasmids to facilitate the construction of 
donor plasmids.  
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Figure 6.8 Optimization of Di-CRISPR using a fluorescent protein. 
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Figure 6.9 Dose-dependence of the copy numbers of the chromosomally integrated cassettes, 
including mCherry (A) and n-butanol biosynthetic pathway (B and C). Colonies were randomly 
picked up from the Di-CRISPR library with different selection pressures (antibiotic 
concentrations) and characterized for their fluorescence intensities (A) or n-butanol production 
levels (B and C). D) The copy numbers of the upstream module (rPu) and downstream module 
(rPd) on both plasmids and chromosomes, which were obtained under the same selection 
pressure, were determined by qPCR. E) Compared with the plasmid containing strain, the 
integration strain showed much higher stability under no selection pressure condition.   
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Figure 6.10 Combination of iPOAD and COMPACTER for the optimization of long 
biosynthetic pathways. The combined strategy shows advantages of expanding the dynamic 
range of pathway optimization tools and achieving global optimization of the desired 
biosynthetic pathway. 
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Figure 6.11 Protocol of Di-CRISPR for multiplex integration of long pathways. Cas9 plasmid 
and donor plasmids were co-transformed into ΔGGAA strain, and the resultant recombinant 
strain was pre-cultured in SC-WLU containing 10 g/L galactose for 2 days. Then 100 µL culture 
was transferred to fresh SC-HW(L)U containing 20 g/L galactose to increase the copy number of 
the Cas9 plasmid for efficient delta integration. After three serial transfers, the yeast cells were 
transferred to SC-H(L) containing 20 g/L galactose to suicide the donor plasmids. To completely 
eliminate the donor plasmids, yeast cells were spread into plates containing both FAA and FOA. 
Then the cells were collected and re-spread into plates containing different concentrations of 
G418 and hygromycin. Quality control (QC) was performed as indicated to confirm the 
elimination of donor plasmids. 
 
 
